Allele-specific	O
silencing	O
of	O
mutant	O
Myh6	O
transcripts	O
in	O
mice	O
suppresses	O
hypertrophic	O
cardiomyopathy	O
.	O

Dominant	O
mutations	O
in	O
sarcomere	O
proteins	O
such	O
as	O
the	O
myosin	O
heavy	O
chains	O
(MHC)	O
are	O
the	O
leading	O
genetic	O
causes	O
of	O
human	O
hypertrophic	O
cardiomyopathy	O
(HCM)	O
and	O
dilated	O
cardiomyopathy	O
.	O

We	O
found	O
that	O
expression	O
of	O
the	O
HCM-causing	O
cardiac	O
MHC	O
gene	O
(Myh6)	O
R403Q	B-DNAMutation
mutation	O
in	O
mice	O
can	O
be	O
selectively	O
silenced	O
by	O
an	O
RNA	O
interference	O
(RNAi)	O
cassette	O
delivered	O
by	O
an	O
adeno-associated	O
virus	O
vector	O
.	O

RNAi-transduced	O
MHC(403/+)	O
mice	O
developed	O
neither	O
hypertrophy	O
nor	O
myocardial	O
fibrosis	O
,	O
the	O
pathologic	O
manifestations	O
of	O
HCM	O
,	O
for	O
at	O
least	O
6	O
months	O
.	O

Because	O
inhibition	O
of	O
HCM	O
was	O
achieved	O
by	O
only	O
a	O
25%	O
reduction	O
in	O
the	O
levels	O
of	O
the	O
mutant	O
transcripts	O
,	O
we	O
suggest	O
that	O
the	O
variable	O
clinical	O
phenotype	O
in	O
HCM	O
patients	O
reflects	O
allele-specific	O
expression	O
and	O
that	O
partial	O
silencing	O
of	O
mutant	O
transcripts	O
may	O
have	O
therapeutic	O
benefit	O
.	O

The	O
molecular	O
basis	O
for	O
attractive	O
salt-taste	O
coding	O
in	O
Drosophila	O
.	O

Below	O
a	O
certain	O
level	O
,	O
table	O
salt	O
(NaCl)	O
is	O
beneficial	O
for	O
animals	O
,	O
whereas	O
excessive	O
salt	O
is	O
harmful	O
.	O

However	O
,	O
it	O
remains	O
unclear	O
how	O
low-	O
and	O
high-salt	O
taste	O
perceptions	O
are	O
differentially	O
encoded	O
.	O

We	O
identified	O
a	O
salt-taste	O
coding	O
mechanism	O
in	O
Drosophila	O
melanogaster	O
.	O

Flies	O
use	O
distinct	O
types	O
of	O
gustatory	O
receptor	O
neurons	O
(GRNs)	O
to	O
respond	O
to	O
different	O
concentrations	O
of	O
salt	O
.	O

We	O
demonstrated	O
that	O
a	O
member	O
of	O
the	O
newly	O
discovered	O
ionotropic	O
glutamate	O
receptor	O
(IR)	O
family	O
,	O
IR76b	O
,	O
functioned	O
in	O
the	O
detection	O
of	O
low	O
salt	O
and	O
was	O
a	O
Na(+)	O
channel	O
.	O

The	O
loss	B-DNAMutation
of	O
IR76b	O
selectively	O
impaired	O
the	O
attractive	O
pathway	O
,	O
leaving	O
salt-aversive	O
GRNs	O
unaffected	O
.	O

Consequently	O
,	O
low	O
salt	O
became	O
aversive	O
.	O

Our	O
work	O
demonstrated	O
that	O
the	O
opposing	O
behavioral	O
responses	O
to	O
low	O
and	O
high	O
salt	O
were	O
determined	O
largely	O
by	O
an	O
elegant	O
bimodal	O
switch	O
system	O
operating	O
in	O
GRNs	O
.	O

Comprehensive	O
genomic	O
characterization	O
of	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinomas	O
.	O

The	O
Cancer	O
Genome	O
Atlas	O
profiled	O
279	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinomas	O
(HNSCCs)	O
to	O
provide	O
a	O
comprehensive	O
landscape	O
of	O
somatic	O
genomic	O
alterations	O
.	O

Here	O
we	O
show	O
that	O
human-papillomavirus-associated	O
tumours	O
are	O
dominated	O
by	O
helical	B-DNAMutation
domain	I-DNAMutation
mutations	I-DNAMutation
of	O
the	O
oncogene	B-DNAMutation
PIK3CA	I-DNAMutation
,	O
novel	O
alterations	O
involving	O
loss	B-DNAMutation
of	I-DNAMutation
TRAF3	I-DNAMutation
,	O
and	O
amplification	O
of	O
the	O
cell	O
cycle	O
gene	O
E2F1	O
.	O

Smoking-related	O
HNSCCs	O
demonstrate	O
near	O
universal	O
loss-of-function	O
TP53	O
mutations	O
and	O
CDKN2A	O
inactivation	O
with	O
frequent	O
copy	O
number	O
alterations	O
including	O
amplification	B-DNAMutation
of	I-DNAMutation
3q26/28	I-DNAMutation
and	I-DNAMutation
11q13/22	I-DNAMutation
.	O

A	O
subgroup	O
of	O
oral	O
cavity	O
tumours	O
with	O
favourable	O
clinical	O
outcomes	O
displayed	O
infrequent	O
copy	O
number	O
alterations	O
in	O
conjunction	O
with	O
activating	O
mutations	O
of	O
HRAS	O
or	O
PIK3CA	O
,	O
coupled	O
with	O
inactivating	O
mutations	O
of	O
CASP8	O
,	O
NOTCH1	O
and	O
TP53	O
.	O

Other	O
distinct	O
subgroups	O
contained	O
loss-of-function	O
alterations	O
of	O
the	O
chromatin	O
modifier	O
NSD1	O
,	O
WNT	O
pathway	O
genes	O
AJUBA	O
and	O
FAT1	O
,	O
and	O
activation	O
of	O
oxidative	O
stress	O
factor	O
NFE2L2	O
,	O
mainly	O
in	O
laryngeal	O
tumours	O
.	O

Therapeutic	O
candidate	O
alterations	O
were	O
identified	O
in	O
most	O
HNSCCs	O
.	O

Saturation	O
editing	O
of	O
genomic	O
regions	O
by	O
multiplex	O
homology-directed	O
repair	O
.	O

Saturation	O
mutagenesis--coupled	O
to	O
an	O
appropriate	O
biological	O
assay--represents	O
a	O
fundamental	O
means	O
of	O
achieving	O
a	O
high-resolution	O
understanding	O
of	O
regulatory	O
and	O
protein-coding	O
nucleic	O
acid	O
sequences	O
of	O
interest	O
.	O

However	O
,	O
mutagenized	O
sequences	O
introduced	O
in	O
trans	O
on	O
episomes	O
or	O
via	O
random	O
or	O
"safe-harbour"	O
integration	O
fail	O
to	O
capture	O
the	O
native	O
context	O
of	O
the	O
endogenous	O
chromosomal	O
locus	O
.	O

This	O
shortcoming	O
markedly	O
limits	O
the	O
interpretability	O
of	O
the	O
resulting	O
measurements	O
of	O
mutational	O
impact	O
.	O

Here	O
,	O
we	O
couple	O
CRISPR/Cas9	O
RNA-guided	O
cleavage	O
with	O
multiplex	O
homology-directed	O
repair	O
using	O
a	O
complex	O
library	O
of	O
donor	O
templates	O
to	O
demonstrate	O
saturation	O
editing	O
of	O
genomic	O
regions	O
.	O

In	B-DNAMutation
exon	I-DNAMutation
18	I-DNAMutation
of	I-DNAMutation
BRCA1	I-DNAMutation
,	I-DNAMutation
we	I-DNAMutation
replace	I-DNAMutation
a	I-DNAMutation
six-base-pair	I-DNAMutation
(bp)	I-DNAMutation
genomic	I-DNAMutation
region	I-DNAMutation
with	I-DNAMutation
all	I-DNAMutation
possible	I-DNAMutation
hexamers	I-DNAMutation
,	O
or	O
the	B-DNAMutation
full	I-DNAMutation
exon	I-DNAMutation
with	I-DNAMutation
all	I-DNAMutation
possible	I-DNAMutation
single	I-DNAMutation
nucleotide	I-DNAMutation
variants	I-DNAMutation
(SNVs)	I-DNAMutation
,	O
and	O
measure	O
strong	O
effects	O
on	O
transcript	O
abundance	O
attributable	O
to	O
nonsense-mediated	O
decay	O
and	O
exonic	O
splicing	O
elements	O
.	O

We	O
similarly	O
perform	O
saturation	O
genome	O
editing	O
of	O
a	O
well-conserved	O
coding	O
region	O
of	O
an	O
essential	O
gene	O
,	O
DBR1	O
,	O
and	O
measure	O
relative	O
effects	O
on	O
growth	O
that	O
correlate	O
with	O
functional	O
impact	O
.	O

Measurement	O
of	O
the	O
functional	O
consequences	O
of	O
large	O
numbers	O
of	O
mutations	O
with	O
saturation	O
genome	O
editing	O
will	O
potentially	O
facilitate	O
high-resolution	O
functional	O
dissection	O
of	O
both	O
cis-regulatory	O
elements	O
and	O
trans-acting	O
factors	O
,	O
as	O
well	O
as	O
the	O
interpretation	O
of	O
variants	O
of	O
uncertain	O
significance	O
observed	O
in	O
clinical	O
sequencing	O
.	O

Comprehensive	O
genomic	O
profiles	O
of	O
small	O
cell	O
lung	O
cancer	O
.	O

We	O
have	O
sequenced	O
the	O
genomes	O
of	O
110	O
small	O
cell	O
lung	O
cancers	O
(SCLC)	O
,	O
one	O
of	O
the	O
deadliest	O
human	O
cancers	O
.	O

In	O
nearly	O
all	O
the	O
tumours	O
analysed	O
we	O
found	O
bi-allelic	O
inactivation	O
of	O
TP53	O
and	O
RB1	O
,	O
sometimes	O
by	O
complex	O
genomic	O
rearrangements	O
.	O

Two	O
tumours	O
with	O
wild-type	O
RB1	O
had	O
evidence	O
of	O
chromothripsis	O
leading	O
to	O
overexpression	O
of	O
cyclin	O
D1	O
(	O
encoded	O
by	O
the	O
CCND1	O
gene	O
)	O
,	O
revealing	O
an	O
alternative	O
mechanism	O
of	O
Rb1	O
deregulation	O
.	O

Thus	O
,	O
loss	B-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
tumour	I-DNAMutation
suppressors	I-DNAMutation
TP53	I-DNAMutation
and	I-DNAMutation
RB1	I-DNAMutation
is	O
obligatory	O
in	O
SCLC	O
.	O

We	O
discovered	O
somatic	O
genomic	O
rearrangements	O
of	O
TP73	O
that	O
create	O
an	O
oncogenic	O
version	O
of	O
this	O
gene	O
,	B-DNAMutation
TP73Δex2/3	I-DNAMutation
.	O

In	O
rare	O
cases	O
,	O
SCLC	O
tumours	O
exhibited	O
kinase	O
gene	O
mutations	O
,	O
providing	O
a	O
possible	O
therapeutic	O
opportunity	O
for	O
individual	O
patients	O
.	O

Finally	O
,	O
we	O
observed	O
inactivating	O
mutations	O
in	O
NOTCH	O
family	O
genes	O
in	O
25%	O
of	O
human	O
SCLC	O
.	O

Accordingly	O
,	O
activation	O
of	O
Notch	O
signalling	O
in	O
a	O
pre-clinical	O
SCLC	O
mouse	O
model	O
strikingly	O
reduced	O
the	O
number	O
of	O
tumours	O
and	O
extended	O
the	O
survival	O
of	O
the	O
mutant	O
mice	O
.	O

Furthermore	O
,	O
neuroendocrine	O
gene	O
expression	O
was	O
abrogated	O
by	O
Notch	O
activity	O
in	O
SCLC	O
cells	O
.	O

This	O
first	O
comprehensive	O
study	O
of	O
somatic	O
genome	O
alterations	O
in	O
SCLC	O
uncovers	O
several	O
key	O
biological	O
processes	O
and	O
identifies	O
candidate	O
therapeutic	O
targets	O
in	O
this	O
highly	O
lethal	O
form	O
of	O
cancer	O
.	O

Ultraviolet	O
radiation	O
accelerates	O
BRAF-driven	B-DANMutation
melanomagenesis	O
by	O
targeting	O
TP53	B-DANMutation
.	O

Cutaneous	O
melanoma	O
is	O
epidemiologically	O
linked	O
to	O
ultraviolet	O
radiation	O
(UVR)	O
,	O
but	O
the	O
molecular	O
mechanisms	O
by	O
which	O
UVR	O
drives	O
melanomagenesis	O
remain	O
unclear	O
.	O

The	O
most	O
common	O
somatic	O
mutation	O
in	O
melanoma	O
is	O
a	O
V600E	B-DNAMutation
substitution	O
in	O
BRAF	B-DNAMutation
,	O
which	O
is	O
an	O
early	O
event	O
.	O

To	O
investigate	O
how	O
UVR	O
accelerates	O
oncogenic	O
BRAF-driven	B-DNAMutation
melanomagenesis	O
,	O
we	O
used	O
a	O
BRAF(V600E)	B-DNAMutation
mouse	O
model	O
.	O

In	O
mice	O
expressing	O
BRAF(V600E)	B-DNAMutation
in	O
their	O
melanocytes	O
,	O
a	O
single	O
dose	O
of	O
UVR	O
that	O
mimicked	O
mild	O
sunburn	O
in	O
humans	O
induced	O
clonal	O
expansion	O
of	O
the	O
melanocytes	O
,	O
and	O
repeated	O
doses	O
of	O
UVR	O
increased	O
melanoma	O
burden	O
.	O

Here	O
we	O
show	O
that	O
sunscreen	O
(	O
UVA	O
superior	O
,	O
UVB	O
sun	O
protection	O
factor	O
(SPF)	O
50	O
)	O
delayed	O
the	O
onset	O
of	O
UVR-driven	O
melanoma	O
,	O
but	O
only	O
provided	O
partial	O
protection	O
.	O

The	O
UVR-exposed	O
tumours	O
showed	O
increased	O
numbers	O
of	O
single	O
nucleotide	O
variants	O
and	O
we	O
observed	O
mutations	O
(	O
H39Y	B-DNAMutation
,	O
S124F	B-DNAMutation
,	O
R245C	B-DNAMutation
,	O
R270C	B-DNAMutation
,	O
C272G	B-DNAMutation
)	O
in	O
the	O
Trp53	B-DNAMutation
tumour	O
suppressor	O
in	O
approximately	O
40%	O
of	O
cases	O
.	O

TP53	B-DNAMutation
is	O
an	O
accepted	O
UVR	O
target	O
in	O
human	O
non-melanoma	O
skin	O
cancer	O
,	O
but	O
is	O
not	O
thought	O
to	O
have	O
a	O
major	O
role	O
in	O
melanoma	O
.	O

However	O
,	O
we	O
show	O
that	O
,	O
in	O
mice	O
,	O
mutant	O
Trp53	B-DNAMutation
accelerated	O
BRAF(V600E)-driven	B-DNAMutation
melanomagenesis	O
,	O
and	O
that	O
TP53	B-DNAMutation
mutations	O
are	O
linked	O
to	O
evidence	O
of	O
UVR-induced	O
DNA	O
damage	O
in	O
human	O
melanoma	O
.	O

Thus	O
,	O
we	O
provide	O
mechanistic	O
insight	O
into	O
epidemiological	O
data	O
linking	O
UVR	O
to	O
acquired	O
naevi	O
in	O
humans	O
.	O

Furthermore	O
,	O
we	O
identify	O
TP53/Trp53	B-DNAMutation
as	O
a	O
UVR-target	O
gene	O
that	O
cooperates	O
with	O
BRAF(V600E)	B-DNAMutation
to	O
induce	O
melanoma	O
,	O
providing	O
molecular	O
insight	O
into	O
how	O
UVR	O
accelerates	O
melanomagenesis	O
.	O

Our	O
study	O
validates	O
public	O
health	O
campaigns	O
that	O
promote	O
sunscreen	O
protection	O
for	O
individuals	O
at	O
risk	O
of	O
melanoma	O
.	O

A	O
stable	O
transcription	O
factor	O
complex	O
nucleated	O
by	O
oligomeric	O
AML1-ETO	O
controls	O
leukaemogenesis	O
.	O

Transcription	O
factors	O
are	O
frequently	O
altered	O
in	O
leukaemia	O
through	O
chromosomal	O
translocation	O
,	O
mutation	O
or	O
aberrant	O
expression	O
.	O

AML1-ETO	O
,	O
a	O
fusion	O
protein	O
generated	O
by	O
the	O
t(8;21)	B-DNAMutation
translocation	I-DNAMutation
in	O
acute	O
myeloid	O
leukaemia	O
,	O
is	O
a	O
transcription	O
factor	O
implicated	O
in	O
both	O
gene	O
repression	O
and	O
activation	O
.	O

AML1-ETO	O
oligomerization	O
,	O
mediated	O
by	O
the	O
NHR2	O
domain	O
,	O
is	O
critical	O
for	O
leukaemogenesis	O
,	O
making	O
it	O
important	O
to	O
identify	O
co-regulatory	O
factors	O
that	O
'read'	O
the	O
NHR2	O
oligomerization	O
and	O
contribute	O
to	O
leukaemogenesis	O
.	O

Here	O
we	O
show	O
that	O
,	O
in	O
human	O
leukaemic	O
cells	O
,	O
AML1-ETO	O
resides	O
in	O
and	O
functions	O
through	O
a	O
stable	O
AML1-ETO-containing	O
transcription	O
factor	O
complex	O
(AETFC)	O
that	O
contains	O
several	O
haematopoietic	O
transcription	O
(co)factors	O
.	O

These	O
AETFC	O
components	O
stabilize	O
the	O
complex	O
through	O
multivalent	O
interactions	O
,	O
provide	O
multiple	O
DNA-binding	O
domains	O
for	O
diverse	O
target	O
genes	O
,	O
co-localize	O
genome	O
wide	O
,	O
cooperatively	O
regulate	O
gene	O
expression	O
,	O
and	O
contribute	O
to	O
leukaemogenesis	O
.	O

Within	O
the	O
AETFC	O
complex	O
,	O
AML1-ETO	O
oligomerization	O
is	O
required	O
for	O
a	O
specific	O
interaction	O
between	O
the	O
oligomerized	O
NHR2	O
domain	O
and	O
a	O
novel	O
NHR2-binding	O
(N2B)	O
motif	O
in	O
E	O
proteins	O
.	O

Crystallographic	O
analysis	O
of	O
the	O
NHR2-N2B	O
complex	O
reveals	O
a	O
unique	O
interaction	O
pattern	O
in	O
which	O
an	O
N2B	O
peptide	O
makes	O
direct	O
contact	O
with	O
side	O
chains	O
of	O
two	O
NHR2	O
domains	O
as	O
a	O
dimer	O
,	O
providing	O
a	O
novel	O
model	O
of	O
how	O
dimeric/oligomeric	O
transcription	O
factors	O
create	O
a	O
new	O
protein-binding	O
interface	O
through	O
dimerization/oligomerization	O
.	O

Intriguingly	O
,	O
disruption	O
of	O
this	O
interaction	O
by	O
point	O
mutations	O
abrogates	O
AML1-ETO-induced	O
haematopoietic	O
stem/progenitor	O
cell	O
self-renewal	O
and	O
leukaemogenesis	O
.	O

These	O
results	O
reveal	O
new	O
mechanisms	O
of	O
action	O
of	O
AML1-ETO	O
,	O
and	O
provide	O
a	O
potential	O
therapeutic	O
target	O
in	O
t(8;21)-positive	B-DNAMutation
acute	O
myeloid	O
leukaemia	O
.	O

Axitinib	O
effectively	O
inhibits	O
BCR-ABL1(T315I)	B-DANMutation
with	O
a	O
distinct	O
binding	O
conformation	O
.	O

The	O
BCR-ABL1	O
fusion	O
gene	O
is	O
a	O
driver	O
oncogene	O
in	O
chronic	O
myeloid	O
leukaemia	O
and	O
30-50%	O
of	O
cases	O
of	O
adult	O
acute	O
lymphoblastic	O
leukaemia	O
.	O

Introduction	O
of	O
ABL1	O
kinase	O
inhibitors	O
(	O
for	O
example	O
,	O
imatinib	O
)	O
has	O
markedly	O
improved	O
patient	O
survival	O
,	O
but	O
acquired	O
drug	O
resistance	O
remains	O
a	O
challenge	O
.	O

Point	O
mutations	O
in	O
the	O
ABL1	O
kinase	O
domain	O
weaken	O
inhibitor	O
binding	O
and	O
represent	O
the	O
most	O
common	O
clinical	O
resistance	O
mechanism	O
.	O

The	O
BCR-ABL1	O
kinase	O
domain	O
gatekeeper	O
mutation	O
Thr315Ile	B-DNAMutation
T315I	B-DNAMutation
confers	O
resistance	O
to	O
all	O
approved	O
ABL1	O
inhibitors	O
except	O
ponatinib	O
,	O
which	O
has	O
toxicity	O
limitations	O
.	O

Here	O
we	O
combine	O
comprehensive	O
drug	O
sensitivity	O
and	O
resistance	O
profiling	O
of	O
patient	O
cells	O
ex	O
vivo	O
with	O
structural	O
analysis	O
to	O
establish	O
the	O
VEGFR	O
tyrosine	O
kinase	O
inhibitor	O
axitinib	O
as	O
a	O
selective	O
and	O
effective	O
inhibitor	O
for	O
T315I-mutant	B-DNAMutation
BCR-ABL1-driven	O
leukaemia	O
.	O

Axitinib	O
potently	O
inhibited	O
BCR-ABL1(T315I)	B-DNAMutation
,	O
at	O
both	O
biochemical	O
and	O
cellular	O
levels	O
,	O
by	O
binding	O
to	O
the	O
active	O
form	O
of	O
ABL1(T315I)	B-DNAMutation
in	O
a	O
mutation-selective	O
binding	O
mode	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
T315I	B-DNAMutation
mutation	O
shifts	O
the	O
conformational	O
equilibrium	O
of	O
the	O
kinase	O
in	O
favour	O
of	O
an	O
active	O
(DFG-in)	O
A-loop	O
conformation	O
,	O
which	O
has	O
more	O
optimal	O
binding	O
interactions	O
with	O
axitinib	O
.	O

Treatment	O
of	O
a	O
T315I	B-DNAMutation
chronic	O
myeloid	O
leukaemia	O
patient	O
with	O
axitinib	O
resulted	O
in	O
a	O
rapid	O
reduction	O
of	O
T315I-positive	B-DNAMutation
cells	O
from	O
bone	O
marrow	O
.	O

Taken	O
together	O
,	O
our	O
findings	O
demonstrate	O
an	O
unexpected	O
opportunity	O
to	O
repurpose	O
axitinib	O
,	O
an	O
anti-angiogenic	O
drug	O
approved	O
for	O
renal	O
cancer	O
,	O
as	O
an	O
inhibitor	O
for	O
ABL1	O
gatekeeper	O
mutant	O
drug-resistant	O
leukaemia	O
patients	O
.	O

This	O
study	O
shows	O
that	O
wild-type	O
proteins	O
do	O
not	O
always	O
sample	O
the	O
conformations	O
available	O
to	O
disease-relevant	O
mutant	O
proteins	O
and	O
that	O
comprehensive	O
drug	O
testing	O
of	O
patient-derived	O
cells	O
can	O
identify	O
unpredictable	O
,	O
clinically	O
significant	O
drug-repositioning	O
opportunities	O
.	O

KNOX2	B-DANMutation
genes	O
regulate	O
the	O
haploid-to-diploid	O
morphological	O
transition	O
in	O
land	O
plants	O
.	O

Unlike	O
animals	O
,	O
land	O
plants	O
undergo	O
an	O
alternation	O
of	O
generations	O
,	O
producing	O
multicellular	O
bodies	O
in	O
both	O
haploid	O
(	O
1n	O
:	O
gametophyte	O
)	O
and	O
diploid	O
(	O
2n	O
:	O
sporophyte	O
)	O
generations	O
.	O

Plant	O
body	O
plans	O
in	O
each	O
generation	O
are	O
regulated	O
by	O
distinct	O
developmental	O
programs	O
initiated	O
at	O
either	O
meiosis	O
or	O
fertilization	O
,	O
respectively	O
.	O

In	O
mosses	O
,	O
the	O
haploid	O
gametophyte	O
generation	O
is	O
dominant	O
,	O
whereas	O
in	O
vascular	O
plants-including	O
ferns	O
,	O
gymnosperms	O
,	O
and	O
angiosperms-the	O
diploid	O
sporophyte	O
generation	O
is	O
dominant	O
.	O

Deletion	B-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
class	I-DNAMutation
2	I-DNAMutation
KNOTTED1-LIKE	I-DNAMutation
HOMEOBOX	I-DNAMutation
KNOX2	B-DNAMutation
transcription	O
factors	O
in	O
the	O
moss	O
Physcomitrella	O
patens	O
results	O
in	O
the	O
development	O
of	O
gametophyte	O
bodies	O
from	O
diploid	O
embryos	O
without	O
meiosis	O
.	O

Thus	O
,	O
KNOX2	B-DNAMutation
acts	O
to	O
prevent	O
the	O
haploid-specific	O
body	O
plan	O
from	O
developing	O
in	O
the	O
diploid	O
plant	O
body	O
,	O
indicating	O
a	O
critical	O
role	O
for	O
the	O
evolution	O
of	O
KNOX2	B-DNAMutation
in	O
establishing	O
an	O
alternation	O
of	O
generations	O
in	O
land	O
plants	O
.	O

Recurrent	O
somatic	O
mutations	O
underlie	O
corticotropin-independent	O
Cushing's	O
syndrome	O
.	O

Cushing's	O
syndrome	O
is	O
caused	O
by	O
excess	O
cortisol	O
production	O
from	O
the	O
adrenocortical	O
gland	O
.	O

In	O
corticotropin-independent	O
Cushing's	O
syndrome	O
,	O
the	O
excess	O
cortisol	O
production	O
is	O
primarily	O
attributed	O
to	O
an	O
adrenocortical	O
adenoma	O
,	O
in	O
which	O
the	O
underlying	O
molecular	O
pathogenesis	O
has	O
been	O
poorly	O
understood	O
.	O

We	O
report	O
a	O
hotspot	O
mutation	O
L206R	B-DNAMutation
in	O
PRKACA	B-DNAMutation
,	O
which	O
encodes	O
the	O
catalytic	O
subunit	O
of	O
cyclic	O
adenosine	O
monophosphate	O
(cAMP)-dependent	O
protein	O
kinase	O
PKA	B-DNAMutation
,	O
in	O
more	O
than	O
50%	O
of	O
cases	O
with	O
adrenocortical	O
adenomas	O
associated	O
with	O
corticotropin-independent	O
Cushing's	O
syndrome	O
.	O

The	O
L206R	B-DNAMutation
PRKACA	B-DNAMutation
mutant	O
abolished	O
its	O
binding	O
to	O
the	O
regulatory	O
subunit	O
of	O
PKA	B-DNAMutation
PRKAR1A	B-DNAMutation
that	O
inhibits	O
catalytic	O
activity	O
of	O
PRKACA	B-DNAMutation
,	O
leading	O
to	O
constitutive	O
,	O
cAMP-independent	O
PKA	B-DNAMutation
activation	O
.	O

These	O
results	O
highlight	O
the	O
major	O
role	O
of	O
cAMP-independent	O
activation	O
of	O
cAMP/PKA	B-DNAMutation
signaling	O
by	O
somatic	O
mutations	O
in	O
corticotropin-independent	O
Cushing's	O
syndrome	O
,	O
providing	O
insights	O
into	O
the	O
diagnosis	O
and	O
therapeutics	O
of	O
this	O
syndrome	O
.	O

SOX2	B-DANMutation
controls	O
tumour	O
initiation	O
and	O
cancer	O
stem-cell	O
functions	O
in	O
squamous-cell	O
carcinoma	O
.	O

Cancer	O
stem	O
cells	O
(CSCs)	O
have	O
been	O
reported	O
in	O
various	O
cancers	O
,	O
including	O
in	O
skin	O
squamous-cell	O
carcinoma	O
(SCC)	O
.	O

The	O
molecular	O
mechanisms	O
regulating	O
tumour	O
initiation	O
and	O
stemness	O
are	O
still	O
poorly	O
characterized	O
.	O

Here	O
we	O
find	O
that	O
Sox2	O
,	O
a	O
transcription	O
factor	O
expressed	O
in	O
various	O
types	O
of	O
embryonic	O
and	O
adult	O
stem	O
cells	O
,	O
was	O
the	O
most	O
upregulated	O
transcription	O
factor	O
in	O
the	O
CSCs	O
of	O
squamous	O
skin	O
tumours	O
in	O
mice	O
.	O

SOX2	B-DNAMutation
is	O
absent	O
in	O
normal	O
epidermis	O
but	O
begins	O
to	O
be	O
expressed	O
in	O
the	O
vast	O
majority	O
of	O
mouse	O
and	O
human	O
pre-neoplastic	O
skin	O
tumours	O
,	O
and	O
continues	O
to	O
be	O
expressed	O
in	O
a	O
heterogeneous	O
manner	O
in	O
invasive	O
mouse	O
and	O
human	O
SCCs	O
.	O

In	O
contrast	O
to	O
other	O
SCCs	O
,	O
in	O
which	O
SOX2	B-DNAMutation
is	O
frequently	O
genetically	O
amplified	O
,	O
the	O
expression	O
of	O
SOX2	B-DNAMutation
in	O
mouse	O
and	O
human	O
skin	O
SCCs	O
is	O
transcriptionally	O
regulated	O
.	O

Conditional	O
deletion	B-DNAMutation
of	I-DNAMutation
Sox2	I-DNAMutation
in	O
the	O
mouse	O
epidermis	O
markedly	O
decreases	O
skin	O
tumour	O
formation	O
after	O
chemical-induced	O
carcinogenesis	O
.	O

Using	O
green	O
fluorescent	O
protein	O
(GFP)	O
as	O
a	O
reporter	O
of	O
Sox2	O
transcriptional	O
expression	O
(	O
SOX2-GFP	B-DNAMutation
knock-in	O
mice	O
)	O
,	O
we	O
showed	O
that	O
SOX2-expressing	B-DNAMutation
cells	O
in	O
invasive	O
SCC	O
are	O
greatly	O
enriched	O
in	O
tumour-propagating	O
cells	O
,	O
which	O
further	O
increase	O
upon	O
serial	O
transplantations	O
.	O

Lineage	O
ablation	O
of	O
SOX2-expressing	B-DNAMutation
cells	O
within	O
primary	O
benign	O
and	O
malignant	O
SCCs	O
leads	O
to	O
tumour	O
regression	O
,	O
consistent	O
with	O
the	O
critical	O
role	O
of	O
SOX2-expressing	B-DNAMutation
cells	O
in	O
tumour	O
maintenance	O
.	O

Conditional	O
Sox2	B-DNAMutation
deletion	I-DNAMutation
in	O
pre-existing	O
skin	O
papilloma	O
and	O
SCC	O
leads	O
to	O
tumour	O
regression	O
and	O
decreases	O
the	O
ability	O
of	O
cancer	O
cells	O
to	O
be	O
propagated	O
upon	O
transplantation	O
into	O
immunodeficient	O
mice	O
,	O
supporting	O
the	O
essential	O
role	O
of	O
SOX2	B-DNAMutation
in	O
regulating	O
CSC	O
functions	O
.	O

Transcriptional	O
profiling	O
of	O
SOX2-GFP-expressing	B-DNAMutation
CSCs	O
and	O
of	O
tumour	O
epithelial	O
cells	O
upon	O
Sox2	B-DNAMutation
deletion	I-DNAMutation
uncovered	O
a	O
gene	O
network	O
regulated	O
by	O
SOX2	B-DNAMutation
in	O
primary	O
tumour	O
cells	O
in	O
vivo	O
.	O

Chromatin	O
immunoprecipitation	O
identified	O
several	O
direct	O
SOX2	B-DNAMutation
target	O
genes	O
controlling	O
tumour	O
stemness	O
,	O
survival	O
,	O
proliferation	O
,	O
adhesion	O
,	O
invasion	O
and	O
paraneoplastic	O
syndrome	O
.	O

We	O
demonstrate	O
that	O
SOX2	B-DNAMutation
,	O
by	O
marking	O
and	O
regulating	O
the	O
functions	O
of	O
skin	O
tumour-initiating	O
cells	O
and	O
CSCs	O
,	O
establishes	O
a	O
continuum	O
between	O
tumour	O
initiation	O
and	O
progression	O
in	O
primary	O
skin	O
tumours	O
.	O

Infectious	O
disease	O
.	O

Life-threatening	O
influenza	O
and	O
impaired	O
interferon	O
amplification	O
in	O
human	O
IRF7	O
deficiency	O
.	O

Severe	O
influenza	O
disease	O
strikes	O
otherwise	O
healthy	O
children	O
and	O
remains	O
unexplained	O
.	O

We	O
report	O
compound	O
heterozygous	O
null	B-DNAMutation
mutations	I-DNAMutation
in	I-DNAMutation
IRF7	I-DNAMutation
,	O
which	O
encodes	O
the	O
transcription	O
factor	O
interferon	O
regulatory	O
factor	O
7	O
,	O
in	O
an	O
otherwise	O
healthy	O
child	O
who	O
suffered	O
life-threatening	O
influenza	O
during	O
primary	O
infection	O
.	O

In	O
response	O
to	O
influenza	O
virus	O
,	O
the	O
patient's	O
leukocytes	O
and	O
plasmacytoid	O
dendritic	O
cells	O
produced	O
very	O
little	O
type	O
I	O
and	O
III	O
interferons	O
(IFNs)	O
.	O

Moreover	O
,	O
the	O
patient's	O
dermal	O
fibroblasts	O
and	O
induced	O
pluripotent	O
stem	O
cell	O
(iPSC)-derived	O
pulmonary	O
epithelial	O
cells	O
produced	O
reduced	O
amounts	O
of	O
type	O
I	O
IFN	O
and	O
displayed	O
increased	O
influenza	O
virus	O
replication	O
.	O

These	O
findings	O
suggest	O
that	O
IRF7-dependent	O
amplification	O
of	O
type	O
I	O
and	O
III	O
IFNs	O
is	O
required	O
for	O
protection	O
against	O
primary	O
infection	O
by	O
influenza	O
virus	O
in	O
humans	O
.	O

They	O
also	O
show	O
that	O
severe	O
influenza	O
may	O
result	O
from	O
single-gene	O
inborn	O
errors	O
of	O
immunity	O
.	O

Human	O
CLP1	O
mutations	O
alter	O
tRNA	O
biogenesis	O
,	O
affecting	O
both	O
peripheral	O
and	O
central	O
nervous	O
system	O
function	O
.	O

CLP1	O
is	O
a	O
RNA	O
kinase	O
involved	O
in	O
tRNA	O
splicing	O
.	O

Recently	O
,	O
CLP1	O
kinase-dead	O
mice	O
were	O
shown	O
to	O
display	O
a	O
neuromuscular	O
disorder	O
with	O
loss	O
of	O
motor	O
neurons	O
and	O
muscle	O
paralysis	O
.	O

Human	O
genome	O
analyses	O
now	O
identified	O
a	O
CLP1	O
homozygous	O
missense	O
mutation	O
p.R140H	B-DNAMutation
in	O
five	O
unrelated	O
families	O
,	O
leading	O
to	O
a	O
loss	O
of	O
CLP1	O
interaction	O
with	O
the	O
tRNA	O
splicing	O
endonuclease	O
(TSEN)	O
complex	O
,	O
largely	O
reduced	O
pre-tRNA	O
cleavage	O
activity	O
,	O
and	O
accumulation	O
of	O
linear	O
tRNA	O
introns	O
.	O

The	O
affected	O
individuals	O
develop	O
severe	O
motor-sensory	O
defects	O
,	O
cortical	O
dysgenesis	O
,	O
and	O
microcephaly	O
.	O

Mice	O
carrying	O
kinase-dead	O
CLP1	O
also	O
displayed	O
microcephaly	O
and	O
reduced	O
cortical	O
brain	O
volume	O
due	O
to	O
the	O
enhanced	O
cell	O
death	O
of	O
neuronal	O
progenitors	O
that	O
is	O
associated	O
with	O
reduced	O
numbers	O
of	O
cortical	O
neurons	O
.	O

Our	O
data	O
elucidate	O
a	O
neurological	O
syndrome	O
defined	O
by	O
CLP1	O
mutations	O
that	O
impair	O
tRNA	O
splicing	O
.	O

Reduction	O
of	O
a	O
founder	O
mutation	O
to	O
homozygosity	O
illustrates	O
the	O
importance	O
of	O
rare	O
variations	O
in	O
disease	O
and	O
supports	O
the	O
clan	O
genomics	O
hypothesis	O
.	O

CNVs	B-DANMutation
conferring	O
risk	O
of	O
autism	O
or	O
schizophrenia	O
affect	O
cognition	O
in	O
controls	O
.	O

In	O
a	O
small	O
fraction	O
of	O
patients	O
with	O
schizophrenia	O
or	O
autism	O
,	O
alleles	O
of	O
copy-number	B-DNAMutation
variants	I-DNAMutation
CNVs	B-DNAMutation
in	O
their	O
genomes	O
are	O
probably	O
the	O
strongest	O
factors	O
contributing	O
to	O
the	O
pathogenesis	O
of	O
the	O
disease	O
.	O

These	O
CNVs	B-DNAMutation
may	O
provide	O
an	O
entry	O
point	O
for	O
investigations	O
into	O
the	O
mechanisms	O
of	O
brain	O
function	O
and	O
dysfunction	O
alike	O
.	O

They	O
are	O
not	O
fully	O
penetrant	O
and	O
offer	O
an	O
opportunity	O
to	O
study	O
their	O
effects	O
separate	O
from	O
that	O
of	O
manifest	O
disease	O
.	O

Here	O
we	O
show	O
in	O
an	O
Icelandic	O
sample	O
that	O
a	O
few	O
of	O
the	O
CNVs	B-DNAMutation
clearly	O
alter	O
fecundity	O
(	O
measured	O
as	O
the	O
number	O
of	O
children	O
by	O
age	O
45	O
)	O
.	O

Furthermore	O
,	O
we	O
use	O
various	O
tests	O
of	O
cognitive	O
function	O
to	O
demonstrate	O
that	O
control	O
subjects	O
carrying	O
the	O
CNVs	B-DNAMutation
perform	O
at	O
a	O
level	O
that	O
is	O
between	O
that	O
of	O
schizophrenia	O
patients	O
and	O
population	O
controls	O
.	O

The	O
CNVs	B-DNAMutation
do	O
not	O
all	O
affect	O
the	O
same	O
cognitive	O
domains	O
,	O
hence	O
the	O
cognitive	O
deficits	O
that	O
drive	O
or	O
accompany	O
the	O
pathogenesis	O
vary	O
from	O
one	O
CNV	B-DNAMutation
to	O
another	O
.	O

Controls	O
carrying	O
the	O
chromosome	O
15q11.2	B-DNAMutation
deletion	I-DNAMutation
between	I-DNAMutation
breakpoints	I-DNAMutation
1	I-DNAMutation
and	I-DNAMutation
2	I-DNAMutation
(	O
15q11.2(BP1-BP2	B-DNAMutation
)	I-DNAMutation
deletion	I-DNAMutation
)	O
have	O
a	O
history	O
of	O
dyslexia	O
and	O
dyscalculia	O
,	O
even	O
after	O
adjusting	O
for	O
IQ	O
in	O
the	O
analysis	O
,	O
and	O
the	O
CNV	B-DNAMutation
only	O
confers	O
modest	O
effects	O
on	O
other	O
cognitive	O
traits	O
.	O

The	O
15q11.2(BP1-BP2)	B-DNAMutation
deletion	I-DNAMutation
affects	O
brain	O
structure	O
in	O
a	O
pattern	O
consistent	O
with	O
both	O
that	O
observed	O
during	O
first-episode	O
psychosis	O
in	O
schizophrenia	O
and	O
that	O
of	O
structural	O
correlates	O
in	O
dyslexia	O
.	O

TREM2	O
lipid	O
sensing	O
sustains	O
the	O
microglial	O
response	O
in	O
an	O
Alzheimer's	O
disease	O
model	O
.	O

Triggering	O
receptor	O
expressed	O
on	O
myeloid	O
cells	O
2	O
(TREM2)	O
is	O
a	O
microglial	O
surface	O
receptor	O
that	O
triggers	O
intracellular	O
protein	O
tyrosine	O
phosphorylation	O
.	O

Recent	O
genome-wide	O
association	O
studies	O
have	O
shown	O
that	O
a	O
rare	O
R47H	B-DNAMutation
mutation	O
of	O
TREM2	O
correlates	O
with	O
a	O
substantial	O
increase	O
in	O
the	O
risk	O
of	O
developing	O
Alzheimer's	O
disease	O
(AD)	O
.	O

To	O
address	O
the	O
basis	O
for	O
this	O
genetic	O
association	O
,	O
we	O
studied	O
TREM2	O
deficiency	O
in	O
the	O
5XFAD	O
mouse	O
model	O
of	O
AD	O
.	O

We	O
found	O
that	O
TREM2	O
deficiency	O
and	O
haploinsufficiency	O
augment	O
β-amyloid	O
(Aβ)	O
accumulation	O
due	O
to	O
a	O
dysfunctional	O
response	O
of	O
microglia	O
,	O
which	O
fail	O
to	O
cluster	O
around	O
Aβ	O
plaques	O
and	O
become	O
apoptotic	O
.	O

We	O
further	O
demonstrate	O
that	O
TREM2	O
senses	O
a	O
broad	O
array	O
of	O
anionic	O
and	O
zwitterionic	O
lipids	O
known	O
to	O
associate	O
with	O
fibrillar	O
Aβ	O
in	O
lipid	O
membranes	O
and	O
to	O
be	O
exposed	O
on	O
the	O
surface	O
of	O
damaged	O
neurons	O
.	O

Remarkably	O
,	B-DNAMutation
the	I-DNAMutation
R47H	O
mutation	O
impairs	O
TREM2	O
detection	O
of	O
lipid	O
ligands	O
.	O

Thus	O
,	O
TREM2	O
detects	O
damage-associated	O
lipid	O
patterns	O
associated	O
with	O
neurodegeneration	O
,	O
sustaining	O
the	O
microglial	O
response	O
to	O
Aβ	O
accumulation	O
.	O

Landscape	O
of	O
genomic	O
alterations	O
in	O
cervical	O
carcinomas	O
.	O

Cervical	O
cancer	O
is	O
responsible	O
for	O
10-15%	O
of	O
cancer-related	O
deaths	O
in	O
women	O
worldwide	O
.	O

The	O
aetiological	O
role	O
of	O
infection	O
with	O
high-risk	O
human	O
papilloma	O
viruses	O
(HPVs)	O
in	O
cervical	O
carcinomas	O
is	O
well	O
established	O
.	O

Previous	O
studies	O
have	O
also	O
implicated	O
somatic	O
mutations	O
in	O
PIK3CA	O
,	O
PTEN	O
,	O
TP53	O
,	O
STK11	O
and	O
KRAS	O
as	O
well	O
as	O
several	O
copy-number	O
alterations	O
in	O
the	O
pathogenesis	O
of	O
cervical	O
carcinomas	O
.	O

Here	O
we	O
report	O
whole-exome	O
sequencing	O
analysis	O
of	O
115	O
cervical	O
carcinoma-normal	O
paired	O
samples	O
,	O
transcriptome	O
sequencing	O
of	O
79	O
cases	O
and	O
whole-genome	O
sequencing	O
of	O
14	O
tumour-normal	O
pairs	O
.	O

Previously	O
unknown	O
somatic	O
mutations	O
in	O
79	O
primary	O
squamous	O
cell	O
carcinomas	O
include	O
recurrent	O
E322K	B-DNAMutation
substitutions	O
in	O
the	O
MAPK1	O
gene	O
(8%)	O
,	O
inactivating	O
mutations	O
in	O
the	O
HLA-B	O
gene	O
(9%)	O
,	O
and	O
mutations	O
in	O
EP300	O
(16%)	O
,	O
FBXW7	O
(15%)	O
,	O
NFE2L2	O
(4%)	O
,	O
TP53	O
(5%)	O
and	O
ERBB2	O
(6%)	O
.	O

We	O
also	O
observe	O
somatic	O
ELF3	O
(13%)	O
and	O
CBFB	O
(8%)	O
mutations	O
in	O
24	O
adenocarcinomas	O
.	O

Squamous	O
cell	O
carcinomas	O
have	O
higher	O
frequencies	O
of	O
somatic	O
nucleotide	B-DNAMutation
substitutions	I-DNAMutation
occurring	I-DNAMutation
at	I-DNAMutation
cytosines	I-DNAMutation
preceded	I-DNAMutation
by	I-DNAMutation
thymines	I-DNAMutation
(	I-DNAMutation
Tp*C	I-DNAMutation
sites	I-DNAMutation
)	O
than	O
adenocarcinomas	O
.	O

Gene	O
expression	O
levels	O
at	O
HPV	O
integration	O
sites	O
were	O
statistically	O
significantly	O
higher	O
in	O
tumours	O
with	O
HPV	O
integration	O
compared	O
with	O
expression	O
of	O
the	O
same	O
genes	O
in	O
tumours	O
without	O
viral	O
integration	O
at	O
the	O
same	O
site	O
.	O

These	O
data	O
demonstrate	O
several	O
recurrent	O
genomic	O
alterations	O
in	O
cervical	O
carcinomas	O
that	O
suggest	O
new	O
strategies	O
to	O
combat	O
this	O
disease	O
.	O

Crystal	O
structure	O
of	O
pre-activated	O
arrestin	O
p44	O
.	O

Arrestins	O
interact	O
with	O
G-protein-coupled	O
receptors	O
(GPCRs)	O
to	O
block	O
interaction	O
with	O
G	O
proteins	O
and	O
initiate	O
G-protein-independent	O
signalling	O
.	O

Arrestins	O
have	O
a	O
bi-lobed	O
structure	O
that	O
is	O
stabilized	O
by	O
a	O
long	O
carboxy-terminal	O
tail	O
(C-tail)	O
,	O
and	O
displacement	O
of	O
the	O
C-tail	O
by	O
receptor-attached	O
phosphates	O
activates	O
arrestins	O
for	O
binding	O
active	O
GPCRs	O
.	O

Structures	O
of	O
the	O
inactive	O
state	O
of	O
arrestin	O
are	O
available	O
,	O
but	O
it	O
is	O
not	O
known	O
how	O
C-tail	B-DNAMutation
displacement	I-DNAMutation
activates	O
arrestin	O
for	O
receptor	O
coupling	O
.	O

Here	O
we	O
present	O
a	O
3.0 Å	O
crystal	O
structure	O
of	O
the	O
bovine	O
arrestin-1	O
splice	O
variant	O
p44	O
,	O
in	O
which	O
the	O
activation	O
step	O
is	O
mimicked	O
by	I-DNAMutation
C-tail	I-DNAMutation
truncation	I-DNAMutation
.	O

The	O
structure	O
of	O
this	O
pre-activated	O
arrestin	O
is	O
profoundly	O
different	O
from	O
the	O
basal	O
state	O
and	O
gives	O
insight	O
into	O
the	O
activation	O
mechanism	O
.	O

p44	O
displays	O
breakage	O
of	O
the	O
central	O
polar	O
core	O
and	O
other	O
interlobe	O
hydrogen-bond	O
networks	O
,	O
leading	O
to	O
a	O
∼21°	O
rotation	O
of	O
the	O
two	O
lobes	O
as	O
compared	O
to	O
basal	O
arrestin-1	O
.	O

Rearrangements	O
in	O
key	O
receptor-binding	O
loops	O
in	O
the	O
central	O
crest	O
region	O
include	O
the	O
finger	O
loop	O
,	O
loop	O
139	O
(	O
refs	O
8	O
,	O
10	O
,	O
11	O
)	O
and	O
the	O
sequence	O
Asp 296-Asn 305	O
(	O
or	O
gate	O
loop	O
)	O
,	O
here	O
identified	O
as	O
controlling	O
the	O
polar	O
core	O
.	O

We	O
verified	O
the	O
role	O
of	O
these	O
conformational	O
alterations	O
in	O
arrestin	O
activation	O
and	O
receptor	O
binding	O
by	O
site-directed	O
fluorescence	O
spectroscopy	O
.	O

The	O
data	O
indicate	O
a	O
mechanism	O
for	O
arrestin	O
activation	B-DNAMutation
in	I-DNAMutation
which	I-DNAMutation
C-tail	I-DNAMutation
displacement	I-DNAMutation
releases	O
critical	O
central-crest	O
loops	O
from	O
restricted	O
to	O
extended	O
receptor-interacting	O
conformations	O
.	O

In	O
parallel	O
,	O
increased	O
flexibility	O
between	O
the	O
two	O
lobes	O
facilitates	O
a	O
proper	O
fitting	O
of	O
arrestin	O
to	O
the	O
active	O
receptor	O
surface	O
.	O

Our	O
results	O
provide	O
a	O
snapshot	O
of	O
an	O
arrestin	O
ready	O
to	O
bind	O
the	O
active	O
receptor	O
,	O
and	O
give	O
an	O
insight	O
into	O
the	O
role	O
of	O
naturally	O
occurring	O
truncated	O
arrestins	O
in	O
the	O
visual	O
system	O
.	O

COUP-TFII	O
inhibits	O
TGF-β-induced	O
growth	O
barrier	O
to	O
promote	O
prostate	O
tumorigenesis	O
.	O

Mutations	O
in	O
phosphatase	O
and	O
tensin	O
homologue	O
(PTEN)	O
or	O
genomic	O
alterations	O
in	O
the	O
phosphatidylinositol-3-OH	O
kinase-signalling	O
pathway	O
are	O
the	O
most	O
common	O
genetic	O
alterations	O
reported	O
in	O
human	O
prostate	O
cancer	O
.	O

However	O
,	O
the	O
precise	O
mechanism	O
underlying	O
how	O
indolent	O
tumours	O
with	O
PTEN	O
alterations	O
acquire	O
metastatic	O
potential	O
remains	O
poorly	O
understood	O
.	O

Recent	O
studies	O
suggest	O
that	O
upregulation	O
of	O
transforming	O
growth	O
factor	O
(TGF)-β	O
signalling	O
triggered	O
by	B-DNAMutation
PTEN	I-DNAMutation
loss	I-DNAMutation
will	O
form	O
a	O
growth	O
barrier	O
as	O
a	O
defence	O
mechanism	O
to	O
constrain	O
prostate	O
cancer	O
progression	O
,	O
underscoring	O
that	O
TGF-β	O
signalling	O
might	O
represent	O
a	O
pre-invasive	O
checkpoint	O
to	O
prevent	O
PTEN-mediated	O
prostate	O
tumorigenesis	O
.	O

Here	O
we	O
show	O
that	O
COUP	O
transcription	O
factor	O
II	O
(	O
COUP-TFII	O
,	O
also	O
known	O
as	O
NR2F2	O
)	O
,	O
a	O
member	O
of	O
the	O
nuclear	O
receptor	O
superfamily	O
,	O
serves	O
as	O
a	O
key	O
regulator	O
to	O
inhibit	O
SMAD4-dependent	O
transcription	O
,	O
and	O
consequently	O
overrides	O
the	O
TGF-β-dependent	O
checkpoint	O
for	O
PTEN-null	O
indolent	O
tumours	O
.	O

Overexpression	O
of	O
COUP-TFII	O
in	O
the	O
mouse	O
prostate	O
epithelium	O
cooperates	O
with	B-DNAMutation
PTEN	I-DNAMutation
deletion	I-DNAMutation
to	O
augment	O
malignant	O
progression	O
and	O
produce	O
an	O
aggressive	O
metastasis-prone	O
tumour	O
.	O

The	O
functional	O
counteraction	O
between	O
COUP-TFII	O
and	O
SMAD4	O
is	O
reinforced	O
by	O
genetically	O
engineered	O
mouse	O
models	O
in	O
which	O
conditional	B-DNAMutation
loss	I-DNAMutation
of	I-DNAMutation
SMAD4	O
diminishes	O
the	O
inhibitory	O
effects	O
elicited	O
by	O
COUP-TFII	O
ablation	O
.	O

The	O
biological	O
significance	O
of	O
COUP-TFII	O
in	O
prostate	O
carcinogenesis	O
is	O
substantiated	O
by	O
patient	O
sample	O
analysis	O
,	O
in	O
which	O
COUP-TFII	O
expression	O
or	O
activity	O
is	O
tightly	O
correlated	O
with	O
tumour	O
recurrence	O
and	O
disease	O
progression	O
,	O
whereas	O
it	O
is	O
inversely	O
associated	O
with	O
TGF-β	O
signalling	O
.	O

These	O
findings	O
reveal	O
that	O
the	O
destruction	O
of	O
the	O
TGF-β-dependent	O
barrier	O
by	O
COUP-TFII	O
is	O
crucial	O
for	O
the	O
progression	O
of	O
PTEN-mutant	O
prostate	O
cancer	O
into	O
a	O
life-threatening	O
disease	O
,	O
and	O
supports	O
COUP-TFII	O
as	O
a	O
potential	O
drug	O
target	O
for	O
the	O
intervention	O
of	O
metastatic	O
human	O
prostate	O
cancer	O
.	O

β-Cell	O
Insulin	O
Secretion	O
Requires	O
the	O
Ubiquitin	O
Ligase	O
COP1	O
.	O

A	O
variety	O
of	O
signals	O
finely	O
tune	O
insulin	O
secretion	O
by	O
pancreatic	O
β	O
cells	O
to	O
prevent	O
both	O
hyper-and	O
hypoglycemic	O
states	O
.	O

Here	O
,	O
we	O
show	O
that	O
post-translational	O
regulation	O
of	O
the	O
transcription	O
factors	O
ETV1	O
,	O
ETV4	O
,	O
and	O
ETV5	O
by	O
the	O
ubiquitin	O
ligase	O
COP1	O
(	O
also	O
called	O
RFWD2	O
)	O
in	O
β	O
cells	O
is	O
critical	O
for	O
insulin	O
secretion	O
.	O

Mice	B-DNAMutation
lacking	I-DNAMutation
COP1	O
in	O
β	O
cells	O
developed	O
diabetes	O
due	O
to	O
insulin	O
granule	O
docking	O
defects	O
that	O
were	O
fully	O
rescued	O
by	O
genetic	B-DNAMutation
deletion	I-DNAMutation
of	O
Etv1	O
,	O
Etv4	O
,	O
and	O
Etv5	O
.	O

Genes	O
regulated	O
by	O
ETV1	O
,	O
ETV4	O
,	O
or	O
ETV5	O
in	O
the	O
absence	O
of	O
mouse	O
COP1	O
were	O
enriched	O
in	O
human	O
diabetes-associated	O
genes	O
,	O
suggesting	O
that	O
they	O
also	O
influence	O
human	O
β-cell	O
pathophysiology	O
.	O

In	O
normal	O
β	O
cells	O
,	O
ETV4	O
was	O
stabilized	O
upon	O
membrane	O
depolarization	O
and	O
limited	O
insulin	O
secretion	O
under	O
hyperglycemic	O
conditions	O
.	O

Collectively	O
,	O
our	O
data	O
reveal	O
that	O
ETVs	O
negatively	O
regulate	O
insulin	O
secretion	O
for	O
the	O
maintenance	O
of	O
normoglycemia	O
.	O

Ubiquitous	O
L1	O
mosaicism	O
in	O
hippocampal	O
neurons	O
.	O

Somatic	O
LINE-1	O
(L1)	O
retrotransposition	O
during	O
neurogenesis	O
is	O
a	O
potential	O
source	O
of	O
genotypic	O
variation	O
among	O
neurons	O
.	O

As	O
a	O
neurogenic	O
niche	O
,	O
the	O
hippocampus	O
supports	O
pronounced	O
L1	O
activity	O
.	O

However	O
,	O
the	O
basal	O
parameters	O
and	O
biological	O
impact	O
of	O
L1-driven	O
mosaicism	O
remain	O
unclear	O
.	O

Here	O
,	O
we	O
performed	O
single-cell	O
retrotransposon	O
capture	O
sequencing	O
(RC-seq)	O
on	O
individual	O
human	O
hippocampal	O
neurons	O
and	O
glia	O
,	O
as	O
well	O
as	O
cortical	O
neurons	O
.	O

An	O
estimated	O
13.7	B-DNAMutation
somatic	I-DNAMutation
L1	I-DNAMutation
insertions	I-DNAMutation
occurred	O
per	O
hippocampal	O
neuron	O
and	O
carried	O
the	O
sequence	O
hallmarks	O
of	O
target-primed	O
reverse	O
transcription	O
.	O

Notably	O
,	O
hippocampal	B-DNAMutation
neuron	I-DNAMutation
L1	I-DNAMutation
insertions	I-DNAMutation
were	O
specifically	O
enriched	O
in	O
transcribed	O
neuronal	O
stem	O
cell	O
enhancers	O
and	O
hippocampus	O
genes	O
,	O
increasing	O
their	O
probability	O
of	O
functional	O
relevance	O
.	O

In	O
addition	O
,	O
bias	O
against	O
intronic	B-DNAMutation
L1	I-DNAMutation
insertions	I-DNAMutation
sense	O
oriented	O
relative	O
to	O
their	O
host	O
gene	O
was	O
observed	O
,	O
perhaps	O
indicating	O
moderate	O
selection	O
against	O
this	O
configuration	O
in	O
vivo	O
.	O

These	O
experiments	O
demonstrate	O
pervasive	O
L1	O
mosaicism	O
at	O
genomic	O
loci	O
expressed	O
in	O
hippocampal	O
neurons	O
.	O

∆F508	I-DANMutation
CFTR	I-DANMutation
interactome	O
remodelling	O
promotes	O
rescue	O
of	O
cystic	O
fibrosis	B-DNAMutation
.	O

Deletion	I-DNAMutation
of	I-DNAMutation
phenylalanine	I-DNAMutation
508	O
of	O
the	B-DNAMutation
cystic	I-DNAMutation
fibrosis	I-DNAMutation
transmembrane	I-DNAMutation
conductance	I-DNAMutation
regulator	I-DNAMutation
(	I-DNAMutation
∆F508	I-DNAMutation
CFTR	O
)	O
is	O
the	O
major	O
cause	O
of	O
cystic	O
fibrosis	O
,	O
one	O
of	O
the	O
most	O
common	O
inherited	O
childhood	O
diseases	O
.	O

The	O
mutated	B-DNAMutation
CFTR	O
anion	O
channel	O
is	O
not	O
fully	O
glycosylated	O
and	O
shows	O
minimal	O
activity	O
in	O
bronchial	O
epithelial	O
cells	O
of	O
patients	O
with	O
cystic	O
fibrosis	O
.	O

Low	O
temperature	O
or	O
inhibition	O
of	O
histone	O
deacetylases	O
can	O
partly	O
rescue	B-DNAMutation
∆F508	O
CFTR	O
cellular	O
processing	O
defects	O
and	O
function	O
.	O

A	O
favourable	O
change	B-DNAMutation
of	I-DNAMutation
∆F508	I-DNAMutation
CFTR	O
protein-protein	O
interactions	O
was	O
proposed	O
as	O
a	O
mechanism	O
of	O
rescue	O
;	O
however	B-DNAMutation
,	O
CFTR	O
interactome	O
dynamics	O
during	O
temperature	O
shift	O
and	O
inhibition	O
of	O
histone	O
deacetylases	O
are	O
unknown	O
.	O

Here	O
we	O
report	O
the	O
first	O
comprehensive	O
analysis	B-DNAMutation
of	I-DNAMutation
the	O
CFTR	B-DNAMutation
and	O
∆F508	I-DNAMutation
CFTR	O
interactome	O
and	O
its	O
dynamics	O
during	O
temperature	O
shift	O
and	O
inhibition	O
of	O
histone	O
deacetylases	O
.	O

By	O
using	O
a	O
novel	O
deep	O
proteomic	O
analysis	O
method	O
,	O
we	O
identify	O
638	O
individual	O
high-confidence	B-DNAMutation
CFTR	O
interactors	O
and	O
discover	B-DNAMutation
a	O
∆F508	O
deletion-specific	O
interactome	O
,	O
which	O
is	O
extensively	O
remodelled	O
upon	O
rescue	O
.	O

Detailed	O
analysis	O
of	O
the	O
interactome	O
remodelling	O
identifies	O
key	O
novel	O
interactors	O
,	O
whose	O
loss	B-DNAMutation
promote	O
∆F508	O
CFTR	O
channel	O
function	O
in	O
primary	O
cystic	O
fibrosis	O
epithelia	O
or	O
which	O
are	B-DNAMutation
critical	I-DNAMutation
for	O
CFTR	O
biogenesis	O
.	O

Our	O
results	O
demonstrate	O
that	O
global	O
remodelling	B-DNAMutation
of	O
∆F508	O
CFTR	O
interactions	O
is	O
crucial	O
for	O
rescue	O
,	O
and	O
provide	O
comprehensive	O
insight	O
into	O
the	O
molecular	O
disease	O
mechanisms	O
of	O
cystic	O
fibrosis	B-DNAMutation
caused	I-DNAMutation
by	I-DNAMutation
deletion	O
of	O
F508	O
.	O

SHANK3	B-DANMutation
and	O
IGF1	B-DANMutation
restore	O
synaptic	O
deficits	O
in	O
neurons	O
from	O
22q13	B-DANMutation
deletion	I-DANMutation
syndrome	O
patients	O
.	O

Phelan-McDermid	O
syndrome	O
(PMDS)	O
is	O
a	O
complex	O
neurodevelopmental	O
disorder	O
characterized	O
by	O
global	O
developmental	O
delay	O
,	O
severely	O
impaired	O
speech	O
,	O
intellectual	O
disability	O
,	O
and	O
an	O
increased	O
risk	O
of	O
autism	O
spectrum	O
disorders	O
(ASDs)	O
.	O

PMDS	O
is	O
caused	O
by	O
heterozygous	B-DNAMutation
deletions	I-DNAMutation
of	I-DNAMutation
chromosome	I-DNAMutation
22q13.3	I-DNAMutation
.	O

Among	O
the	O
genes	O
in	O
the	O
deleted	B-DNAMutation
region	I-DNAMutation
is	I-DNAMutation
SHANK3	I-DNAMutation
,	O
which	O
encodes	O
a	O
protein	O
in	O
the	O
postsynaptic	O
density	O
(PSD)	O
.	O

Rare	O
mutations	O
in	O
SHANK3	B-DNAMutation
have	O
been	O
associated	O
with	O
idiopathic	O
ASDs	O
,	O
non-syndromic	O
intellectual	O
disability	O
,	O
and	O
schizophrenia	O
.	O

Although	O
SHANK3	B-DNAMutation
is	O
considered	O
to	O
be	O
the	O
most	O
likely	O
candidate	O
gene	O
for	O
the	O
neurological	O
abnormalities	O
in	O
PMDS	O
patients	O
,	O
the	O
cellular	O
and	O
molecular	O
phenotypes	O
associated	O
with	O
this	O
syndrome	O
in	O
human	O
neurons	O
are	O
unknown	O
.	O

We	O
generated	O
induced	O
pluripotent	O
stem	O
(iPS)	O
cells	O
from	O
individuals	O
with	O
PMDS	O
and	O
autism	O
and	O
used	O
them	O
to	O
produce	O
functional	O
neurons	O
.	O

We	O
show	O
that	O
PMDS	O
neurons	O
have	O
reduced	O
SHANK3	B-DNAMutation
expression	O
and	O
major	O
defects	O
in	O
excitatory	O
,	O
but	O
not	O
inhibitory	O
,	O
synaptic	O
transmission	O
.	O

Excitatory	O
synaptic	O
transmission	O
in	O
PMDS	O
neurons	O
can	O
be	O
corrected	O
by	O
restoring	O
SHANK3	B-DNAMutation
expression	O
or	O
by	O
treating	O
neurons	O
with	O
insulin-like	O
growth	O
factor	O
1	O
IGF1	B-DNAMutation
.	O

IGF1	B-DNAMutation
treatment	O
promotes	O
formation	O
of	O
mature	O
excitatory	O
synapses	O
that	O
lack	O
SHANK3	B-DNAMutation
but	O
contain	O
PSD95	O
and	O
N-methyl-D-aspartate	O
(NMDA)	O
receptors	O
with	O
fast	O
deactivation	O
kinetics	O
.	O

Our	O
findings	O
provide	O
direct	O
evidence	O
for	O
a	O
disruption	O
in	O
the	O
ratio	O
of	O
cellular	O
excitation	O
and	O
inhibition	O
in	O
PMDS	O
neurons	O
,	O
and	O
point	O
to	O
a	O
molecular	O
pathway	O
that	O
can	O
be	O
recruited	O
to	O
restore	O
it	O
.	O

A	O
gain-of-function	O
mutation	O
in	O
DHT	O
synthesis	O
in	O
castration-resistant	O
prostate	O
cancer	O
.	O

Growth	O
of	O
prostate	O
cancer	O
cells	O
is	O
dependent	O
upon	O
androgen	O
stimulation	O
of	O
the	O
androgen	O
receptor	O
(AR)	O
.	O

Dihydrotestosterone	O
(DHT)	O
,	O
the	O
most	O
potent	O
androgen	O
,	O
is	O
usually	O
synthesized	O
in	O
the	O
prostate	O
from	O
testosterone	O
secreted	O
by	O
the	O
testis	O
.	O

Following	O
chemical	O
or	O
surgical	O
castration	O
,	O
prostate	O
cancers	O
usually	O
shrink	O
owing	O
to	O
testosterone	O
deprivation	O
.	O

However	O
,	O
tumors	O
often	O
recur	O
,	O
forming	O
castration-resistant	O
prostate	O
cancer	O
(CRPC)	O
.	O

Here	O
,	O
we	O
show	O
that	O
CRPC	O
sometimes	O
expresses	O
a	O
gain-of-stability	O
mutation	O
that	O
leads	O
to	O
a	O
gain-of-function	O
in	O
3β-hydroxysteroid	O
dehydrogenase	O
type	O
1	O
(3βHSD1)	O
,	O
which	O
catalyzes	O
the	O
initial	O
rate-limiting	O
step	O
in	O
conversion	O
of	O
the	O
adrenal-derived	O
steroid	O
dehydroepiandrosterone	O
to	O
DHT	O
.	O

The	O
mutation	B-DNAMutation
(N367T)	I-DNAMutation
does	O
not	O
affect	O
catalytic	O
function	O
,	O
but	O
it	O
renders	O
the	O
enzyme	O
resistant	O
to	O
ubiquitination	O
and	O
degradation	O
,	O
leading	O
to	O
profound	O
accumulation	O
.	O

Whereas	O
dehydroepiandrosterone	O
conversion	O
to	O
DHT	O
is	O
usually	O
very	O
limited	O
,	O
expression	O
of	O
367T	O
accelerates	O
this	O
conversion	O
and	O
provides	O
the	O
DHT	O
necessary	O
to	O
activate	O
the	O
AR	O
.	O

We	O
suggest	O
that	O
3βHSD1	O
is	O
a	O
valid	O
target	O
for	O
the	O
treatment	O
of	O
CRPC	O
.	O

Histone	O
deacetylase	O
3	O
coordinates	O
commensal-bacteria-dependent	O
intestinal	O
homeostasis	O
.	O

The	O
development	O
and	O
severity	O
of	O
inflammatory	O
bowel	O
diseases	O
and	O
other	O
chronic	O
inflammatory	O
conditions	O
can	O
be	O
influenced	O
by	O
host	O
genetic	O
and	O
environmental	O
factors	O
,	O
including	O
signals	O
derived	O
from	O
commensal	O
bacteria	O
.	O

However	O
,	O
the	O
mechanisms	O
that	O
integrate	O
these	O
diverse	O
cues	O
remain	O
undefined	O
.	O

Here	O
we	O
demonstrate	O
that	O
mice	O
with	O
an	O
intestinal	O
epithelial	O
cell	O
(IEC)-specific	O
deletion	B-DNAMutation
of	O
the	O
epigenome-modifying	O
enzyme	O
histone	O
deacetylase	O
3	O
(	O
HDAC3(ΔIEC	B-DNAMutation
)	O
mice	O
)	O
exhibited	O
extensive	O
dysregulation	O
of	O
IEC-intrinsic	O
gene	O
expression	O
,	O
including	O
decreased	O
basal	O
expression	O
of	O
genes	O
associated	O
with	O
antimicrobial	O
defence	O
.	O

Critically	O
,	O
conventionally	O
housed	O
HDAC3(ΔIEC)	B-DNAMutation
mice	O
demonstrated	O
loss	O
of	O
Paneth	O
cells	O
,	O
impaired	O
IEC	O
function	O
and	O
alterations	O
in	O
the	O
composition	O
of	O
intestinal	O
commensal	O
bacteria	O
.	O

In	O
addition	O
,	O
HDAC3(ΔIEC)	B-DNAMutation
mice	O
showed	O
significantly	O
increased	O
susceptibility	O
to	O
intestinal	O
damage	O
and	O
inflammation	O
,	O
indicating	O
that	O
epithelial	O
expression	O
of	O
HDAC3	O
has	O
a	O
central	O
role	O
in	O
maintaining	O
intestinal	O
homeostasis	O
.	O

Re-derivation	O
of	O
HDAC3(ΔIEC)	B-DNAMutation
mice	O
into	O
germ-free	O
conditions	O
revealed	O
that	O
dysregulated	O
IEC	O
gene	O
expression	O
,	O
Paneth	O
cell	O
homeostasis	O
and	O
intestinal	O
barrier	O
function	O
were	O
largely	O
restored	O
in	O
the	O
absence	O
of	O
commensal	O
bacteria	O
.	O

Although	O
the	O
specific	O
mechanisms	O
through	O
which	O
IEC-intrinsic	O
HDAC3	O
expression	O
regulates	O
these	O
complex	O
phenotypes	O
remain	O
to	O
be	O
determined	O
,	O
these	O
data	O
indicate	O
that	O
HDAC3	O
is	O
a	O
critical	O
factor	O
that	O
integrates	O
commensal-bacteria-derived	O
signals	O
to	O
calibrate	O
epithelial	O
cell	O
responses	O
required	O
to	O
establish	O
normal	O
host-commensal	O
relationships	O
and	O
maintain	O
intestinal	O
homeostasis	O
.	O

Inhibition	O
of	O
PRC2	O
activity	O
by	O
a	O
gain-of-function	O
H3	O
mutation	O
found	O
in	O
pediatric	O
glioblastoma	O
.	O

Sequencing	O
of	O
pediatric	O
gliomas	O
has	O
identified	O
missense	O
mutations	O
Lys27Met	B-DNAMutation
K27M	B-DNAMutation
and	O
Gly34Arg/Val	B-DNAMutation
G34R/V	B-DNAMutation
in	O
genes	O
encoding	O
histone	O
H3.3	O
(H3F3A)	O
and	O
H3.1	O
(HIST3H1B)	O
.	O

We	O
report	O
that	O
human	O
diffuse	O
intrinsic	O
pontine	O
gliomas	O
(DIPGs)	O
containing	O
the	O
K27M	B-DNAMutation
mutation	O
display	O
significantly	O
lower	O
overall	O
amounts	O
of	O
H3	O
with	O
trimethylated	O
lysine	O
27	O
(H3K27me3)	O
and	O
that	O
histone	O
H3K27M	B-DNAMutation
transgenes	O
are	O
sufficient	O
to	O
reduce	O
the	O
amounts	O
of	O
H3K27me3	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

We	O
find	O
that	O
H3K27M	B-DNAMutation
inhibits	O
the	O
enzymatic	O
activity	O
of	O
the	O
Polycomb	O
repressive	O
complex	O
2	O
through	O
interaction	O
with	O
the	O
EZH2	O
subunit	O
.	O

In	O
addition	O
,	O
transgenes	O
containing	O
lysine-to-methionine	B-DNAMutation
substitutions	I-DNAMutation
at	I-DNAMutation
other	I-DNAMutation
known	I-DNAMutation
methylated	I-DNAMutation
lysines	I-DNAMutation
(	I-DNAMutation
H3K9	I-DNAMutation
and	I-DNAMutation
H3K36	I-DNAMutation
)	O
are	O
sufficient	O
to	O
cause	O
specific	O
reduction	O
in	O
methylation	O
through	O
inhibition	O
of	O
SET-domain	O
enzymes	O
.	O

We	O
propose	O
that	O
K-to-M	O
substitutions	O
may	O
represent	O
a	O
mechanism	O
to	O
alter	O
epigenetic	O
states	O
in	O
a	O
variety	O
of	O
pathologies	O
.	O

Inhibition	O
of	O
RNA	O
helicase	O
Brr2	O
by	O
the	O
C-terminal	O
tail	O
of	O
the	O
spliceosomal	O
protein	O
Prp8	B-DANMutation
.	O

The	O
Ski2-like	O
RNA	O
helicase	O
Brr2	O
is	O
a	O
core	O
component	O
of	O
the	O
spliceosome	O
that	O
must	O
be	O
tightly	O
regulated	O
to	O
ensure	O
correct	O
timing	O
of	O
spliceosome	O
activation	O
.	O

Little	O
is	O
known	O
about	O
mechanisms	O
of	O
regulation	O
of	O
Ski2-like	O
helicases	O
by	O
protein	O
cofactors	O
.	O

Here	O
we	O
show	O
by	O
crystal	O
structure	O
and	O
biochemical	O
analyses	O
that	O
the	O
Prp8	B-DNAMutation
protein	O
,	O
a	O
major	O
regulator	O
of	O
the	O
spliceosome	O
,	O
can	O
insert	O
its	O
C-terminal	O
tail	O
into	O
Brr2's	O
RNA-binding	O
tunnel	O
,	O
thereby	O
intermittently	O
blocking	O
Brr2's	O
RNA-binding	O
,	O
adenosine	O
triphosphatase	O
,	O
and	O
U4/U6	O
unwinding	O
activities	O
.	O

Inefficient	O
Brr2	O
repression	O
is	O
the	O
only	O
recognizable	O
phenotype	O
associated	O
with	O
certain	O
retinitis	O
pigmentosa-linked	O
Prp8	B-DNAMutation
mutations	B-DNAMutation
that	I-DNAMutation
map	I-DNAMutation
to	I-DNAMutation
its	I-DNAMutation
C-terminal	I-DNAMutation
tail	I-DNAMutation
.	O

Our	O
data	O
show	O
how	O
a	O
Ski2-like	O
RNA	O
helicase	O
can	O
be	O
reversibly	O
inhibited	O
by	O
a	O
protein	O
cofactor	O
that	O
directly	O
competes	O
with	O
RNA	O
substrate	O
binding	O
.	O

Substitutions	O
near	O
the	O
receptor	O
binding	O
site	O
determine	O
major	O
antigenic	O
change	O
during	O
influenza	O
virus	O
evolution	O
.	O

The	O
molecular	O
basis	O
of	O
antigenic	O
drift	O
was	O
determined	O
for	O
the	O
hemagglutinin	O
(HA)	O
of	O
human	O
influenza	O
A/H3N2	O
virus	O
.	O

From	O
1968	O
to	O
2003	O
,	O
antigenic	O
change	O
was	O
caused	O
mainly	O
by	O
single	B-DNAMutation
amino	I-DNAMutation
acid	I-DNAMutation
substitutions	I-DNAMutation
,	I-DNAMutation
which	I-DNAMutation
occurred	I-DNAMutation
at	I-DNAMutation
only	I-DNAMutation
seven	I-DNAMutation
positions	I-DNAMutation
in	I-DNAMutation
HA	I-DNAMutation
immediately	I-DNAMutation
adjacent	I-DNAMutation
to	I-DNAMutation
the	I-DNAMutation
receptor	I-DNAMutation
binding	I-DNAMutation
site	I-DNAMutation
.	O

Most	O
of	O
these	O
substitutions	O
were	O
involved	O
in	O
antigenic	O
change	O
more	O
than	O
once	O
.	O

Equivalent	O
positions	O
were	O
responsible	O
for	O
the	O
recent	O
antigenic	O
changes	O
of	O
influenza	O
B	O
and	O
A/H1N1	O
viruses	O
.	O

Substitution	B-DNAMutation
of	I-DNAMutation
a	I-DNAMutation
single	I-DNAMutation
amino	I-DNAMutation
acid	I-DNAMutation
at	I-DNAMutation
one	I-DNAMutation
of	I-DNAMutation
these	I-DNAMutation
positions	I-DNAMutation
substantially	O
changed	O
the	O
virus-specific	O
antibody	O
response	O
in	O
infected	O
ferrets	O
.	O

These	O
findings	O
have	O
potentially	O
far-reaching	O
consequences	O
for	O
understanding	O
the	O
evolutionary	O
mechanisms	O
that	O
govern	O
influenza	O
viruses	O
.	O

RNA	O
function	O
.	O

Ribosome	O
stalling	O
induced	O
by	O
mutation	O
of	O
a	O
CNS-specific	O
tRNA	O
causes	O
neurodegeneration	O
.	O

In	O
higher	O
eukaryotes	O
,	O
transfer	O
RNAs	O
(tRNAs)	O
with	O
the	O
same	O
anticodon	O
are	O
encoded	O
by	O
multiple	O
nuclear	O
genes	O
,	O
and	O
little	O
is	O
known	O
about	O
how	O
mutations	O
in	O
these	O
genes	O
affect	O
translation	O
and	O
cellular	O
homeostasis	O
.	O

Similarly	O
,	O
the	O
surveillance	O
systems	O
that	O
respond	O
to	O
such	O
defects	O
in	O
higher	O
eukaryotes	O
are	O
not	O
clear	O
.	O

Here	O
,	O
we	O
discover	O
that	O
loss	B-DNAMutation
of	I-DNAMutation
GTPBP2	I-DNAMutation
,	O
a	O
novel	O
binding	O
partner	O
of	O
the	O
ribosome	O
recycling	O
protein	O
Pelota	O
,	O
in	O
mice	O
with	O
a	O
mutation	O
in	O
a	O
tRNA	O
gene	O
that	O
is	O
specifically	O
expressed	O
in	O
the	O
central	O
nervous	O
system	O
causes	O
ribosome	O
stalling	O
and	O
widespread	O
neurodegeneration	O
.	O

Our	O
results	O
not	O
only	O
define	O
GTPBP2	O
as	O
a	O
ribosome	O
rescue	O
factor	O
but	O
also	O
unmask	O
the	O
disease	O
potential	O
of	O
mutations	O
in	O
nuclear-encoded	O
tRNA	O
genes	O
.	O

Cell-state-specific	O
metabolic	O
dependency	O
in	O
hematopoiesis	O
and	O
leukemogenesis	O
.	O

The	O
balance	O
between	O
oxidative	O
and	O
nonoxidative	O
glucose	O
metabolism	O
is	O
essential	O
for	O
a	O
number	O
of	O
pathophysiological	O
processes	O
.	O

By	O
deleting	O
enzymes	O
that	O
affect	O
aerobic	O
glycolysis	O
with	O
different	O
potencies	O
,	O
we	O
examine	O
how	O
modulating	O
glucose	O
metabolism	O
specifically	O
affects	O
hematopoietic	O
and	O
leukemic	O
cell	O
populations	O
.	O

We	O
find	O
that	O
a	O
deficiency	O
in	O
the	O
M2	O
pyruvate	O
kinase	O
isoform	O
(PKM2)	O
reduces	O
the	O
levels	O
of	O
metabolic	O
intermediates	O
important	O
for	O
biosynthesis	O
and	O
impairs	O
progenitor	O
function	O
without	O
perturbing	O
hematopoietic	O
stem	O
cells	O
(HSCs)	O
,	O
whereas	O
lactate	B-DNAMutation
dehydrogenase	I-DNAMutation
A	I-DNAMutation
(LDHA)	I-DNAMutation
deletion	I-DNAMutation
significantly	O
inhibits	O
the	O
function	O
of	O
both	O
HSCs	O
and	O
progenitors	O
during	O
hematopoiesis	O
.	O

In	O
contrast	O
,	O
leukemia	O
initiation	O
by	O
transforming	O
alleles	O
putatively	O
affecting	O
either	O
HSCs	O
or	O
progenitors	O
is	O
inhibited	O
in	O
the	O
absence	B-DNAMutation
of	I-DNAMutation
either	I-DNAMutation
PKM2	I-DNAMutation
or	I-DNAMutation
LDHA	I-DNAMutation
,	O
indicating	O
that	O
the	O
cell-state-specific	O
responses	O
to	O
metabolic	O
manipulation	O
in	O
hematopoiesis	O
do	O
not	O
apply	O
to	O
the	O
setting	O
of	O
leukemia	O
.	O

This	O
finding	O
suggests	O
that	O
fine-tuning	O
the	O
level	O
of	O
glycolysis	O
may be	O
explored	O
therapeutically	O
for	O
treating	O
leukemia	O
while	O
preserving	O
HSC	O
function	O
.	O

Use	O
of	O
human	O
embryonic	O
stem	O
cells	O
to	O
model	O
pediatric	O
gliomas	O
with	O
H3.3K27M	B-DANMutation
histone	O
mutation	O
.	O

Over	O
70%	O
of	O
diffuse	O
intrinsic	O
pediatric	O
gliomas	O
,	O
an	O
aggressive	O
brainstem	O
tumor	O
,	O
harbor	O
heterozygous	O
mutations	O
that	O
create	O
a	O
K27M	B-DNAMutation
amino	O
acid	O
substitution	O
(	O
methionine	B-DNAMutation
replaces	I-DNAMutation
lysine	I-DNAMutation
27	I-DNAMutation
)	O
in	O
the	O
tail	O
of	O
histone	O
H3.3	O
.	O

The	O
role	O
of	O
the	O
H3.3K27M	B-DNAMutation
mutation	O
in	O
tumorigenesis	O
is	O
not	O
fully	O
understood	O
.	O

Here	O
,	O
we	O
use	O
a	O
human	O
embryonic	O
stem	O
cell	O
system	O
to	O
model	O
this	O
tumor	O
.	O

We	O
show	O
that	O
H3.3K27M	B-DNAMutation
expression	O
synergizes	O
with	O
p53	O
loss	O
and	O
PDGFRA	O
activation	O
in	O
neural	O
progenitor	O
cells	O
derived	O
from	O
human	O
embryonic	O
stem	O
cells	O
,	O
resulting	O
in	O
neoplastic	O
transformation	O
.	O

Genome-wide	O
analyses	O
indicate	O
a	O
resetting	O
of	O
the	O
transformed	O
precursors	O
to	O
a	O
developmentally	O
more	O
primitive	O
stem	O
cell	O
state	O
,	O
with	O
evidence	O
of	O
major	O
modifications	O
of	O
histone	O
marks	O
at	O
several	O
master	O
regulator	O
genes	O
.	O

Drug	O
screening	O
assays	O
identified	O
a	O
compound	O
targeting	O
the	O
protein	O
menin	O
as	O
an	O
inhibitor	O
of	O
tumor	O
cell	O
growth	O
in	O
vitro	O
and	O
in	O
mice	O
.	O

Gle1	O
functions	O
during	O
mRNA	O
export	O
in	O
an	O
oligomeric	O
complex	O
that	O
is	O
altered	O
in	O
human	O
disease	O
.	O

The	O
conserved	O
multifunctional	O
protein	O
Gle1	O
regulates	O
gene	O
expression	O
at	O
multiple	O
steps	O
:	O
nuclear	O
mRNA	O
export	O
,	O
translation	O
initiation	O
,	O
and	O
translation	O
termination	O
.	O

A	O
GLE1	O
mutation	O
(FinMajor)	O
is	O
causally	O
linked	O
to	O
human	O
lethal	O
congenital	O
contracture	O
syndrome-1	O
(LCCS1)	O
;	O
however	O
,	O
the	O
resulting	O
perturbations	O
on	O
Gle1	O
molecular	O
function	O
were	O
unknown	O
.	O

FinMajor	O
results	O
in	O
a	O
proline-phenylalanine-glutamine	B-DNAMutation
peptide	I-DNAMutation
insertion	I-DNAMutation
within	I-DNAMutation
the	I-DNAMutation
uncharacterized	I-DNAMutation
Gle1	I-DNAMutation
coiled-coil	I-DNAMutation
domain	I-DNAMutation
.	O

Here	O
,	O
we	O
find	O
that	O
Gle1	O
self-associates	O
both	O
in	O
vitro	O
and	O
in	O
living	O
cells	O
via	O
the	O
coiled-coil	O
domain	O
.	O

Electron	O
microscopy	O
reveals	O
that	O
high-molecular-mass	O
Gle1	O
oligomers	O
form	O
?26	O
nm	O
diameter	O
disk-shaped	O
particles	O
.	O

With	O
the	O
Gle1-FinMajor	O
protein	O
,	O
these	O
particles	O
are	O
malformed	O
.	O

Moreover	O
,	O
functional	O
assays	O
document	O
a	O
specific	O
requirement	O
for	O
proper	O
Gle1	O
oligomerization	O
during	O
mRNA	O
export	O
,	O
but	O
not	O
for	O
Gle1's	O
roles	O
in	O
translation	O
.	O

These	O
results	O
identify	O
a	O
mechanistic	O
step	O
in	O
Gle1's	O
mRNA	O
export	O
function	O
at	O
nuclear	O
pore	O
complexes	O
and	O
directly	O
implicate	O
altered	O
export	O
in	O
LCCS1	O
disease	O
pathology	O
.	O

Cancer-associated	O
PTEN	B-DANMutation
mutants	O
act	O
in	O
a	O
dominant-negative	O
manner	O
to	O
suppress	O
PTEN	B-DANMutation
protein	O
function	O
.	O

PTEN	B-DNAMutation
dysfunction	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
pathogenesis	O
of	O
hereditary	O
and	O
sporadic	O
cancers	O
.	O

Here	O
,	O
we	O
show	O
that	O
PTEN	B-DNAMutation
homodimerizes	O
and	O
,	O
in	O
this	O
active	O
conformation	O
,	O
exerts	O
lipid	O
phosphatase	O
activity	O
on	O
PtdIns(3,4,5)P3	O
.	O

We	O
demonstrate	O
that	O
catalytically	O
inactive	O
cancer-associated	O
PTEN	B-DNAMutation
mutants	O
heterodimerize	O
with	O
wild-type	O
PTEN	B-DNAMutation
and	O
constrain	O
its	O
phosphatase	O
activity	O
in	O
a	O
dominant-negative	O
manner	O
.	O

To	O
study	O
the	O
consequences	O
of	O
homo-	O
and	O
heterodimerization	O
of	O
wild-type	O
and	O
mutant	O
PTEN	B-DNAMutation
in	O
vivo	O
,	O
we	O
generated	O
Pten	B-DNAMutation
knockin	O
mice	O
harboring	O
two	O
cancer-associated	O
PTEN	B-DNAMutation
mutations	O
(	O
PtenC124S	B-DNAMutation
and	O
PtenG129E	B-DNAMutation
)	O
.	O

Heterozygous	O
Pten(C124S/+)	B-DNAMutation
and	O
Pten(G129E/+)	B-DNAMutation
cells	O
and	O
tissues	O
exhibit	O
increased	O
sensitivity	O
to	O
PI3-K/Akt	O
activation	O
compared	O
to	O
wild-type	O
and	O
Pten(+/-)	B-DNAMutation
counterparts	O
,	O
whereas	O
this	O
difference	O
is	O
no	O
longer	O
apparent	O
between	O
Pten(C124S/-)	B-DNAMutation
and	O
Pten(-/-)	B-DNAMutation
cells	O
.	O

Notably	O
,	O
Pten	B-DNAMutation
KI	O
mice	O
are	O
more	O
tumor	O
prone	O
and	O
display	O
features	O
reminiscent	O
of	O
complete	O
Pten	B-DNAMutation
loss	O
.	O

Our	O
findings	O
reveal	O
that	O
PTEN	B-DNAMutation
loss	O
and	O
PTEN	B-DNAMutation
mutations	O
are	O
not	O
synonymous	O
and	O
define	O
a	O
working	O
model	O
for	O
the	O
function	O
and	O
regulation	O
of	O
PTEN	B-DNAMutation
.	O

The	O
toxicity	O
of	O
antiprion	O
antibodies	O
is	O
mediated	O
by	O
the	O
flexible	O
tail	O
of	O
the	O
prion	O
protein	O
.	O

Prion	O
infections	O
cause	O
lethal	O
neurodegeneration	O
.	O

This	O
process	O
requires	O
the	O
cellular	O
prion	O
protein	O
(	O
PrP(C	B-DNAMutation
)	O
;	O
ref	O
.	O

1	O
)	O
,	O
which	O
contains	O
a	O
globular	O
domain	O
hinged	O
to	O
a	O
long	O
amino-proximal	O
flexible	O
tail	O
.	O

Here	O
we	O
describe	O
rapid	O
neurotoxicity	O
in	O
mice	O
and	O
cerebellar	O
organotypic	O
cultured	O
slices	O
exposed	O
to	O
ligands	O
targeting	O
the	O
α1	O
and	O
α3	O
helices	O
of	O
the	B-DNAMutation
PrP(C)	I-DNAMutation
globular	O
domain	O
.	O

Ligands	O
included	O
seven	O
distinct	O
monoclonal	O
antibodies	O
,	O
monovalent	O
Fab1	O
fragments	O
and	O
recombinant	O
single-chain	O
variable	O
fragment	O
miniantibodies	O
.	O

Similar	O
to	O
prion	O
infections	O
,	O
the	O
toxicity	O
of	O
globular	O
domain	O
ligands	O
required	O
neuronal	B-DNAMutation
PrP(C)	I-DNAMutation
,	O
was	O
exacerbated	O
by	B-DNAMutation
PrP(C)	I-DNAMutation
overexpression	O
,	O
was	O
associated	O
with	O
calpain	O
activation	O
and	O
was	O
antagonized	O
by	O
calpain	O
inhibitors	O
.	O

Neurodegeneration	O
was	O
accompanied	O
by	O
a	O
burst	O
of	O
reactive	O
oxygen	O
species	O
,	O
and	O
was	O
suppressed	O
by	O
antioxidants	O
.	O

Furthermore	O
,	O
genetic	O
ablation	O
of	O
the	O
superoxide-producing	O
enzyme	B-DNAMutation
NOX2	I-DNAMutation
(	O
also	O
known	O
as	B-DNAMutation
CYBB	I-DNAMutation
)	O
protected	O
mice	O
from	O
globular	O
domain	O
ligand	O
toxicity	O
.	O

We	O
also	O
found	O
that	O
neurotoxicity	O
was	O
prevented	O
by	B-DNAMutation
deletions	I-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
octapeptide	I-DNAMutation
repeats	I-DNAMutation
within	I-DNAMutation
the	I-DNAMutation
flexible	I-DNAMutation
tail	I-DNAMutation
.	O

These	O
deletions	O
did	O
not	O
appreciably	O
compromise	O
globular	O
domain	O
antibody	O
binding	O
,	O
suggesting	O
that	O
the	O
flexible	O
tail	O
is	O
required	O
to	O
transmit	O
toxic	O
signals	O
that	O
originate	O
from	O
the	O
globular	O
domain	O
and	O
trigger	O
oxidative	O
stress	O
and	O
calpain	O
activation	O
.	O

Supporting	O
this	O
view	O
,	O
various	B-DNAMutation
octapeptide	I-DNAMutation
ligands	O
were	O
not	O
only	O
innocuous	O
to	O
both	O
cerebellar	O
organotypic	O
cultured	O
slices	O
and	O
mice	O
,	O
but	O
also	O
prevented	O
the	O
toxicity	O
of	O
globular	O
domain	O
ligands	O
while	O
not	O
interfering	O
with	O
their	O
binding	O
.	O

We	O
conclude	O
that	B-DNAMutation
PrP(C)	I-DNAMutation
consists	O
of	O
two	O
functionally	O
distinct	O
modules	O
,	O
with	O
the	O
globular	O
domain	O
and	O
the	O
flexible	O
tail	O
exerting	O
regulatory	O
and	O
executive	O
functions	O
,	O
respectively	B-DNAMutation
.	I-DNAMutation
Octapeptide	I-DNAMutation
ligands	O
also	O
prolonged	O
the	O
life	O
of	O
mice	O
expressing	O
the	O
toxic	B-DNAMutation
PrP(C)	I-DNAMutation
mutant	B-DNAMutation
,	I-DNAMutation
PrP(Δ94-134)	B-DNAMutation
,	O
indicating	O
that	O
the	O
flexible	O
tail	O
mediates	O
toxicity	O
in	O
two	O
distinct	B-DNAMutation
PrP(C)-related	I-DNAMutation
conditions	O
.	O

Flexible	O
tail-mediated	O
toxicity	O
may	O
conceivably	O
play	O
a	O
role	O
in	O
further	O
prion	O
pathologies	O
,	O
such	O
as	O
familial	O
Creutzfeldt-Jakob	O
disease	O
in	O
humans	O
bearing	O
supernumerary	O
octapeptides	O
.	O

Criteria	O
for	O
inference	O
of	O
chromothripsis	B-DANMutation
in	O
cancer	O
genomes	O
.	O

Chromothripsis	B-DNAMutation
scars	O
the	O
genome	O
when	O
localized	O
chromosome	O
shattering	O
and	O
repair	O
occurs	O
in	O
a	O
one-off	B-DNAMutation
catastrophe	I-DNAMutation
.	O

Outcomes	O
of	O
this	O
process	O
are	O
detectable	O
as	O
massive	B-DNAMutation
DNA	I-DNAMutation
rearrangements	I-DNAMutation
affecting	O
one	O
or	O
a	O
few	O
chromosomes	O
.	O

Although	O
recent	O
findings	O
suggest	O
a	O
crucial	O
role	O
of	O
chromothripsis	B-DNAMutation
in	O
cancer	O
development	O
,	O
the	O
reproducible	O
inference	O
of	O
this	O
process	O
remains	O
challenging	O
,	O
requiring	O
that	O
cataclysmic	B-DNAMutation
one-off	I-DNAMutation
rearrangements	I-DNAMutation
be	O
distinguished	O
from	O
localized	O
lesions	O
that	O
occur	O
progressively	O
.	O

We	O
describe	O
conceptual	O
criteria	O
for	O
the	O
inference	O
of	O
chromothripsis	B-DNAMutation
,	O
based	O
on	O
ruling	O
out	O
the	O
alternative	O
hypothesis	O
that	O
stepwise	O
rearrangements	O
occurred	O
.	O

Robust	O
means	O
of	O
inference	O
may	O
facilitate	O
in-depth	O
studies	O
on	O
the	O
impact	O
of	O
,	O
and	O
the	O
mechanisms	O
underlying	O
,	O
chromothripsis	B-DNAMutation
.	O

Genetic	O
and	O
clonal	O
dissection	O
of	O
murine	O
small	O
cell	O
lung	O
carcinoma	O
progression	O
by	O
genome	O
sequencing	O
.	O

Small	O
cell	O
lung	O
carcinoma	O
(SCLC)	O
is	O
a	O
highly	O
lethal	O
,	O
smoking-associated	O
cancer	O
with	O
few	O
known	O
targetable	O
genetic	O
alterations	O
.	O

Using	O
genome	O
sequencing	O
,	O
we	O
characterized	O
the	O
somatic	O
evolution	O
of	O
a	O
genetically	O
engineered	O
mouse	O
model	O
(GEMM)	O
of	O
SCLC	O
initiated	O
by	O
loss	B-DNAMutation
of	I-DNAMutation
Trp53	I-DNAMutation
and	I-DNAMutation
Rb1	I-DNAMutation
.	O

We	O
identified	O
alterations	O
in	O
DNA	O
copy	O
number	O
and	O
complex	O
genomic	O
rearrangements	O
and	O
demonstrated	O
a	O
low	O
somatic	O
point	O
mutation	O
frequency	O
in	O
the	O
absence	O
of	O
tobacco	O
mutagens	O
.	O

Alterations	O
targeting	O
the	O
tumor	O
suppressor	O
Pten	O
occurred	O
in	O
the	O
majority	O
of	O
murine	O
SCLC	O
studied	O
,	O
and	O
engineered	B-DNAMutation
Pten	I-DNAMutation
deletion	I-DNAMutation
accelerated	O
murine	O
SCLC	O
and	O
abrogated	B-DNAMutation
loss	I-DNAMutation
of	I-DNAMutation
Chr19	I-DNAMutation
in	I-DNAMutation
Trp53	I-DNAMutation
;	I-DNAMutation
Rb1	I-DNAMutation
;	I-DNAMutation
Pten	I-DNAMutation
compound	I-DNAMutation
mutant	I-DNAMutation
tumors	I-DNAMutation
.	O

Finally	O
,	O
we	O
found	O
evidence	O
for	O
polyclonal	O
and	O
sequential	O
metastatic	O
spread	O
of	O
murine	O
SCLC	O
by	O
comparative	O
sequencing	O
of	O
families	O
of	O
related	O
primary	O
tumors	O
and	O
metastases	O
.	O

We	O
propose	O
a	O
temporal	O
model	O
of	O
SCLC	O
tumorigenesis	O
with	O
implications	O
for	O
human	O
SCLC	O
therapeutics	O
and	O
the	O
nature	O
of	O
cancer-genome	O
evolution	O
in	O
GEMMs	O
.	O

Following	O
gene	O
duplication	O
,	O
paralog	O
interference	O
constrains	O
transcriptional	O
circuit	O
evolution	O
.	O

Most	O
models	O
of	O
gene	O
duplication	O
assume	O
that	O
the	O
ancestral	O
functions	O
of	O
the	O
preduplication	O
gene	O
are	O
independent	O
and	O
can	O
therefore	O
be	O
neatly	O
partitioned	O
between	O
descendant	O
paralogs	O
.	O

However	O
,	O
many	O
gene	O
products	O
,	O
such	O
as	O
transcriptional	O
regulators	O
,	O
are	O
components	O
within	O
cooperative	O
assemblies	O
;	O
here	O
,	O
we	O
show	O
that	O
a	O
natural	O
consequence	O
of	O
duplication	O
and	O
divergence	O
of	O
such	O
proteins	O
can	O
be	O
competitive	O
interference	O
between	O
the	O
paralogs	O
.	O

Our	O
example	O
is	O
based	O
on	O
the	O
duplication	B-DNAMutation
of	O
the	O
essential	O
MADS-box	O
transcriptional	O
regulator	O
Mcm1	O
,	O
which	O
is	O
found	O
in	O
all	O
fungi	O
and	O
regulates	O
a	O
large	O
set	O
of	O
genes	O
.	O

We	O
show	O
that	O
a	O
set	O
of	O
historical	O
amino	O
acid	O
sequence	O
substitutions	O
minimized	O
paralog	O
interference	O
in	O
contemporary	O
species	O
and	O
,	O
in	O
doing	O
so	O
,	O
increased	O
the	O
molecular	O
complexity	O
of	O
this	O
gene	O
regulatory	O
network	O
.	O

We	O
propose	O
that	O
paralog	O
interference	O
is	O
a	O
common	O
constraint	O
on	O
gene	O
duplicate	O
evolution	O
,	O
and	O
its	O
resolution	O
,	O
which	O
can	O
generate	O
additional	O
regulatory	O
complexity	O
,	O
is	O
needed	O
to	O
stabilize	O
duplicated	O
genes	O
in	O
the	O
genome	O
.	O

Mutations	O
in	O
DCHS1	B-DANMutation
cause	O
mitral	O
valve	O
prolapse	O
.	O

Mitral	O
valve	O
prolapse	O
(MVP)	O
is	O
a	O
common	O
cardiac	O
valve	O
disease	O
that	O
affects	O
nearly	O
1	O
in	O
40	O
individuals	O
.	O

It	O
can	O
manifest	O
as	O
mitral	O
regurgitation	O
and	O
is	O
the	O
leading	O
indication	O
for	O
mitral	O
valve	O
surgery	O
.	O

Despite	O
a	O
clear	O
heritable	O
component	O
,	O
the	O
genetic	O
aetiology	O
leading	O
to	O
non-syndromic	O
MVP	O
has	O
remained	O
elusive	O
.	O

Four	O
affected	O
individuals	O
from	O
a	O
large	O
multigenerational	O
family	O
segregating	O
non-syndromic	O
MVP	O
underwent	O
capture	O
sequencing	O
of	O
the	O
linked	O
interval	O
on	O
chromosome	O
11	O
.	O

We	O
report	O
a	O
missense	O
mutation	O
in	O
the	O
DCHS1	B-DNAMutation
gene	O
,	O
the	O
human	O
homologue	O
of	O
the	O
Drosophila	O
cell	O
polarity	O
gene	O
dachsous	O
(ds)	O
,	O
that	O
segregates	O
with	O
MVP	O
in	O
the	O
family	O
.	O

Morpholino	B-DNAMutation
knockdown	I-DNAMutation
of	O
the	O
zebrafish	O
homologue	O
dachsous1b	B-DNAMutation
resulted	O
in	O
a	O
cardiac	O
atrioventricular	O
canal	O
defect	O
that	O
could	O
be	O
rescued	O
by	O
wild-type	O
human	O
DCHS1	B-DNAMutation
,	O
but	O
not	O
by	O
DCHS1	B-DNAMutation
messenger	O
RNA	O
with	O
the	O
familial	O
mutation	O
.	O

Further	O
genetic	O
studies	O
identified	O
two	O
additional	O
families	O
in	O
which	O
a	O
second	O
deleterious	O
DCHS1	B-DNAMutation
mutation	O
segregates	O
with	O
MVP	O
.	O

Both	O
DCHS1	B-DNAMutation
mutations	O
reduce	O
protein	O
stability	O
as	O
demonstrated	O
in	O
zebrafish	O
,	O
cultured	O
cells	O
and	O
,	O
notably	O
,	O
in	O
mitral	O
valve	O
interstitial	O
cells	O
(MVICs)	O
obtained	O
during	O
mitral	O
valve	O
repair	O
surgery	O
of	O
a	O
proband	O
.	O

Dchs1(+/-)	O
mice	O
had	O
prolapse	O
of	O
thickened	O
mitral	O
leaflets	O
,	O
which	O
could	O
be	O
traced	O
back	O
to	O
developmental	O
errors	O
in	O
valve	O
morphogenesis	O
.	O

DCHS1	B-DNAMutation
deficiency	O
in	O
MVP	O
patient	O
MVICs	O
,	O
as	O
well	O
as	O
in	O
Dchs1(+/-)	O
mouse	O
MVICs	O
,	O
result	O
in	O
altered	O
migration	O
and	O
cellular	O
patterning	O
,	O
supporting	O
these	O
processes	O
as	O
aetiological	O
underpinnings	O
for	O
the	O
disease	O
.	O

Understanding	O
the	O
role	O
of	O
DCHS1	B-DNAMutation
in	O
mitral	O
valve	O
development	O
and	O
MVP	O
pathogenesis	O
holds	O
potential	O
for	O
therapeutic	O
insights	O
for	O
this	O
very	O
common	O
disease	O
.	O

Insulator	O
dysfunction	O
and	O
oncogene	O
activation	O
in	O
IDH	B-DANMutation
mutant	O
gliomas	O
.	O

Gain-of-function	O
IDH	B-DNAMutation
mutations	O
are	O
initiating	O
events	O
that	O
define	O
major	O
clinical	O
and	O
prognostic	O
classes	O
of	O
gliomas	O
.	O

Mutant	O
IDH	B-DNAMutation
protein	O
produces	O
a	O
new	O
onco-metabolite	O
,	O
2-hydroxyglutarate	O
,	O
which	O
interferes	O
with	O
iron-dependent	O
hydroxylases	O
,	O
including	O
the	O
TET	O
family	O
of	O
5'-methylcytosine	O
hydroxylases	O
.	O

TET	O
enzymes	O
catalyse	O
a	O
key	O
step	O
in	O
the	O
removal	O
of	O
DNA	O
methylation	O
.	O

IDH	B-DNAMutation
mutant	O
gliomas	O
thus	O
manifest	O
a	O
CpG	O
island	O
methylator	O
phenotype	O
(G-CIMP)	O
,	O
although	O
the	O
functional	O
importance	O
of	O
this	O
altered	O
epigenetic	O
state	O
remains	O
unclear	O
.	O

Here	O
we	O
show	O
that	O
human	O
IDH	B-DNAMutation
mutant	O
gliomas	O
exhibit	O
hypermethylation	O
at	O
cohesin	O
and	O
CCCTC-binding	O
factor	O
(CTCF)-binding	B-DNAMutation
sites	O
,	O
compromising	O
binding	O
of	O
this	O
methylation-sensitive	O
insulator	O
protein	O
.	O

Reduced	O
CTCF	B-DNAMutation
binding	O
is	O
associated	O
with	O
loss	O
of	O
insulation	O
between	O
topological	O
domains	O
and	O
aberrant	O
gene	O
activation	O
.	O

We	O
specifically	O
demonstrate	O
that	O
loss	B-DNAMutation
of	I-DNAMutation
CTCF	I-DNAMutation
at	I-DNAMutation
a	I-DNAMutation
domain	I-DNAMutation
boundary	I-DNAMutation
permits	O
a	O
constitutive	O
enhancer	O
to	O
interact	O
aberrantly	O
with	O
the	O
receptor	O
tyrosine	O
kinase	O
gene	O
PDGFRA	B-DNAMutation
,	O
a	O
prominent	O
glioma	O
oncogene	O
.	O

Treatment	O
of	O
IDH	B-DNAMutation
mutant	O
gliomaspheres	O
with	O
a	O
demethylating	O
agent	O
partially	O
restores	O
insulator	O
function	O
and	O
downregulates	O
PDGFRA	B-DNAMutation
.	O

Conversely	O
,	O
CRISPR-mediated	O
disruption	O
of	O
the	O
CTCF	B-DNAMutation
motif	O
in	O
IDH	B-DNAMutation
wild-type	O
gliomaspheres	O
upregulates	O
PDGFRA	B-DNAMutation
and	O
increases	O
proliferation	O
.	O

Our	O
study	O
suggests	O
that	O
IDH	B-DNAMutation
mutations	O
promote	O
gliomagenesis	O
by	O
disrupting	O
chromosomal	O
topology	O
and	O
allowing	O
aberrant	O
regulatory	O
interactions	O
that	O
induce	O
oncogene	O
expression	O
.	O

Constitutional	O
and	O
somatic	O
rearrangement	O
of	O
chromosome	O
21	O
in	O
acute	O
lymphoblastic	O
leukaemia	O
.	O

Changes	O
in	O
gene	O
dosage	O
are	O
a	O
major	O
driver	O
of	O
cancer	O
,	O
known	O
to	O
be	O
caused	O
by	O
a	O
finite	O
,	O
but	O
increasingly	O
well	O
annotated	O
,	O
repertoire	O
of	O
mutational	O
mechanisms	O
.	O

This	O
can	O
potentially	O
generate	O
correlated	O
copy-number	O
alterations	O
across	O
hundreds	O
of	O
linked	O
genes	O
,	O
as	O
exemplified	O
by	O
the	O
2%	O
of	O
childhood	O
acute	O
lymphoblastic	O
leukaemia	O
(ALL)	O
with	O
recurrent	O
amplification	B-DNAMutation
of	I-DNAMutation
megabase	I-DNAMutation
regions	I-DNAMutation
of	I-DNAMutation
chromosome	I-DNAMutation
21	I-DNAMutation
iAMP21	B-DNAMutation
.	O

We	O
used	O
genomic	O
,	O
cytogenetic	O
and	O
transcriptional	O
analysis	O
,	O
coupled	O
with	O
novel	O
bioinformatic	O
approaches	O
,	O
to	O
reconstruct	O
the	O
evolution	O
of	O
iAMP21	B-DNAMutation
ALL	O
.	O

Here	O
we	O
show	O
that	O
individuals	O
born	O
with	O
the	O
rare	O
constitutional	O
Robertsonian	B-DNAMutation
translocation	I-DNAMutation
between	I-DNAMutation
chromosomes	I-DNAMutation
15	I-DNAMutation
and	I-DNAMutation
21	I-DNAMutation
,	O
rob(15;21)(q10;q10)c	B-DNAMutation
,	O
have	O
approximately	O
2,700-fold	O
increased	O
risk	O
of	O
developing	O
iAMP21	B-DNAMutation
ALL	O
compared	O
to	O
the	O
general	O
population	O
.	O

In	O
such	O
cases	O
,	O
amplification	O
is	O
initiated	O
by	O
a	O
chromothripsis	O
event	O
involving	O
both	O
sister	O
chromatids	O
of	O
the	O
Robertsonian	O
chromosome	O
,	O
a	O
novel	O
mechanism	O
for	O
cancer	O
predisposition	O
.	O

In	O
sporadic	O
iAMP21	B-DNAMutation
,	O
breakage-fusion-bridge	O
cycles	O
are	O
typically	O
the	O
initiating	O
event	O
,	O
often	O
followed	O
by	O
chromothripsis	O
.	O

In	O
both	O
sporadic	O
and	O
rob(15;21)c-associated	B-DNAMutation
iAMP21	B-DNAMutation
,	O
the	O
final	O
stages	O
frequently	O
involve	O
duplications	O
of	O
the	O
entire	O
abnormal	O
chromosome	O
.	O

The	O
end-product	O
is	O
a	O
derivative	O
of	O
chromosome	O
21	O
or	O
the	O
rob(15;21)c	B-DNAMutation
chromosome	O
with	O
gene	O
dosage	O
optimized	O
for	O
leukaemic	O
potential	O
,	O
showing	O
constrained	O
copy-number	O
levels	O
over	O
multiple	O
linked	O
genes	O
.	O

Thus	O
,	O
dicentric	O
chromosomes	O
may	O
be	O
an	O
important	O
precipitant	O
of	O
chromothripsis	O
,	O
as	O
we	O
show	O
rob(15;21)c	B-DNAMutation
to	O
be	O
constitutionally	O
dicentric	O
and	O
breakage-fusion-bridge	O
cycles	O
generate	O
dicentric	O
chromosomes	O
somatically	O
.	O

Furthermore	O
,	O
our	O
data	O
illustrate	O
that	O
several	O
cancer-specific	O
mutational	O
processes	O
,	O
applied	O
sequentially	O
,	O
can	O
coordinate	O
to	O
fashion	O
copy-number	O
profiles	O
over	O
large	O
genomic	O
scales	O
,	O
incrementally	O
refining	O
the	O
fitness	O
benefits	O
of	O
aggregated	O
gene	O
dosage	O
changes	O
.	O

Control	O
of	O
somatic	O
tissue	O
differentiation	O
by	O
the	O
long	O
non-coding	O
RNA	O
TINCR	O
.	O

Several	O
of	O
the	O
thousands	O
of	O
human	O
long	O
non-coding	O
RNAs	O
(lncRNAs)	O
have	O
been	O
functionally	O
characterized	O
;	O
however	O
,	O
potential	O
roles	O
for	O
lncRNAs	O
in	O
somatic	O
tissue	O
differentiation	O
remain	O
poorly	O
understood	O
.	O

Here	O
we	O
show	O
that	O
a	O
3.7-kilobase	O
lncRNA	O
,	O
terminal	O
differentiation-induced	O
ncRNA	O
(TINCR)	O
,	O
controls	O
human	O
epidermal	O
differentiation	O
by	O
a	O
post-transcriptional	O
mechanism	O
.	O

TINCR	O
is	O
required	O
for	O
high	O
messenger	O
RNA	O
abundance	O
of	O
key	O
differentiation	O
genes	O
,	O
many	O
of	O
which	O
are	O
mutated	O
in	O
human	O
skin	O
diseases	O
,	O
including	O
FLG	O
,	O
LOR	O
,	O
ALOXE3	O
,	O
ALOX12B	O
,	O
ABCA12	O
,	O
CASP14	O
and	O
ELOVL3	O
.	O

TINCR-deficient	O
epidermis	O
lacked	O
terminal	O
differentiation	O
ultrastructure	O
,	O
including	O
keratohyalin	O
granules	O
and	O
intact	O
lamellar	O
bodies	O
.	O

Genome-scale	O
RNA	O
interactome	O
analysis	O
revealed	O
that	O
TINCR	O
interacts	O
with	O
a	O
range	O
of	O
differentiation	O
mRNAs	O
.	O

TINCR-mRNA	O
interaction	O
occurs	O
through	O
a	O
25-nucleotide	O
'TINCR	O
box'	O
motif	O
that	O
is	O
strongly	O
enriched	O
in	O
interacting	O
mRNAs	O
and	O
required	O
for	O
TINCR	O
binding	O
.	O

A	O
high-throughput	O
screen	O
to	O
analyse	O
TINCR	O
binding	O
capacity	O
to	O
approximately	O
9,400	O
human	O
recombinant	O
proteins	O
revealed	O
direct	O
binding	O
of	O
TINCR	O
RNA	O
to	O
the	O
staufen1	O
(STAU1)	O
protein	O
.	O

STAU1-deficient	O
tissue	O
recapitulated	O
the	O
impaired	O
differentiation	O
seen	O
with	O
TINCR	O
depletion	O
.	O

Loss	B-DNAMutation
of	O
UPF1	O
and	O
UPF2	O
,	O
both	O
of	O
which	O
are	O
required	O
for	O
STAU1-mediated	O
RNA	O
decay	O
,	O
however	O
,	O
did	O
not	O
have	O
differentiation	O
effects	O
.	O

Instead	O
,	O
the	O
TINCR-STAU1	O
complex	O
seems	O
to	O
mediate	O
stabilization	O
of	O
differentiation	O
mRNAs	O
,	O
such	O
as	O
KRT80	O
.	O

These	O
data	O
identify	O
TINCR	O
as	O
a	O
key	O
lncRNA	O
required	O
for	O
somatic	O
tissue	O
differentiation	O
,	O
which	O
occurs	O
through	O
lncRNA	O
binding	O
to	O
differentiation	O
mRNAs	O
to	O
ensure	O
their	O
expression	O
.	O

Conversion	O
of	O
channelrhodopsin	O
into	O
a	O
light-gated	O
chloride	O
channel	O
.	O

The	O
field	O
of	O
optogenetics	O
uses	O
channelrhodopsins	O
(ChRs)	O
for	O
light-induced	O
neuronal	O
activation	O
.	O

However	O
,	O
optimized	O
tools	O
for	O
cellular	O
inhibition	O
at	O
moderate	O
light	O
levels	O
are	O
lacking	O
.	O

We	O
found	O
that	O
replacement	B-DNAMutation
of	I-DNAMutation
E90	I-DNAMutation
in	I-DNAMutation
the	I-DNAMutation
central	I-DNAMutation
gate	I-DNAMutation
of	I-DNAMutation
ChR	I-DNAMutation
with	I-DNAMutation
positively	I-DNAMutation
charged	I-DNAMutation
residues	I-DNAMutation
produces	O
chloride-conducting	O
ChRs	O
(ChloCs)	O
with	O
only	O
negligible	O
cation	O
conductance	O
.	O

Molecular	O
dynamics	O
modeling	O
unveiled	O
that	O
a	O
high-affinity	O
Cl(-)-binding	O
site	O
had	O
been	O
generated	O
near	O
the	O
gate	O
.	O

Stabilizing	O
the	O
open	O
state	O
dramatically	O
increased	O
the	O
operational	O
light	O
sensitivity	O
of	O
expressing	O
cells	O
(	O
slow	O
ChloC	O
)	O
.	O

In	O
CA1	O
pyramidal	O
cells	O
,	O
ChloCs	O
completely	O
inhibited	O
action	O
potentials	O
triggered	O
by	O
depolarizing	O
current	O
injections	O
or	O
synaptic	O
stimulation	O
.	O

Thus	O
,	O
by	O
inverting	O
the	O
charge	O
of	O
the	O
selectivity	O
filter	O
,	O
we	O
have	O
created	O
a	O
class	O
of	O
directly	O
light-gated	O
anion	O
channels	O
that	O
can	O
be	O
used	O
to	O
block	O
neuronal	O
output	O
in	O
a	O
fully	O
reversible	O
fashion	O
.	O

Structural	O
basis	O
for	O
hijacking	O
of	O
cellular	O
LxxLL	O
motifs	O
by	O
papillomavirus	O
E6	B-DANMutation
oncoproteins	O
.	O

E6	B-DNAMutation
viral	O
oncoproteins	O
are	O
key	O
players	O
in	O
epithelial	O
tumors	O
induced	O
by	O
papillomaviruses	O
in	O
vertebrates	O
,	O
including	O
cervical	O
cancer	O
in	O
humans	O
.	O

E6	B-DNAMutation
proteins	O
target	O
many	O
host	O
proteins	O
by	O
specifically	O
interacting	O
with	O
acidic	O
LxxLL	O
motifs	O
.	O

We	O
solved	O
the	O
crystal	O
structures	O
of	O
bovine	B-DNAMutation
BPV1	B-DNAMutation
and	O
human	B-DNAMutation
HPV16	B-DNAMutation
papillomavirus	O
E6	B-DNAMutation
proteins	O
bound	O
to	O
LxxLL	O
peptides	O
from	O
the	O
focal	O
adhesion	O
protein	O
paxillin	O
and	O
the	O
ubiquitin	O
ligase	O
E6AP	O
,	O
respectively	O
.	O

In	O
both	O
E6	B-DNAMutation
proteins	O
,	O
two	O
zinc	O
domains	O
and	O
a	O
linker	O
helix	O
form	O
a	O
basic-hydrophobic	O
pocket	O
,	O
which	O
captures	O
helical	O
LxxLL	O
motifs	O
in	O
a	O
way	O
compatible	O
with	O
other	O
interaction	O
modes	O
.	O

Mutational	B-DNAMutation
inactivation	I-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
LxxLL	I-DNAMutation
binding	I-DNAMutation
pocket	I-DNAMutation
disrupts	O
the	O
oncogenic	O
activities	O
of	O
both	O
E6	B-DNAMutation
proteins	O
.	O

This	O
work	O
reveals	O
the	O
structural	O
basis	O
of	O
both	O
the	O
multifunctionality	O
and	O
the	O
oncogenicity	O
of	O
E6	B-DNAMutation
proteins	O
.	O

Inappropriate	O
p53	O
activation	O
during	O
development	O
induces	O
features	O
of	O
CHARGE	O
syndrome	O
.	O

CHARGE	O
syndrome	O
is	O
a	O
multiple	O
anomaly	O
disorder	O
in	O
which	O
patients	O
present	O
with	O
a	O
variety	O
of	O
phenotypes	O
,	O
including	O
ocular	O
coloboma	O
,	O
heart	O
defects	O
,	O
choanal	O
atresia	O
,	O
retarded	O
growth	O
and	O
development	O
,	O
genitourinary	O
hypoplasia	O
and	O
ear	O
abnormalities	O
.	O

Despite	O
70-90%	O
of	O
CHARGE	O
syndrome	O
cases	O
resulting	O
from	O
mutations	O
in	O
the	O
gene	O
CHD7	O
,	O
which	O
encodes	O
an	O
ATP-dependent	O
chromatin	O
remodeller	O
,	O
the	O
pathways	O
underlying	O
the	O
diverse	O
phenotypes	O
remain	O
poorly	O
understood	O
.	O

Surprisingly	O
,	O
our	O
studies	O
of	O
a	O
knock-in	B-DNAMutation
mutant	I-DNAMutation
mouse	I-DNAMutation
strain	I-DNAMutation
that	I-DNAMutation
expresses	I-DNAMutation
a	I-DNAMutation
stabilized	I-DNAMutation
and	I-DNAMutation
transcriptionally	I-DNAMutation
dead	I-DNAMutation
variant	I-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
tumour-suppressor	I-DNAMutation
protein	I-DNAMutation
p53	I-DNAMutation
(p53(25,26,53,54))	I-DNAMutation
,	O
along	O
with	O
a	O
wild-type	O
allele	O
of	O
p53	O
(	O
also	O
known	O
as	O
Trp53	O
)	O
,	O
revealed	O
late-gestational	O
embryonic	O
lethality	O
associated	O
with	O
a	O
host	O
of	O
phenotypes	O
that	O
are	O
characteristic	O
of	O
CHARGE	O
syndrome	O
,	O
including	O
coloboma	O
,	O
inner	O
and	O
outer	O
ear	O
malformations	O
,	O
heart	O
outflow	O
tract	O
defects	O
and	O
craniofacial	O
defects	O
.	O

We	O
found	O
that	O
the	O
p53(25,26,53,54)	O
mutant	O
protein	O
stabilized	O
and	O
hyperactivated	O
wild-type	O
p53	O
,	O
which	O
then	O
inappropriately	O
induced	O
its	O
target	O
genes	O
and	O
triggered	O
cell-cycle	O
arrest	O
or	O
apoptosis	O
during	O
development	O
.	O

Importantly	O
,	O
these	O
phenotypes	O
were	O
only	O
observed	O
with	O
a	O
wild-type	O
p53	O
allele	O
,	O
as	O
p53(25,26,53,54)(/-)	O
embryos	O
were	O
fully	O
viable	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
CHD7	O
can	O
bind	O
to	O
the	O
p53	O
promoter	O
,	O
thereby	O
negatively	O
regulating	O
p53	O
expression	O
,	O
and	O
that	O
CHD7	B-DNAMutation
loss	I-DNAMutation
in	O
mouse	O
neural	O
crest	O
cells	O
or	O
samples	O
from	O
patients	O
with	O
CHARGE	O
syndrome	O
results	O
in	O
p53	O
activation	O
.	O

Strikingly	O
,	O
we	O
found	O
that	O
p53	O
heterozygosity	O
partially	O
rescued	O
the	O
phenotypes	O
in	O
Chd7-null	O
mouse	O
embryos	O
,	O
demonstrating	O
that	O
p53	O
contributes	O
to	O
the	O
phenotypes	O
that	O
result	O
from	O
CHD7	B-DNAMutation
loss	I-DNAMutation
.	O

Thus	O
,	O
inappropriate	O
p53	O
activation	O
during	O
development	O
can	O
promote	O
CHARGE	O
phenotypes	O
,	O
supporting	O
the	O
idea	O
that	O
p53	O
has	O
a	O
critical	O
role	O
in	O
developmental	O
syndromes	O
and	O
providing	O
important	O
insight	O
into	O
the	O
mechanisms	O
underlying	O
CHARGE	O
syndrome	O
.	O

Social	O
reward	O
requires	O
coordinated	O
activity	O
of	O
nucleus	O
accumbens	O
oxytocin	O
and	O
serotonin	O
.	O

Social	O
behaviours	O
in	O
species	O
as	O
diverse	O
as	O
honey	O
bees	O
and	O
humans	O
promote	O
group	O
survival	O
but	O
often	O
come	O
at	O
some	O
cost	O
to	O
the	O
individual	O
.	O

Although	O
reinforcement	O
of	O
adaptive	O
social	O
interactions	O
is	O
ostensibly	O
required	O
for	O
the	O
evolutionary	O
persistence	O
of	O
these	O
behaviours	O
,	O
the	O
neural	O
mechanisms	O
by	O
which	O
social	O
reward	O
is	O
encoded	O
by	O
the	O
brain	O
are	O
largely	O
unknown	O
.	O

Here	O
we	O
demonstrate	O
that	O
in	O
mice	O
oxytocin	O
acts	O
as	O
a	O
social	O
reinforcement	O
signal	O
within	O
the	O
nucleus	O
accumbens	O
core	O
,	O
where	O
it	O
elicits	O
a	O
presynaptically	O
expressed	O
long-term	O
depression	O
of	O
excitatory	O
synaptic	O
transmission	O
in	O
medium	O
spiny	O
neurons	O
.	O

Although	O
the	O
nucleus	O
accumbens	O
receives	O
oxytocin-receptor-containing	O
inputs	O
from	O
several	O
brain	O
regions	O
,	O
genetic	O
deletion	B-DNAMutation
of	I-DNAMutation
these	I-DNAMutation
receptors	I-DNAMutation
specifically	O
from	O
dorsal	O
raphe	O
nucleus	O
,	O
which	O
provides	O
serotonergic	O
(	O
5-hydroxytryptamine	O
;	O
5-HT	O
)	O
innervation	O
to	O
the	O
nucleus	O
accumbens	O
,	O
abolishes	O
the	O
reinforcing	O
properties	O
of	O
social	O
interaction	O
.	O

Furthermore	O
,	O
oxytocin-induced	O
synaptic	O
plasticity	O
requires	O
activation	O
of	O
nucleus	O
accumbens	O
5-HT1B	O
receptors	O
,	O
the	O
blockade	O
of	O
which	O
prevents	O
social	O
reward	O
.	O

These	O
results	O
demonstrate	O
that	O
the	O
rewarding	O
properties	O
of	O
social	O
interaction	O
in	O
mice	O
require	O
the	O
coordinated	O
activity	O
of	O
oxytocin	O
and	O
5-HT	O
in	O
the	O
nucleus	O
accumbens	O
,	O
a	O
mechanistic	O
insight	O
with	O
implications	O
for	O
understanding	O
the	O
pathogenesis	O
of	O
social	O
dysfunction	O
in	O
neuropsychiatric	O
disorders	O
such	O
as	O
autism	O
.	O

A	O
common	O
Greenlandic	O
TBC1D4	O
variant	O
confers	O
muscle	O
insulin	O
resistance	O
and	O
type	O
2	O
diabetes	O
.	O

The	O
Greenlandic	O
population	O
,	O
a	O
small	O
and	O
historically	O
isolated	O
founder	O
population	O
comprising	O
about	O
57,000	O
inhabitants	O
,	O
has	O
experienced	O
a	O
dramatic	O
increase	O
in	O
type	O
2	O
diabetes	O
(T2D)	O
prevalence	O
during	O
the	O
past	O
25	O
years	O
.	O

Motivated	O
by	O
this	O
,	O
we	O
performed	O
association	O
mapping	O
of	O
T2D-related	O
quantitative	O
traits	O
in	O
up	O
to	O
2,575	O
Greenlandic	O
individuals	O
without	O
known	O
diabetes	O
.	O

Using	O
array-based	O
genotyping	O
and	O
exome	O
sequencing	O
,	O
we	O
discovered	O
a	O
nonsense	O
p.Arg684Ter	B-DNAMutation
variant	O
(	O
in	O
which	O
arginine	B-DNAMutation
is	I-DNAMutation
replaced	I-DNAMutation
by	I-DNAMutation
a	I-DNAMutation
termination	I-DNAMutation
codon	I-DNAMutation
)	O
in	O
the	O
gene	O
TBC1D4	O
with	O
an	O
allele	O
frequency	O
of	O
17%	O
.	O

Here	O
we	O
show	O
that	O
homozygous	O
carriers	O
of	O
this	O
variant	O
have	O
markedly	O
higher	O
concentrations	O
of	O
plasma	O
glucose	O
(	O
β	O
=	O
3.8 mmol l(-1)	O
,	O
P	O
=	O
2.5 × 10(-35)	O
)	O
and	O
serum	O
insulin	O
(	O
β	O
=	O
165 pmol l(-1)	O
,	O
P	O
=	O
1.5 × 10(-20)	O
)	O
2	O
hours	O
after	O
an	O
oral	O
glucose	O
load	O
compared	O
with	O
individuals	O
with	O
other	O
genotypes	O
(	O
both	O
non-carriers	O
and	O
heterozygous	O
carriers	O
)	O
.	O

Furthermore	O
,	O
homozygous	O
carriers	O
have	O
marginally	O
lower	O
concentrations	O
of	O
fasting	O
plasma	O
glucose	O
(	O
β	O
=	O
-0.18	O
mmol l(-1)	O
,	O
P	O
=	O
1.1 × 10(-6)	O
)	O
and	O
fasting	O
serum	O
insulin	O
(	O
β	O
=	O
-8.3 pmol l(-1)	O
,	O
P	O
=	O
0.0014	O
)	O
,	O
and	O
their	O
T2D	O
risk	O
is	O
markedly	O
increased	O
(	O
odds	O
ratio	O
(OR)	O
=	O
10.3	O
,	O
P	O
=	O
1.6 × 10(-24)	O
)	O
.	O

Heterozygous	O
carriers	O
have	O
a	O
moderately	O
higher	O
plasma	O
glucose	O
concentration	O
2	O
hours	O
after	O
an	O
oral	O
glucose	O
load	O
than	O
non-carriers	O
(	O
β	O
=	O
0.43 mmol l(-1)	O
,	O
P	O
=	O
5.3 × 10(-5)	O
)	O
.	O

Analyses	O
of	O
skeletal	O
muscle	O
biopsies	O
showed	O
lower	O
messenger	O
RNA	O
and	O
protein	O
levels	O
of	O
the	O
long	O
isoform	O
of	O
TBC1D4	O
,	O
and	O
lower	O
muscle	O
protein	O
levels	O
of	O
the	O
glucose	B-DNAMutation
transporter	I-DNAMutation
GLUT4	O
,	O
with	O
increasing	O
number	O
of	O
p.Arg684Ter	O
alleles	O
.	O

These	O
findings	O
are	O
concomitant	O
with	O
a	O
severely	O
decreased	O
insulin-stimulated	O
glucose	O
uptake	O
in	O
muscle	O
,	O
leading	O
to	O
postprandial	O
hyperglycaemia	O
,	O
impaired	O
glucose	O
tolerance	O
and	O
T2D	O
.	O

The	O
observed	O
effect	O
sizes	O
are	O
several	O
times	O
larger	O
than	O
any	O
previous	O
findings	O
in	O
large-scale	O
genome-wide	O
association	O
studies	O
of	O
these	O
traits	O
and	O
constitute	O
further	O
proof	O
of	O
the	O
value	O
of	O
conducting	O
genetic	O
association	O
studies	O
outside	O
the	O
traditional	O
setting	O
of	O
large	O
homogeneous	O
populations	O
.	O

Impaired	O
α-TTP-PIPs	I-DANMutation
interaction	O
underlies	O
familial	O
vitamin	O
E	O
deficiency	O
.	O

α-Tocopherol	O
(	O
vitamin	O
E	O
)	O
transfer	O
protein	B-DNAMutation
(α-TTP)	I-DNAMutation
regulates	O
the	O
secretion	O
of	O
α-tocopherol	O
from	O
liver	O
cells	B-DNAMutation
.	I-DNAMutation
Missense	I-DNAMutation
mutations	I-DNAMutation
of	I-DNAMutation
some	I-DNAMutation
arginine	I-DNAMutation
residues	I-DNAMutation
at	I-DNAMutation
the	I-DNAMutation
surface	I-DNAMutation
of	I-DNAMutation
α-TTP	O
cause	O
severe	O
vitamin	O
E	O
deficiency	O
in	O
humans	O
,	O
but	O
the	O
role	O
of	O
these	O
residues	O
is	O
unclear	O
.	O

Here	O
,	O
we	O
found	O
that	O
wild-type	B-DNAMutation
α-TTP	O
bound	O
phosphatidylinositol	O
phosphates	O
(PIPs)	O
,	O
whereas	O
the	O
arginine	O
mutants	O
did	O
not	O
.	O

In	O
addition	O
,	O
PIPs	O
in	O
the	O
target	O
membrane	O
promoted	O
the	O
intermembrane	O
transfer	O
of	O
α-tocopherol	B-DNAMutation
by	O
α-TTP	O
.	O

The	O
crystal	O
structure	B-DNAMutation
of	I-DNAMutation
the	O
α-TTP-PIPs	O
complex	O
revealed	O
that	O
the	O
disease-related	O
arginine	O
residues	O
interacted	O
with	O
phosphate	O
groups	O
of	O
the	O
PIPs	O
and	O
that	O
the	O
PIPs	O
binding	O
caused	O
the	O
lid	O
of	O
the	O
α-tocopherol-binding	O
pocket	O
to	O
open	O
.	O

Thus	O
,	O
PIPs	O
have	O
a	O
role	O
in	O
promoting	O
the	O
release	O
of	O
a	O
ligand	O
from	O
a	O
lipid-transfer	O
protein	O
.	O

SERINC3	O
and	O
SERINC5	O
restrict	O
HIV-1	O
infectivity	O
and	O
are	O
counteracted	O
by	O
Nef	O
.	O

HIV-1	O
Nef	O
and	O
the	O
unrelated	O
mouse	O
leukaemia	O
virus	O
glycosylated	O
Gag	O
(glycoGag)	O
strongly	O
enhance	O
the	O
infectivity	O
of	O
HIV-1	O
virions	O
produced	O
in	O
certain	O
cell	O
types	O
in	O
a	O
clathrin-dependent	O
manner	O
.	O

Here	O
we	O
show	O
that	O
Nef	O
and	O
glycoGag	O
prevent	O
the	O
incorporation	O
of	O
the	O
multipass	O
transmembrane	O
proteins	O
serine	O
incorporator	O
3	O
(SERINC3)	O
and	O
SERINC5	O
into	O
HIV-1	O
virions	O
to	O
an	O
extent	O
that	O
correlates	O
with	O
infectivity	O
enhancement	O
.	O

Silencing	O
of	O
both	O
SERINC3	O
and	O
SERINC5	O
precisely	O
phenocopied	O
the	O
effects	O
of	O
Nef	O
and	O
glycoGag	O
on	O
HIV-1	O
infectivity	O
.	O

The	O
infectivity	O
of	O
nef-deficient	O
virions	O
increased	O
more	O
than	O
100-fold	O
when	O
produced	O
in	O
double-knockout	B-DNAMutation
human	O
CD4(+)	O
T	O
cells	O
that	O
lack	O
both	O
SERINC3	O
and	O
SERINC5	O
,	O
and	O
re-expression	O
experiments	O
confirmed	O
that	O
the	O
absence	O
of	O
SERINC3	O
and	O
SERINC5	O
accounted	O
for	O
the	O
infectivity	O
enhancement	O
.	O

Furthermore	O
,	O
SERINC3	O
and	O
SERINC5	O
together	O
restricted	O
HIV-1	O
replication	O
,	O
and	O
this	O
restriction	O
was	O
evaded	O
by	O
Nef	O
.	O

SERINC3	O
and	O
SERINC5	O
are	O
highly	O
expressed	O
in	O
primary	O
human	O
HIV-1	O
target	O
cells	O
,	O
and	O
inhibiting	O
their	O
downregulation	O
by	O
Nef	O
is	O
a	O
potential	O
strategy	O
to	O
combat	O
HIV/AIDS	O
.	O

Pumilio1	O
haploinsufficiency	O
leads	O
to	O
SCA1-like	O
neurodegeneration	O
by	O
increasing	O
wild-type	O
Ataxin1	O
levels	O
.	O

Spinocerebellar	O
ataxia	O
type	O
1	O
(SCA1)	O
is	O
a	O
paradigmatic	O
neurodegenerative	O
proteinopathy	O
,	O
in	O
which	O
a	O
mutant	O
protein	O
(	O
in	O
this	O
case	O
,	O
ATAXIN1	O
)	O
accumulates	O
in	O
neurons	O
and	O
exerts	O
toxicity	O
;	O
in	O
SCA1	O
,	O
this	O
process	O
causes	O
progressive	O
deterioration	O
of	O
motor	O
coordination	O
.	O

Seeking	O
to	O
understand	O
how	O
post-translational	O
modification	O
of	O
ATAXIN1	O
levels	O
influences	O
disease	O
,	O
we	O
discovered	O
that	O
the	O
RNA-binding	O
protein	O
PUMILIO1	O
(PUM1)	O
not	O
only	O
directly	O
regulates	O
ATAXIN1	O
but	O
also	O
plays	O
an	O
unexpectedly	O
important	O
role	O
in	O
neuronal	O
function	O
.	O

Loss	B-DNAMutation
of	O
Pum1	O
caused	O
progressive	O
motor	O
dysfunction	O
and	O
SCA1-like	O
neurodegeneration	O
with	O
motor	O
impairment	O
,	O
primarily	O
by	O
increasing	O
Ataxin1	O
levels	O
.	O

Breeding	O
Pum1(+/-)	O
mice	O
to	O
SCA1	O
mice	O
(Atxn1(154Q/+))	O
exacerbated	O
disease	O
progression	O
,	O
whereas	O
breeding	O
them	O
to	O
Atxn1(+/-)	O
mice	O
normalized	O
Ataxin1	O
levels	O
and	O
largely	O
rescued	O
the	O
Pum1(+/-)	O
phenotype	O
.	O

Thus	O
,	O
both	O
increased	O
wild-type	O
ATAXIN1	O
levels	O
and	O
PUM1	O
haploinsufficiency	O
could	O
contribute	O
to	O
human	O
neurodegeneration	O
.	O

These	O
results	O
demonstrate	O
the	O
importance	O
of	O
studying	O
post-transcriptional	O
regulation	O
of	O
disease-driving	O
proteins	O
to	O
reveal	O
factors	O
underlying	O
neurodegenerative	O
disease	O
.	O

Prkcz	B-DANMutation
null	O
mice	O
show	O
normal	O
learning	O
and	O
memory	O
.	O

Protein	I-DNAMutation
kinase	I-DNAMutation
M-ζ	I-DNAMutation
(PKM-ζ)	I-DNAMutation
is	O
a	O
constitutively	O
active	O
form	O
of	O
atypical	O
protein	O
kinase	O
C	O
that	O
is	O
exclusively	O
expressed	O
in	O
the	O
brain	O
and	O
implicated	O
in	O
the	O
maintenance	O
of	O
long-term	O
memory	O
.	O

Most	O
studies	O
that	O
support	O
a	O
role	O
for	B-DNAMutation
PKM-ζ	I-DNAMutation
in	O
memory	O
maintenance	O
have	O
used	O
pharmacological	B-DNAMutation
PKM-ζ	I-DNAMutation
inhibitors	O
such	O
as	O
the	O
myristoylated	O
zeta	O
inhibitory	O
peptide	O
(ZIP)	O
or	O
chelerythrine	O
.	O

Here	O
we	O
use	O
a	O
genetic	O
approach	O
and	O
target	O
exon	O
9	O
of	O
the	I-DNAMutation
Prkcz	O
gene	O
to	O
generate	O
mice	O
that	B-DNAMutation
lack	I-DNAMutation
both	I-DNAMutation
protein	I-DNAMutation
kinase	I-DNAMutation
C-ζ	I-DNAMutation
(PKC-ζ)	I-DNAMutation
and	I-DNAMutation
PKM-ζ	I-DNAMutation
(	I-DNAMutation
Prkcz(-/-	I-DNAMutation
)	B-DNAMutation
mice	I-DNAMutation
)	I-DNAMutation
.	I-DNAMutation
Prkcz(-/-)	I-DNAMutation
mice	O
showed	O
normal	O
behaviour	O
in	O
a	O
cage	O
environment	O
and	O
in	O
baseline	O
tests	O
of	O
motor	O
function	O
and	O
sensory	O
perception	O
,	O
but	O
displayed	O
reduced	O
anxiety-like	O
behaviour	O
.	O

Notably	B-DNAMutation
,	I-DNAMutation
Prkcz(-/-)	I-DNAMutation
mice	O
did	O
not	O
show	O
deficits	O
in	O
learning	O
or	O
memory	O
in	O
tests	O
of	O
cued	O
fear	O
conditioning	O
,	O
novel	O
object	O
recognition	O
,	O
object	O
location	O
recognition	O
,	O
conditioned	O
place	O
preference	O
for	O
cocaine	O
,	O
or	O
motor	O
learning	O
,	O
when	O
compared	O
with	O
wild-type	O
littermates	O
.	O

ZIP	O
injection	O
into	O
the	O
nucleus	O
accumbens	O
reduced	O
expression	O
of	O
cocaine-conditioned	O
place	O
preference	B-DNAMutation
in	I-DNAMutation
Prkcz(-/-)	I-DNAMutation
mice	O
.	O

In	O
vitro	O
,	O
ZIP	O
and	O
scrambled	O
ZIP	O
inhibited	B-DNAMutation
PKM-ζ	I-DNAMutation
,	O
PKC-ι	B-DNAMutation
and	O
PKC-ζ	O
with	O
similar	O
inhibition	O
constant	O
(K(i))	O
values	O
.	O

Chelerythrine	O
was	O
a	O
weak	O
inhibitor	B-DNAMutation
of	O
PKM-ζ	O
(	O
K(i	O
)	O
=	O
76 μM	O
)	O
.	O

Our	O
findings	O
show	O
that	B-DNAMutation
absence	I-DNAMutation
of	O
PKM-ζ	O
does	O
not	O
impair	O
learning	O
and	O
memory	O
in	O
mice	O
,	O
and	O
that	O
ZIP	O
can	O
erase	O
reward	O
memory	B-DNAMutation
even	O
when	O
PKM-ζ	O
is	O
not	O
present	O
.	O

Replication	O
stress	O
links	O
structural	O
and	O
numerical	O
cancer	O
chromosomal	O
instability	O
.	O

Cancer	O
chromosomal	O
instability	O
(CIN)	O
results	O
in	O
an	O
increased	O
rate	O
of	O
change	O
of	O
chromosome	O
number	O
and	O
structure	O
and	O
generates	O
intratumour	O
heterogeneity	O
.	O

CIN	O
is	O
observed	O
in	O
most	O
solid	O
tumours	O
and	O
is	O
associated	O
with	O
both	O
poor	O
prognosis	O
and	O
drug	O
resistance	O
.	O

Understanding	O
a	O
mechanistic	O
basis	O
for	O
CIN	O
is	O
therefore	O
paramount	O
.	O

Here	O
we	O
find	O
evidence	O
for	O
impaired	O
replication	O
fork	O
progression	O
and	O
increased	O
DNA	O
replication	O
stress	O
in	O
CIN(+)	O
colorectal	O
cancer	O
(CRC)	O
cells	O
relative	O
to	O
CIN(-)	O
CRC	O
cells	O
,	O
with	O
structural	O
chromosome	O
abnormalities	O
precipitating	O
chromosome	O
missegregation	O
in	O
mitosis	O
.	O

We	O
identify	O
three	O
new	O
CIN-suppressor	O
genes	O
(	O
PIGN	O
(	O
also	O
known	O
as	O
MCD4	O
)	O
,	O
MEX3C	O
(RKHD2)	O
and	O
ZNF516	O
(	O
KIAA0222	O
)	O
)	O
encoded	O
on	O
chromosome	O
18q	O
that	O
are	O
subject	O
to	O
frequent	O
copy	O
number	O
loss	O
in	O
CIN(+)	O
CRC	O
.	O

Chromosome	B-DNAMutation
18q	I-DNAMutation
loss	I-DNAMutation
was	O
temporally	O
associated	O
with	O
aneuploidy	O
onset	O
at	O
the	O
adenoma-carcinoma	O
transition	O
.	O

CIN-suppressor	O
gene	O
silencing	O
leads	O
to	O
DNA	O
replication	O
stress	O
,	O
structural	O
chromosome	O
abnormalities	O
and	O
chromosome	O
missegregation	O
.	O

Supplementing	O
cells	O
with	O
nucleosides	O
,	O
to	O
alleviate	O
replication-associated	O
damage	O
,	O
reduces	O
the	O
frequency	O
of	O
chromosome	O
segregation	O
errors	O
after	O
CIN-suppressor	O
gene	O
silencing	O
,	O
and	O
attenuates	O
segregation	O
errors	O
and	O
DNA	O
damage	O
in	O
CIN(+)	O
cells	O
.	O

These	O
data	O
implicate	O
a	O
central	O
role	O
for	O
replication	O
stress	O
in	O
the	O
generation	O
of	O
structural	O
and	O
numerical	O
CIN	O
,	O
which	O
may	O
inform	O
new	O
therapeutic	O
approaches	O
to	O
limit	O
intratumour	O
heterogeneity	O
.	O

Chromatin	O
remodeling	O
at	O
DNA	O
double-strand	B-DANMutation
breaks	I-DANMutation
.	O

DNA	O
double-strand	B-DNAMutation
breaks	I-DNAMutation
DSBs	B-DNAMutation
can	O
arise	O
from	O
multiple	O
sources	O
,	O
including	O
exposure	O
to	O
ionizing	O
radiation	O
.	O

The	O
repair	O
of	O
DSBs	B-DNAMutation
involves	O
both	O
posttranslational	O
modification	O
of	O
nucleosomes	O
and	O
concentration	O
of	O
DNA-repair	O
proteins	O
at	O
the	O
site	O
of	O
damage	O
.	O

Consequently	O
,	O
nucleosome	O
packing	O
and	O
chromatin	O
architecture	O
surrounding	O
the	O
DSB	B-DNAMutation
may	O
limit	O
the	O
ability	O
of	O
the	O
DNA-damage	O
response	O
to	O
access	O
and	O
repair	O
the	O
break	O
.	O

Here	O
,	O
we	O
review	O
early	O
chromatin-based	O
events	O
that	O
promote	O
the	O
formation	O
of	O
open	O
,	O
relaxed	O
chromatin	O
structures	O
at	O
DSBs	B-DNAMutation
and	O
that	O
allow	O
the	O
DNA-repair	O
machinery	O
to	O
access	O
the	O
spatially	O
confined	O
region	O
surrounding	O
the	O
DSB	B-DNAMutation
,	O
thereby	O
facilitating	O
mammalian	O
DSB	B-DNAMutation
repair	O
.	O

PKM2	O
isoform-specific	O
deletion	B-DANMutation
reveals	O
a	O
differential	O
requirement	O
for	O
pyruvate	O
kinase	O
in	O
tumor	O
cells	O
.	O

The	O
pyruvate	O
kinase	O
M2	O
isoform	O
(PKM2)	O
is	O
expressed	O
in	O
cancer	O
and	O
plays	O
a	O
role	O
in	O
regulating	O
anabolic	O
metabolism	O
.	O

To	O
determine	O
whether	O
PKM2	O
is	O
required	O
for	O
tumor	O
formation	O
or	O
growth	O
,	O
we	O
generated	O
mice	O
with	O
a	O
conditional	O
allele	O
that	O
abolishes	O
PKM2	O
expression	O
without	O
disrupting	O
PKM1	O
expression	O
.	O

PKM2	O
deletion	B-DNAMutation
accelerated	O
mammary	O
tumor	O
formation	O
in	O
a	O
Brca1-loss-driven	O
model	O
of	O
breast	O
cancer	O
.	O

PKM2	O
null	O
tumors	O
displayed	O
heterogeneous	O
PKM1	O
expression	O
,	O
with	O
PKM1	O
found	O
in	O
nonproliferating	O
tumor	O
cells	O
and	O
no	O
detectable	O
pyruvate	O
kinase	O
expression	O
in	O
proliferating	O
cells	O
.	O

This	O
suggests	O
that	O
PKM2	O
is	O
not	O
necessary	O
for	O
tumor	O
cell	O
proliferation	O
and	O
implies	O
that	O
the	O
inactive	O
state	O
of	O
PKM2	O
is	O
associated	O
with	O
the	O
proliferating	O
cell	O
population	O
within	O
tumors	O
,	O
whereas	O
nonproliferating	O
tumor	O
cells	O
require	O
active	O
pyruvate	O
kinase	O
.	O

Consistent	O
with	O
these	O
findings	O
,	O
variable	O
PKM2	O
expression	O
and	O
heterozygous	O
PKM2	O
mutations	O
are	O
found	O
in	O
human	O
tumors	O
.	O

These	O
data	O
suggest	O
that	O
regulation	O
of	O
PKM2	O
activity	O
supports	O
the	O
different	O
metabolic	O
requirements	O
of	O
proliferating	O
and	O
nonproliferating	O
tumor	O
cells	O
.	O

Total	O
synthesis	O
of	O
a	O
functional	O
designer	O
eukaryotic	O
chromosome	O
.	O

Rapid	O
advances	O
in	O
DNA	O
synthesis	O
techniques	O
have	O
made	O
it	O
possible	O
to	O
engineer	O
viruses	O
,	O
biochemical	O
pathways	O
and	O
assemble	O
bacterial	O
genomes	O
.	O

Here	O
,	O
we	O
report	O
the	O
synthesis	O
of	O
a	O
functional	O
272,871-base	O
pair	O
designer	O
eukaryotic	O
chromosome	O
,	O
synIII	O
,	O
which	O
is	O
based	O
on	O
the	O
316,617-base	O
pair	O
native	O
Saccharomyces	O
cerevisiae	O
chromosome	O
III	O
.	O

Changes	O
to	O
synIII	O
include	O
TAG/TAA	B-DNAMutation
stop-codon	I-DNAMutation
replacements	I-DNAMutation
,	O
deletion	B-DNAMutation
of	I-DNAMutation
subtelomeric	I-DNAMutation
regions	I-DNAMutation
,	O
introns	O
,	O
transfer	O
RNAs	O
,	O
transposons	O
,	O
and	O
silent	O
mating	O
loci	O
as	O
well	O
as	O
insertion	O
of	O
loxPsym	O
sites	O
to	O
enable	O
genome	O
scrambling	O
.	O

SynIII	O
is	O
functional	O
in	O
S	O
.	O

cerevisiae	O
.	O

Scrambling	O
of	O
the	O
chromosome	O
in	O
a	O
heterozygous	O
diploid	O
reveals	O
a	O
large	O
increase	O
in	O
a-mater	O
derivatives	O
resulting	O
from	O
loss	B-DNAMutation
of	O
the	O
MATα	O
allele	O
on	O
synIII	O
.	O

The	O
complete	O
design	O
and	O
synthesis	O
of	O
synIII	O
establishes	O
S	O
.	O

cerevisiae	O
as	O
the	O
basis	O
for	O
designer	O
eukaryotic	O
genome	O
biology	O
.	O

Modelling	O
vemurafenib	O
resistance	O
in	O
melanoma	O
reveals	O
a	O
strategy	O
to	O
forestall	O
drug	O
resistance	O
.	O

Mutational	O
activation	O
of	O
BRAF	O
is	O
the	O
most	O
prevalent	O
genetic	O
alteration	O
in	O
human	O
melanoma	O
,	O
with ≥50%	O
of	O
tumours	O
expressing	O
the	O
BRAF(V600E)	B-DNAMutation
oncoprotein	O
.	O

Moreover	O
,	O
the	O
marked	O
tumour	O
regression	O
and	O
improved	O
survival	O
of	O
late-stage	O
BRAF-mutated	O
melanoma	O
patients	O
in	O
response	O
to	O
treatment	O
with	O
vemurafenib	O
demonstrates	O
the	O
essential	O
role	O
of	O
oncogenic	O
BRAF	O
in	O
melanoma	O
maintenance	O
.	O

However	O
,	O
as	O
most	O
patients	O
relapse	O
with	O
lethal	O
drug-resistant	O
disease	O
,	O
understanding	O
and	O
preventing	O
mechanism(s)	O
of	O
resistance	O
is	O
critical	O
to	O
providing	O
improved	O
therapy	O
.	O

Here	O
we	O
investigate	O
the	O
cause	O
and	O
consequences	O
of	O
vemurafenib	O
resistance	O
using	O
two	O
independently	O
derived	O
primary	O
human	O
melanoma	O
xenograft	O
models	O
in	O
which	O
drug	O
resistance	O
is	O
selected	O
by	O
continuous	O
vemurafenib	O
administration	O
.	O

In	O
one	O
of	O
these	O
models	O
,	O
resistant	O
tumours	O
show	O
continued	O
dependency	O
on	O
BRAF(V600E)→MEK→ERK	B-DNAMutation
signalling	O
owing	O
to	O
elevated	B-DNAMutation
BRAF(V600E)	I-DNAMutation
expression	O
.	O

Most	O
importantly	O
,	O
we	O
demonstrate	O
that	O
vemurafenib-resistant	O
melanomas	O
become	O
drug	O
dependent	O
for	O
their	O
continued	O
proliferation	O
,	O
such	O
that	O
cessation	O
of	O
drug	O
administration	O
leads	O
to	O
regression	O
of	O
established	O
drug-resistant	O
tumours	O
.	O

We	O
further	O
demonstrate	O
that	O
a	O
discontinuous	O
dosing	O
strategy	O
,	O
which	O
exploits	O
the	O
fitness	O
disadvantage	O
displayed	O
by	O
drug-resistant	O
cells	O
in	O
the	O
absence	O
of	O
the	O
drug	O
,	O
forestalls	O
the	O
onset	O
of	O
lethal	O
drug-resistant	O
disease	O
.	O

These	O
data	O
highlight	O
the	O
concept	O
that	O
drug-resistant	O
cells	O
may	O
also	O
display	O
drug	O
dependency	O
,	O
such	O
that	O
altered	O
dosing	O
may	O
prevent	O
the	O
emergence	O
of	O
lethal	O
drug	O
resistance	O
.	O

Such	O
observations	O
may	O
contribute	O
to	O
sustaining	O
the	O
durability	O
of	O
the	O
vemurafenib	O
response	O
with	O
the	O
ultimate	O
goal	O
of	O
curative	O
therapy	O
for	O
the	O
subset	O
of	O
melanoma	O
patients	O
with	O
BRAF	O
mutations	O
.	O

Structure-function	O
analysis	O
of	O
STING	O
activation	O
by	O
c[G(2',5')pA(3',5')p]	O
and	O
targeting	O
by	O
antiviral	O
DMXAA	O
.	O

Binding	O
of	O
dsDNA	O
by	O
cyclic	O
GMP-AMP	O
(cGAMP)	O
synthase	O
(cGAS)	O
triggers	O
formation	O
of	O
the	O
metazoan	O
second	O
messenger	O
c[G(2',5')pA(3',5')p]	O
,	O
which	O
binds	O
the	O
signaling	O
protein	O
STING	O
with	O
subsequent	O
activation	O
of	O
the	O
interferon	O
(IFN)	O
pathway	O
.	O

We	O
show	O
that	O
human	O
hSTING(H232)	O
adopts	O
a	O
"closed"	O
conformation	O
upon	O
binding	O
c[G(2',5')pA(3',5')p]	O
and	O
its	O
linkage	O
isomer	O
c[G(2',5')pA(2',5')p]	O
,	O
as	O
does	O
mouse	O
mSting(R231)	O
on	O
binding	O
c[G(2',5')pA(3',5')p]	O
,	O
c[G(3',5')pA(3',5')p]	O
and	O
the	O
antiviral	O
agent	O
DMXAA	O
,	O
leading	O
to	O
similar	O
"closed"	O
conformations	O
.	O

Comparing	O
hSTING	O
to	O
mSting	O
,	O
2',5'-linkage-containing	O
cGAMP	O
isomers	O
were	O
more	O
specific	O
triggers	O
of	O
the	O
IFN	O
pathway	O
compared	O
to	O
the	O
all-3',5'-linkage	O
isomer	O
.	O

Guided	O
by	O
structural	O
information	O
,	O
we	O
identified	O
a	O
unique	O
point	O
mutation	O
S162A	B-DNAMutation
placed	O
within	O
the	O
cyclic-dinucleotide-binding	O
site	O
of	O
hSTING	O
that	O
rendered	O
it	O
sensitive	O
to	O
the	O
otherwise	O
mouse-specific	O
drug	O
DMXAA	O
,	O
a	O
conclusion	O
validated	O
by	O
binding	O
studies	O
.	O

Our	O
structural	O
and	O
functional	O
analysis	O
highlights	O
the	O
unexpected	O
versatility	O
of	O
STING	O
in	O
the	O
recognition	O
of	O
natural	O
and	O
synthetic	O
ligands	O
within	O
a	O
small-molecule	O
pocket	O
created	O
by	O
the	O
dimerization	O
of	O
STING	O
.	O

Dietary	O
modulation	O
of	O
the	O
microbiome	O
affects	O
autoinflammatory	O
disease	O
.	O

The	O
incidences	O
of	O
chronic	O
inflammatory	O
disorders	O
have	O
increased	O
considerably	O
over	O
the	O
past	O
three	O
decades	O
.	O

Recent	O
shifts	O
in	O
dietary	O
consumption	O
may	O
have	O
contributed	O
importantly	O
to	O
this	O
surge	O
,	O
but	O
how	O
dietary	O
consumption	O
modulates	O
inflammatory	O
disease	O
is	O
poorly	O
defined	O
.	O

Pstpip2(cmo)	O
mice	O
,	O
which	O
express	O
a	O
homozygous	O
Leu98Pro	B-DNAMutation
missense	O
mutation	O
in	O
the	O
Pombe	O
Cdc15	O
homology	O
family	O
protein	O
PSTPIP2	O
(	O
proline-serine-threonine	O
phosphatase	O
interacting	O
protein	O
2	O
)	O
,	O
spontaneously	O
develop	O
osteomyelitis	O
that	O
resembles	O
chronic	O
recurrent	O
multifocal	O
osteomyelitis	O
in	O
humans	O
.	O

Recent	O
reports	O
demonstrated	O
a	O
crucial	O
role	O
for	O
interleukin-1β	O
(IL-1β)	O
in	O
osteomyelitis	O
,	O
but	B-DNAMutation
deletion	I-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
inflammasome	I-DNAMutation
components	I-DNAMutation
caspase-1	I-DNAMutation
and	I-DNAMutation
NLRP3	I-DNAMutation
failed	O
to	O
rescue	O
Pstpip2(cmo)	O
mice	O
from	O
inflammatory	O
bone	O
disease	O
.	O

Thus	O
,	O
the	O
upstream	O
mechanisms	O
controlling	O
IL-1β	O
production	O
in	O
Pstpip2(cmo)	O
mice	O
remain	O
to	O
be	O
identified	O
.	O

In	O
addition	O
,	O
the	O
environmental	O
factors	O
driving	O
IL-1β-dependent	O
inflammatory	O
bone	O
erosion	O
are	O
unknown	O
.	O

Here	O
we	O
show	O
that	O
the	O
intestinal	O
microbiota	O
of	O
diseased	O
Pstpip2(cmo)	O
mice	O
was	O
characterized	O
by	O
an	O
outgrowth	O
of	O
Prevotella	O
.	O

Notably	O
,	O
Pstpip2(cmo)	O
mice	O
that	O
were	O
fed	O
a	O
diet	O
rich	O
in	O
fat	O
and	O
cholesterol	O
maintained	O
a	O
normal	O
body	O
weight	O
,	O
but	O
were	O
markedly	O
protected	O
against	O
inflammatory	O
bone	O
disease	O
and	O
bone	O
erosion	O
.	O

Diet-induced	O
protection	O
against	O
osteomyelitis	O
was	O
accompanied	O
by	O
marked	O
reductions	O
in	O
intestinal	O
Prevotella	O
levels	O
and	O
significantly	O
reduced	O
pro-IL-1β	O
expression	O
in	O
distant	O
neutrophils	O
.	O

Furthermore	O
,	O
pro-IL-1β	O
expression	O
was	O
also	O
decreased	O
in	O
Pstpip2(cmo)	O
mice	O
treated	O
with	O
antibiotics	O
,	O
and	O
in	O
wild-type	O
mice	O
that	O
were	O
kept	O
under	O
germ-free	O
conditions	O
.	O

We	O
further	O
demonstrate	B-DNAMutation
that	I-DNAMutation
combined	I-DNAMutation
deletion	I-DNAMutation
of	I-DNAMutation
caspases	I-DNAMutation
1	O
and	O
8	O
was	O
required	O
for	O
protection	O
against	O
IL-1β-dependent	O
inflammatory	O
bone	O
disease	O
,	O
whereas	B-DNAMutation
the	I-DNAMutation
deletion	I-DNAMutation
of	I-DNAMutation
either	I-DNAMutation
caspase	I-DNAMutation
alone	I-DNAMutation
or	I-DNAMutation
of	I-DNAMutation
elastase	I-DNAMutation
or	I-DNAMutation
neutrophil	I-DNAMutation
proteinase	I-DNAMutation
3	O
failed	O
to	O
prevent	O
inflammatory	O
disease	O
.	O

Collectively	O
,	O
this	O
work	O
reveals	O
diet-associated	O
changes	O
in	O
the	O
intestinal	O
microbiome	O
as	O
a	O
crucial	O
factor	O
regulating	O
inflammasome-	O
and	O
caspase-8-mediated	O
maturation	O
of	O
IL-1β	O
and	O
osteomyelitis	O
in	O
Pstpip2(cmo)	O
mice	O
.	O

Crystal	O
structure	O
of	O
the	O
plant	O
dual-affinity	O
nitrate	O
transporter	O
NRT1.1	O
.	O

Nitrate	O
is	O
a	O
primary	O
nutrient	O
for	O
plant	O
growth	O
,	O
but	O
its	O
levels	O
in	O
soil	O
can	O
fluctuate	O
by	O
several	O
orders	O
of	O
magnitude	O
.	O

Previous	O
studies	O
have	O
identified	O
Arabidopsis	O
NRT1.1	O
as	O
a	O
dual-affinity	O
nitrate	O
transporter	O
that	O
can	O
take	O
up	O
nitrate	O
over	O
a	O
wide	O
range	O
of	O
concentrations	O
.	O

The	O
mode	O
of	O
action	O
of	O
NRT1.1	O
is	O
controlled	O
by	O
phosphorylation	O
of	O
a	O
key	O
residue	O
,	O
Thr 101	O
;	O
however	O
,	O
how	O
this	O
post-translational	O
modification	O
switches	O
the	O
transporter	O
between	O
two	O
affinity	O
states	O
remains	O
unclear	O
.	O

Here	O
we	O
report	O
the	O
crystal	O
structure	O
of	O
unphosphorylated	O
NRT1.1	O
,	O
which	O
reveals	O
an	O
unexpected	O
homodimer	O
in	O
the	O
inward-facing	O
conformation	O
.	O

In	O
this	O
low-affinity	O
state	O
,	O
the	O
Thr 101	O
phosphorylation	O
site	O
is	O
embedded	O
in	O
a	O
pocket	O
immediately	O
adjacent	O
to	O
the	O
dimer	O
interface	O
,	O
linking	O
the	O
phosphorylation	O
status	O
of	O
the	O
transporter	O
to	O
its	O
oligomeric	O
state	O
.	O

Using	O
a	O
cell-based	O
fluorescence	O
resonance	O
energy	O
transfer	O
assay	O
,	O
we	O
show	O
that	O
functional	O
NRT1.1	O
dimerizes	O
in	O
the	O
cell	O
membrane	O
and	O
that	O
the	O
phosphomimetic	B-DNAMutation
mutation	I-DNAMutation
of	I-DNAMutation
Thr 101	I-DNAMutation
converts	O
the	O
protein	O
into	O
a	O
monophasic	O
high-affinity	O
transporter	O
by	O
structurally	O
decoupling	O
the	O
dimer	O
.	O

Together	O
with	O
analyses	O
of	O
the	O
substrate	O
transport	O
tunnel	O
,	O
our	O
results	O
establish	O
a	O
phosphorylation-controlled	O
dimerization	O
switch	O
that	O
allows	O
NRT1.1	O
to	O
uptake	O
nitrate	O
with	O
two	O
distinct	O
affinity	O
modes	O
.	O

Tension	O
sensing	O
by	O
Aurora	O
B	O
kinase	O
is	O
independent	O
of	O
survivin-based	O
centromere	O
localization	O
.	O

Accurate	O
segregation	O
of	O
the	O
replicated	O
genome	O
requires	O
chromosome	O
biorientation	O
on	O
the	O
spindle	O
.	O

Biorientation	O
is	O
ensured	O
by	O
Aurora	O
B	O
kinase	O
(Ipl1)	O
,	O
a	O
member	O
of	O
the	O
four-subunit	O
chromosomal	O
passenger	O
complex	O
(CPC)	O
.	O

Localization	O
of	O
the	O
CPC	O
to	O
the	O
inner	O
centromere	O
is	O
central	O
to	O
the	O
current	O
model	O
for	O
how	O
tension	O
ensures	O
chromosome	O
biorientation	O
:	O
kinetochore-spindle	O
attachments	O
that	O
are	O
not	O
under	O
tension	O
remain	O
close	O
to	O
the	O
inner	O
centromere	O
and	O
are	O
destabilized	O
by	O
Aurora	O
B	O
phosphorylation	O
,	O
whereas	O
kinetochores	O
under	O
tension	O
are	O
pulled	O
away	O
from	O
the	O
influence	O
of	O
Aurora	O
B	O
,	O
stabilizing	O
their	O
microtubule	O
attachments	O
.	O

Here	O
we	O
show	O
that	O
an	O
engineered	O
truncation	B-DNAMutation
of	O
the	O
Sli15	O
(	O
known	O
as	O
INCENP	O
in	O
humans	O
)	O
subunit	O
of	O
budding	O
yeast	O
CPC	O
that	O
eliminates	O
association	O
with	O
the	O
inner	O
centromere	O
nevertheless	O
supports	O
proper	O
chromosome	O
segregation	O
during	O
both	O
mitosis	O
and	O
meiosis	O
.	O

Truncated	O
Sli15	O
suppresses	O
the	O
deletion	O
phenotypes	O
of	O
the	O
inner-centromere-targeting	O
proteins	O
survivin	O
(Bir1)	O
,	O
borealin	O
(Nbl1)	O
,	O
Bub1	O
and	O
Sgo1	O
(	O
ref	O
.	O

6	O
)	O
.	O

Unlike	O
wild-type	O
Sli15	O
,	O
truncated	B-DNAMutation
Sli15	O
localizes	O
to	O
pre-anaphase	O
spindle	O
microtubules	O
.	O

Premature	O
targeting	O
of	O
full-length	O
Sli15	O
to	O
microtubules	O
by	O
preventing	O
Cdk1	O
(	O
also	O
known	O
as	O
Cdc28	O
)	O
phosphorylation	O
also	O
suppresses	O
the	O
inviability	O
of	O
Bir1	O
deletion	B-DNAMutation
.	O

These	O
results	O
suggest	O
that	O
activation	O
of	O
Aurora	O
B	O
kinase	O
by	O
clustering	O
either	O
on	O
chromatin	O
or	O
on	O
microtubules	O
is	O
sufficient	O
for	O
chromosome	O
biorientation	O
.	O

OTULIN	B-DANMutation
antagonizes	O
LUBAC	B-DANMutation
signaling	O
by	O
specifically	O
hydrolyzing	O
Met1-linked	O
polyubiquitin	O
.	O

The	O
linear	O
ubiquitin	O
(Ub)	O
chain	O
assembly	O
complex	O
LUBAC	B-DNAMutation
is	O
an	O
E3	B-DNAMutation
ligase	O
that	O
specifically	O
assembles	O
Met1-linked	O
(	O
also	O
known	O
as	O
linear	O
)	O
Ub	O
chains	O
that	O
regulate	O
nuclear	O
factor	O
κB	O
(NF-κB)	O
signaling	O
.	O

Deubiquitinases	O
(DUBs)	O
are	O
key	O
regulators	O
of	O
Ub	O
signaling	O
,	O
but	O
a	O
dedicated	O
DUB	O
for	O
Met1	O
linkages	O
has	O
not	O
been	O
identified	O
.	O

Here	O
,	O
we	O
reveal	O
a	O
previously	O
unannotated	O
human	O
DUB	B-DNAMutation
,	I-DNAMutation
OTULIN	I-DNAMutation
(	O
also	O
known	O
as	O
FAM105B	O
)	O
,	O
which	O
is	O
exquisitely	O
specific	O
for	O
Met1	O
linkages	O
.	O

Crystal	O
structures	O
of	O
the	B-DNAMutation
OTULIN	I-DNAMutation
catalytic	O
domain	O
in	O
complex	O
with	O
diubiquitin	O
reveal	O
Met1-specific	O
Ub-binding	O
sites	O
and	O
a	O
mechanism	O
of	O
substrate-assisted	O
catalysis	O
in	O
which	O
the	O
proximal	O
Ub	O
activates	O
the	O
catalytic	O
triad	O
of	O
the	O
protease	B-DNAMutation
.	I-DNAMutation
Mutation	I-DNAMutation
of	I-DNAMutation
Ub	I-DNAMutation
Glu16	I-DNAMutation
inhibits	B-DNAMutation
OTULIN	I-DNAMutation
activity	O
by	O
reducing	O
kcat	O
240-fold	B-DNAMutation
.	I-DNAMutation
OTULIN	I-DNAMutation
overexpression	O
or	O
knockdown	O
affects	O
NF-κB	O
responses	O
to	I-DNAMutation
LUBAC	I-DNAMutation
,	O
TNFα	O
,	O
and	O
poly(I:C)	O
and	O
sensitizes	O
cells	O
to	O
TNFα-induced	O
cell	O
death	O
.	O

We	O
show	O
that	I-DNAMutation
OTULIN	O
binds	B-DNAMutation
LUBAC	O
and	O
that	O
overexpression	B-DNAMutation
of	I-DNAMutation
OTULIN	O
prevents	O
TNFα-induced	O
NEMO	O
association	O
with	O
ubiquitinated	O
RIPK1	O
.	O

Our	O
data	O
suggest	B-DNAMutation
that	I-DNAMutation
OTULIN	O
regulates	O
Met1-polyUb	O
signaling	O
.	O

Stress	O
responses	O
.	O

Mutations	O
in	O
a	O
translation	O
initiation	O
factor	O
identify	O
the	O
target	O
of	O
a	O
memory-enhancing	O
compound	O
.	O

The	O
integrated	O
stress	O
response	O
ISR	B-DNAMutation
modulates	O
messenger	O
RNA	O
translation	O
to	O
regulate	O
the	O
mammalian	O
unfolded	O
protein	O
response	O
(UPR)	O
,	O
immunity	O
,	O
and	O
memory	O
formation	O
.	O

A	O
chemical	O
ISR	B-DNAMutation
inhibitor	O
,	O
ISRIB	B-DNAMutation
,	O
enhances	O
cognitive	O
function	O
and	O
modulates	O
the	O
UPR	O
in	O
vivo	O
.	O

To	O
explore	O
mechanisms	O
involved	O
in	O
ISRIB	B-DNAMutation
action	O
,	O
we	O
screened	O
cultured	O
mammalian	O
cells	O
for	O
somatic	O
mutations	O
that	O
reversed	O
its	O
effect	O
on	O
the	O
ISR	B-DNAMutation
.	O

Clustered	B-DNAMutation
missense	I-DNAMutation
mutations	I-DNAMutation
were	I-DNAMutation
found	I-DNAMutation
at	I-DNAMutation
the	I-DNAMutation
amino-terminal	I-DNAMutation
portion	I-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
delta	I-DNAMutation
subunit	I-DNAMutation
of	O
guanine	B-DNAMutation
nucleotide	I-DNAMutation
exchange	I-DNAMutation
factor	I-DNAMutation
(GEF)	I-DNAMutation
eIF2B	B-DNAMutation
.	O

When	O
reintroduced	O
by	O
CRISPR-Cas9	O
gene	O
editing	O
of	O
wild-type	O
cells	O
,	O
these	O
mutations	O
reversed	O
both	O
ISRIB-mediated	B-DNAMutation
inhibition	O
of	O
the	O
ISR	B-DNAMutation
and	O
its	O
stimulatory	O
effect	O
on	O
eIF2B	B-DNAMutation
GEF	O
activity	O
toward	O
its	O
substrate	O
,	O
the	O
translation	O
initiation	O
factor	O
eIF2	O
,	O
in	O
vitro	O
.	O

Thus	O
,	O
ISRIB	B-DNAMutation
targets	O
an	O
interaction	O
between	O
eIF2	O
and	O
eIF2B	B-DNAMutation
that	O
lies	O
at	O
the	O
core	O
of	O
the	O
ISR	B-DNAMutation
.	O

Non-invasive	O
analysis	O
of	O
acquired	O
resistance	O
to	O
cancer	O
therapy	O
by	O
sequencing	O
of	O
plasma	O
DNA	O
.	O

Cancers	O
acquire	O
resistance	O
to	O
systemic	O
treatment	O
as	O
a	O
result	O
of	O
clonal	O
evolution	O
and	O
selection	O
.	O

Repeat	O
biopsies	O
to	O
study	O
genomic	O
evolution	O
as	O
a	O
result	O
of	O
therapy	O
are	O
difficult	O
,	O
invasive	O
and	O
may	O
be	O
confounded	O
by	O
intra-tumour	O
heterogeneity	O
.	O

Recent	O
studies	O
have	O
shown	O
that	O
genomic	O
alterations	O
in	O
solid	O
cancers	O
can	O
be	O
characterized	O
by	O
massively	O
parallel	O
sequencing	O
of	O
circulating	O
cell-free	O
tumour	O
DNA	O
released	O
from	O
cancer	O
cells	O
into	O
plasma	O
,	O
representing	O
a	O
non-invasive	O
liquid	O
biopsy	O
.	O

Here	O
we	O
report	O
sequencing	O
of	O
cancer	O
exomes	O
in	O
serial	O
plasma	O
samples	O
to	O
track	O
genomic	O
evolution	O
of	O
metastatic	O
cancers	O
in	O
response	O
to	O
therapy	O
.	O

Six	O
patients	O
with	O
advanced	O
breast	O
,	O
ovarian	O
and	O
lung	O
cancers	O
were	O
followed	O
over	O
1-2	O
years	O
.	O

For	O
each	O
case	O
,	O
exome	O
sequencing	O
was	O
performed	O
on	O
2-5	O
plasma	O
samples	O
(	O
19	O
in	O
total	O
)	O
spanning	O
multiple	O
courses	O
of	O
treatment	O
,	O
at	O
selected	O
time	O
points	O
when	O
the	O
allele	O
fraction	O
of	O
tumour	O
mutations	O
in	O
plasma	O
was	O
high	O
,	O
allowing	O
improved	O
sensitivity	O
.	O

For	O
two	O
cases	O
,	O
synchronous	O
biopsies	O
were	O
also	O
analysed	O
,	O
confirming	O
genome-wide	O
representation	O
of	O
the	O
tumour	O
genome	O
in	O
plasma	O
.	O

Quantification	O
of	O
allele	O
fractions	O
in	O
plasma	O
identified	O
increased	O
representation	O
of	O
mutant	O
alleles	O
in	O
association	O
with	O
emergence	O
of	O
therapy	O
resistance	O
.	O

These	O
included	O
an	O
activating	O
mutation	O
in	O
PIK3CA	O
(	O
phosphatidylinositol-4,5-bisphosphate	O
3-kinase	O
,	O
catalytic	O
subunit	O
alpha	O
)	O
following	O
treatment	O
with	O
paclitaxel	O
;	O
a	O
truncating	O
mutation	O
in	O
RB1	O
(	O
retinoblastoma	O
1	O
)	O
following	O
treatment	O
with	O
cisplatin	O
;	O
a	O
truncating	O
mutation	O
in	O
MED1	O
(	O
mediator	O
complex	O
subunit	O
1	O
)	O
following	O
treatment	O
with	O
tamoxifen	O
and	O
trastuzumab	O
,	O
and	O
following	O
subsequent	O
treatment	O
with	O
lapatinib	O
,	O
a	O
splicing	O
mutation	O
in	O
GAS6	O
(	O
growth	O
arrest-specific	O
6	O
)	O
in	O
the	O
same	O
patient	O
;	O
and	O
a	O
resistance-conferring	O
mutation	O
in	O
EGFR	O
(	O
epidermal	O
growth	O
factor	O
receptor	O
;	O
T790M	B-DNAMutation
)	O
following	O
treatment	O
with	O
gefitinib	O
.	O

These	O
results	O
establish	O
proof	O
of	O
principle	O
that	O
exome-wide	O
analysis	O
of	O
circulating	O
tumour	O
DNA	O
could	O
complement	O
current	O
invasive	O
biopsy	O
approaches	O
to	O
identify	O
mutations	O
associated	O
with	O
acquired	O
drug	O
resistance	O
in	O
advanced	O
cancers	O
.	O

Serial	O
analysis	O
of	O
cancer	O
genomes	O
in	O
plasma	O
constitutes	O
a	O
new	O
paradigm	O
for	O
the	O
study	O
of	O
clonal	O
evolution	O
in	O
human	O
cancers	O
.	O

PHYSIOLOGY	O
.	O

Regulation	O
of	O
breathing	O
by	O
CO₂	O
requires	O
the	O
proton-activated	O
receptor	O
GPR4	O
in	O
retrotrapezoid	O
nucleus	O
neurons	O
.	O

Blood	O
gas	O
and	O
tissue	O
pH	O
regulation	O
depend	O
on	O
the	O
ability	O
of	O
the	O
brain	O
to	O
sense	O
CO2	O
and/or	O
H(+)	O
and	O
alter	O
breathing	O
appropriately	O
,	O
a	O
homeostatic	O
process	O
called	O
central	O
respiratory	O
chemosensitivity	O
.	O

We	O
show	O
that	O
selective	O
expression	O
of	O
the	O
proton-activated	O
receptor	O
GPR4	O
in	O
chemosensory	O
neurons	O
of	O
the	O
mouse	O
retrotrapezoid	O
nucleus	O
(RTN)	O
is	O
required	O
for	O
CO2-stimulated	O
breathing	O
.	O

Genetic	B-DNAMutation
deletion	I-DNAMutation
of	O
GPR4	O
disrupted	O
acidosis-dependent	O
activation	O
of	O
RTN	O
neurons	O
,	O
increased	O
apnea	O
frequency	O
,	O
and	O
blunted	O
ventilatory	O
responses	O
to	O
CO2	O
.	O

Reintroduction	O
of	O
GPR4	O
into	O
RTN	O
neurons	O
restored	O
CO2-dependent	O
RTN	O
neuronal	O
activation	O
and	O
rescued	O
the	O
ventilatory	O
phenotype	O
.	O

Additional	O
elimination	O
of	O
TASK-2	O
(K(2P)5)	O
,	O
a	O
pH-sensitive	O
K(+)	O
channel	O
expressed	O
in	O
RTN	O
neurons	O
,	O
essentially	O
abolished	O
the	O
ventilatory	O
response	O
to	O
CO2	O
.	O

The	O
data	O
identify	O
GPR4	O
and	O
TASK-2	O
as	O
distinct	O
,	O
parallel	O
,	O
and	O
essential	O
central	O
mediators	O
of	O
respiratory	O
chemosensitivity	O
.	O

Toddler	B-DANMutation
:	O
an	O
embryonic	O
signal	O
that	O
promotes	O
cell	O
movement	O
via	O
Apelin	O
receptors	O
.	O

It	O
has	O
been	O
assumed	O
that	O
most	O
,	O
if	O
not	O
all	O
,	O
signals	O
regulating	O
early	O
development	O
have	O
been	O
identified	O
.	O

Contrary	O
to	O
this	O
expectation	O
,	O
we	O
identified	O
28	O
candidate	O
signaling	O
proteins	O
expressed	O
during	O
zebrafish	O
embryogenesis	O
,	O
including	O
Toddler	B-DNAMutation
,	O
a	O
short	O
,	O
conserved	O
,	O
and	O
secreted	O
peptide	O
.	O

Both	B-DNAMutation
absence	I-DNAMutation
and	I-DNAMutation
overproduction	I-DNAMutation
of	I-DNAMutation
Toddler	I-DNAMutation
reduce	O
the	O
movement	O
of	O
mesendodermal	O
cells	O
during	O
zebrafish	O
gastrulation	O
.	O

Local	O
and	O
ubiquitous	O
production	O
of	O
Toddler	B-DNAMutation
promote	O
cell	O
movement	O
,	O
suggesting	O
that	O
Toddler	B-DNAMutation
is	O
neither	O
an	O
attractant	O
nor	O
a	O
repellent	O
but	O
acts	O
globally	O
as	O
a	O
motogen	O
.	O

Toddler	B-DNAMutation
drives	O
internalization	O
of	O
G	O
protein-coupled	O
APJ/Apelin	O
receptors	O
,	O
and	O
activation	O
of	O
APJ/Apelin	O
signaling	O
rescues	O
toddler	O
mutants	O
.	O

These	O
results	O
indicate	O
that	O
Toddler	B-DNAMutation
is	O
an	O
activator	O
of	O
APJ/Apelin	O
receptor	O
signaling	O
,	O
promotes	O
gastrulation	O
movements	O
,	O
and	O
might	O
be	O
the	O
first	O
in	O
a	O
series	O
of	O
uncharacterized	O
developmental	O
signals	O
.	O

Improving	O
survival	O
by	O
exploiting	O
tumour	O
dependence	O
on	O
stabilized	O
mutant	O
p53	O
for	O
treatment	O
.	O

Missense	O
mutations	O
in	O
p53	O
generate	O
aberrant	O
proteins	O
with	O
abrogated	O
tumour	O
suppressor	O
functions	O
that	O
can	O
also	O
acquire	O
oncogenic	O
gain-of-function	O
activities	O
that	O
promote	O
malignant	O
progression	O
,	O
invasion	O
,	O
metastasis	O
and	O
chemoresistance	O
.	O

Mutant	O
p53	O
(mutp53)	O
proteins	O
undergo	O
massive	O
constitutive	O
stabilization	O
specifically	O
in	O
tumours	O
,	O
which	O
is	O
the	O
key	O
requisite	O
for	O
the	O
acquisition	O
of	O
gain-of-functions	O
activities	O
.	O

Although	O
currently	O
11	O
million	O
patients	O
worldwide	O
live	O
with	O
tumours	O
expressing	O
highly	O
stabilized	O
mutp53	O
,	O
it	O
is	O
unknown	O
whether	O
mutp53	O
is	O
a	O
therapeutic	O
target	O
in	O
vivo	O
.	O

Here	O
we	O
use	O
a	O
novel	O
mutp53	O
mouse	O
model	O
expressing	O
an	O
inactivatable	O
R248Q	B-DNAMutation
hotspot	O
mutation	O
(floxQ)	O
to	O
show	O
that	O
tumours	O
depend	O
on	O
sustained	O
mutp53	O
expression	O
.	O

Upon	O
tamoxifen-induced	O
mutp53	O
ablation	O
,	O
allotransplanted	O
and	O
autochthonous	O
tumours	O
curb	O
their	O
growth	O
,	O
thus	O
extending	O
animal	O
survival	O
by	O
37%	O
,	O
and	O
advanced	O
tumours	O
undergo	O
apoptosis	O
and	O
tumour	O
regression	O
or	O
stagnation	O
.	O

The	O
HSP90/HDAC6	O
chaperone	O
machinery	O
,	O
which	O
is	O
significantly	O
upregulated	O
in	O
cancer	O
compared	O
with	O
normal	O
tissues	O
,	O
is	O
a	O
major	O
determinant	O
of	O
mutp53	O
stabilization	O
.	O

We	O
show	O
that	O
long-term	O
HSP90	O
inhibition	O
significantly	O
extends	O
the	O
survival	O
of	O
mutp53	O
Q/-	O
(	O
R248Q	B-DNAMutation
allele	O
)	O
and	O
H/H	O
(	O
R172H	B-DNAMutation
allele	O
)	O
mice	O
by	O
59%	O
and	O
48%	O
,	O
respectively	O
,	O
but	O
not	O
their	O
corresponding	O
p53(-/-)	O
littermates	O
.	O

This	O
mutp53-dependent	O
drug	O
effect	O
occurs	O
in	O
H/H	O
mice	O
treated	O
with	O
17DMAG+SAHA	O
and	O
in	O
H/H	O
and	O
Q/-	O
mice	O
treated	O
with	O
the	O
potent	O
Hsp90	O
inhibitor	O
ganetespib	O
.	O

Notably	O
,	O
drug	O
activity	O
correlates	O
with	O
induction	O
of	O
mutp53	O
degradation	O
,	O
tumour	O
apoptosis	O
and	O
prevention	O
of	O
T-cell	O
lymphomagenesis	O
.	O

These	O
proof-of-principle	O
data	O
identify	O
mutp53	O
as	O
an	O
actionable	O
cancer-specific	O
drug	O
target	O
.	O

MET	O
is	O
required	O
for	O
the	O
recruitment	O
of	O
anti-tumoural	O
neutrophils	O
.	O

Mutations	O
or	O
amplification	O
of	O
the	O
MET	O
proto-oncogene	O
are	O
involved	O
in	O
the	O
pathogenesis	O
of	O
several	O
tumours	O
,	O
which	O
rely	O
on	O
the	O
constitutive	O
engagement	O
of	O
this	O
pathway	O
for	O
their	O
growth	O
and	O
survival	O
.	O

However	O
,	O
MET	O
is	O
expressed	O
not	O
only	O
by	O
cancer	O
cells	O
but	O
also	O
by	O
tumour-associated	O
stromal	O
cells	O
,	O
although	O
its	O
precise	O
role	O
in	O
this	O
compartment	O
is	O
not	O
well	O
characterized	O
.	O

Here	O
we	O
show	O
that	O
MET	O
is	O
required	O
for	O
neutrophil	O
chemoattraction	O
and	O
cytotoxicity	O
in	O
response	O
to	O
its	O
ligand	O
hepatocyte	O
growth	O
factor	O
(HGF)	O
.	O

Met	O
deletion	B-DNAMutation
in	O
mouse	O
neutrophils	O
enhances	O
tumour	O
growth	O
and	O
metastasis	O
.	O

This	O
phenotype	O
correlates	O
with	O
reduced	O
neutrophil	O
infiltration	O
to	O
both	O
the	O
primary	O
tumour	O
and	O
metastatic	O
sites	O
.	O

Similarly	O
,	O
Met	O
is	O
necessary	O
for	O
neutrophil	O
transudation	O
during	O
colitis	O
,	O
skin	O
rash	O
or	O
peritonitis	O
.	O

Mechanistically	O
,	O
Met	O
is	O
induced	O
by	O
tumour-derived	O
tumour	O
necrosis	O
factor	O
(TNF)-α	O
or	O
other	O
inflammatory	O
stimuli	O
in	O
both	O
mouse	O
and	O
human	O
neutrophils	O
.	O

This	O
induction	O
is	O
instrumental	O
for	O
neutrophil	O
transmigration	O
across	O
an	O
activated	O
endothelium	O
and	O
for	O
inducible	O
nitric	O
oxide	O
synthase	O
production	O
upon	O
HGF	O
stimulation	O
.	O

Consequently	O
,	O
HGF/MET-dependent	O
nitric	O
oxide	O
release	O
by	O
neutrophils	O
promotes	O
cancer	O
cell	O
killing	O
,	O
which	O
abates	O
tumour	O
growth	O
and	O
metastasis	O
.	O

After	O
systemic	O
administration	O
of	O
a	O
MET	O
kinase	O
inhibitor	O
,	O
we	O
prove	O
that	O
the	O
therapeutic	O
benefit	O
of	O
MET	O
targeting	O
in	O
cancer	O
cells	O
is	O
partly	O
countered	O
by	O
the	O
pro-tumoural	O
effect	O
arising	O
from	O
MET	O
blockade	O
in	O
neutrophils	O
.	O

Our	O
work	O
identifies	O
an	O
unprecedented	O
role	O
of	O
MET	O
in	O
neutrophils	O
,	O
suggests	O
a	O
potential	O
'Achilles'	O
heel'	O
of	O
MET-targeted	O
therapies	O
in	O
cancer	O
,	O
and	O
supports	O
the	O
rationale	O
for	O
evaluating	O
anti-MET	O
drugs	O
in	O
certain	O
inflammatory	O
diseases	O
.	O

Reversal	O
of	O
female	O
infertility	O
by	O
Chk2	B-DANMutation
ablation	I-DANMutation
reveals	O
the	O
oocyte	O
DNA	O
damage	O
checkpoint	O
pathway	O
.	O

Genetic	O
errors	O
in	O
meiosis	O
can	O
lead	O
to	O
birth	O
defects	O
and	O
spontaneous	O
abortions	O
.	O

Checkpoint	O
mechanisms	O
of	O
hitherto	O
unknown	O
nature	O
eliminate	O
oocytes	O
with	O
unrepaired	O
DNA	O
damage	O
,	O
causing	O
recombination-defective	O
mutant	O
mice	O
to	O
be	O
sterile	O
.	O

Here	O
,	O
we	O
report	O
that	O
checkpoint	O
kinase	O
2	O
(	O
Chk2	O
or	O
Chek2	O
)	O
,	O
is	O
essential	O
for	O
culling	O
mouse	O
oocytes	O
bearing	O
unrepaired	O
meiotic	O
or	O
induced	O
DNA	B-DNAMutation
double-strand	I-DNAMutation
breaks	I-DNAMutation
DSBs	B-DNAMutation
.	O

Female	O
infertility	O
caused	O
by	O
a	O
meiotic	O
recombination	O
mutation	O
or	O
irradiation	O
was	O
reversed	O
by	O
mutation	O
of	O
Chk2	O
.	O

Both	O
meiotically	O
programmed	O
and	O
induced	O
DSBs	B-DNAMutation
trigger	O
CHK2-dependent	O
activation	O
of	O
TRP53	O
(p53)	O
and	O
TRP63	O
(p63)	O
,	O
effecting	O
oocyte	O
elimination	O
.	O

These	O
data	O
establish	O
CHK2	O
as	O
essential	O
for	O
DNA	O
damage	O
surveillance	O
in	O
female	O
meiosis	O
and	O
indicate	O
that	O
the	O
oocyte	O
DSB	O
damage	O
response	O
primarily	O
involves	O
a	O
pathway	O
hierarchy	O
in	O
which	O
ataxia	O
telangiectasia	O
and	O
Rad3-related	O
(ATR)	O
signals	O
to	O
CHK2	O
,	O
which	O
then	O
activates	O
p53	O
and	O
p63	O
.	O

Genomic	O
analysis	O
of	O
non-NF2	O
meningiomas	O
reveals	O
mutations	O
in	O
TRAF7	O
,	O
KLF4	O
,	O
AKT1	O
,	O
and	O
SMO	O
.	O

We	O
report	O
genomic	O
analysis	O
of	O
300	O
meningiomas	O
,	O
the	O
most	O
common	O
primary	O
brain	O
tumors	O
,	O
leading	O
to	O
the	O
discovery	O
of	O
mutations	O
in	O
TRAF7	O
,	O
a	O
proapoptotic	O
E3	O
ubiquitin	O
ligase	O
,	O
in	O
nearly	O
one-fourth	O
of	O
all	O
meningiomas	O
.	O

Mutations	O
in	O
TRAF7	O
commonly	O
occurred	O
with	O
a	O
recurrent	O
mutation	O
K409Q	B-DNAMutation
in	O
KLF4	O
,	O
a	O
transcription	O
factor	O
known	O
for	O
its	O
role	O
in	O
inducing	O
pluripotency	O
,	O
or	O
with	O
AKT1(E17K)	O
,	O
a	O
mutation	O
known	O
to	O
activate	O
the	O
PI3K	O
pathway	O
.	O

SMO	O
mutations	O
,	O
which	O
activate	O
Hedgehog	O
signaling	O
,	O
were	O
identified	O
in	O
~5%	O
of	O
non-NF2	O
mutant	O
meningiomas	O
.	O

These	O
non-NF2	O
meningiomas	O
were	O
clinically	O
distinctive-nearly	O
always	O
benign	O
,	O
with	O
chromosomal	O
stability	O
,	O
and	O
originating	O
from	O
the	O
medial	O
skull	O
base	O
.	O

In	O
contrast	O
,	O
meningiomas	O
with	O
mutant	O
NF2	O
and/or	O
chromosome	O
22	O
loss	O
were	O
more	O
likely	O
to	O
be	O
atypical	O
,	O
showing	O
genomic	O
instability	O
,	O
and	O
localizing	O
to	O
the	O
cerebral	O
and	O
cerebellar	O
hemispheres	O
.	O

Collectively	O
,	O
these	O
findings	O
identify	O
distinct	O
meningioma	O
subtypes	O
,	O
suggesting	O
avenues	O
for	O
targeted	O
therapeutics	O
.	O

A	O
single	O
oncogenic	O
enhancer	O
rearrangement	O
causes	O
concomitant	O
EVI1	O
and	O
GATA2	O
deregulation	O
in	O
leukemia	O
.	O

Chromosomal	O
rearrangements	O
without	O
gene	O
fusions	O
have	O
been	O
implicated	O
in	O
leukemogenesis	O
by	O
causing	O
deregulation	O
of	O
proto-oncogenes	O
via	O
relocation	O
of	O
cryptic	O
regulatory	O
DNA	O
elements	O
.	O

AML	B-DNAMutation
with	I-DNAMutation
inv(3)/t(3;3)	I-DNAMutation
is	O
associated	O
with	O
aberrant	B-DNAMutation
expression	I-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
stem-cell	I-DNAMutation
regulator	I-DNAMutation
EVI1	I-DNAMutation
.	O

Applying	O
functional	O
genomics	O
and	O
genome-engineering	O
,	O
we	O
demonstrate	O
that	O
both	B-DNAMutation
3q	I-DNAMutation
rearrangements	I-DNAMutation
reposition	I-DNAMutation
a	I-DNAMutation
distal	I-DNAMutation
GATA2	I-DNAMutation
enhancer	I-DNAMutation
to	O
ectopically	O
activate	O
EVI1	O
and	O
simultaneously	O
confer	O
GATA2	O
functional	O
haploinsufficiency	O
,	O
previously	O
identified	O
as	O
the	O
cause	O
of	O
sporadic	O
familial	O
AML/MDS	O
and	O
MonoMac/Emberger	O
syndromes	O
.	O

Genomic	B-DNAMutation
excision	I-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
ectopic	I-DNAMutation
enhancer	I-DNAMutation
restored	O
EVI1	O
silencing	O
and	O
led	O
to	O
growth	O
inhibition	O
and	O
differentiation	O
of	O
AML	O
cells	O
,	O
which	O
could	O
be	O
replicated	O
by	O
pharmacologic	O
BET	O
inhibition	O
.	O

Our	O
data	O
show	O
that	O
structural	O
rearrangements	O
involving	O
the	O
chromosomal	O
repositioning	O
of	O
a	O
single	O
enhancer	O
can	O
cause	O
deregulation	O
of	O
two	O
unrelated	O
distal	O
genes	O
,	O
with	O
cancer	O
as	O
the	O
outcome	O
.	O

RECQL5	O
controls	O
transcript	O
elongation	O
and	O
suppresses	O
genome	O
instability	O
associated	O
with	O
transcription	O
stress	O
.	O

RECQL5	O
is	O
the	O
sole	O
member	O
of	O
the	O
RECQ	O
family	O
of	O
helicases	O
associated	O
with	O
RNA	O
polymerase	O
II	O
(RNAPII)	O
.	O

We	O
now	O
show	O
that	O
RECQL5	O
is	O
a	O
general	O
elongation	O
factor	O
that	O
is	O
important	O
for	O
preserving	O
genome	O
stability	O
during	O
transcription	O
.	O

Depletion	O
or	O
overexpression	O
of	O
RECQL5	O
results	O
in	O
corresponding	O
shifts	O
in	O
the	O
genome-wide	O
RNAPII	O
density	O
profile	O
.	O

Elongation	O
is	O
particularly	O
affected	O
,	O
with	O
RECQL5	O
depletion	O
causing	O
a	O
striking	O
increase	O
in	O
the	O
average	O
rate	O
,	O
concurrent	O
with	O
increased	O
stalling	O
,	O
pausing	O
,	O
arrest	O
,	O
and/or	O
backtracking	O
(	O
transcription	O
stress	O
)	O
.	O

RECQL5	O
therefore	O
controls	O
the	O
movement	O
of	O
RNAPII	O
across	O
genes	O
.	O

Loss	B-DNAMutation
of	O
RECQL5	O
also	O
results	O
in	O
the	O
loss	O
or	O
gain	O
of	O
genomic	O
regions	O
,	O
with	O
the	O
breakpoints	O
of	O
lost	O
regions	O
located	O
in	O
genes	O
and	O
common	O
fragile	O
sites	O
.	O

The	O
chromosomal	O
breakpoints	O
overlap	O
with	O
areas	O
of	O
elevated	O
transcription	O
stress	O
,	O
suggesting	O
that	O
RECQL5	O
suppresses	O
such	O
stress	O
and	O
its	O
detrimental	O
effects	O
,	O
and	O
thereby	O
prevents	O
genome	O
instability	O
in	O
the	O
transcribed	O
region	O
of	O
genes	O
.	O

Targeted	O
inhibition	O
of	O
mutant	O
IDH2	O
in	O
leukemia	O
cells	O
induces	O
cellular	O
differentiation	O
.	O

A	O
number	O
of	O
human	O
cancers	O
harbor	O
somatic	O
point	O
mutations	O
in	O
the	O
genes	O
encoding	O
isocitrate	O
dehydrogenases	O
1	O
and	O
2	O
(	O
IDH1	O
and	O
IDH2	O
)	O
.	O

These	O
mutations	O
alter	O
residues	O
in	O
the	O
enzyme	O
active	O
sites	O
and	O
confer	O
a	O
gain-of-function	O
in	O
cancer	O
cells	O
,	O
resulting	O
in	O
the	O
accumulation	O
and	O
secretion	O
of	O
the	O
oncometabolite	O
(R)-2-hydroxyglutarate	O
(2HG)	O
.	O

We	O
developed	O
a	O
small	O
molecule	O
,	O
AGI-6780	O
,	O
that	O
potently	O
and	O
selectively	O
inhibits	O
the	O
tumor-associated	O
mutant	O
IDH2/R140Q	B-DNAMutation
.	O

A	O
crystal	O
structure	O
of	O
AGI-6780	O
complexed	O
with	O
IDH2/R140Q	B-DNAMutation
revealed	O
that	O
the	O
inhibitor	O
binds	O
in	O
an	O
allosteric	O
manner	O
at	O
the	O
dimer	O
interface	O
.	O

The	O
results	O
of	O
steady-state	O
enzymology	O
analysis	O
were	O
consistent	O
with	O
allostery	O
and	O
slow-tight	O
binding	O
by	O
AGI-6780	O
.	O

Treatment	O
with	O
AGI-6780	O
induced	O
differentiation	O
of	O
TF-1	O
erythroleukemia	O
and	O
primary	O
human	O
acute	O
myelogenous	O
leukemia	O
cells	O
in	O
vitro	O
.	O

These	O
data	O
provide	O
proof-of-concept	O
that	O
inhibitors	O
targeting	O
mutant	O
IDH2/R140Q	B-DNAMutation
could	O
have	O
potential	O
applications	O
as	O
a	O
differentiation	O
therapy	O
for	O
cancer	O
.	O

An	O
AT-hook	O
domain	O
in	O
MeCP2	B-DANMutation
determines	O
the	O
clinical	O
course	O
of	O
Rett	O
syndrome	O
and	O
related	O
disorders	O
.	O

Mutations	O
in	O
the	O
X-linked	O
MECP2	O
cause	O
Rett	O
syndrome	O
,	O
a	O
devastating	O
neurological	O
disorder	O
typified	O
by	O
a	O
period	O
of	O
apparently	O
normal	O
development	O
followed	O
by	O
loss	O
of	O
cognitive	O
and	O
psychomotor	O
skills	O
.	O

Data	O
from	O
rare	O
male	O
patients	O
suggest	O
symptom	O
onset	O
and	O
severity	O
can	O
be	O
influenced	O
by	O
the	O
location	B-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
mutation	I-DNAMutation
,	I-DNAMutation
with	I-DNAMutation
amino	I-DNAMutation
acids	I-DNAMutation
270	I-DNAMutation
and	I-DNAMutation
273	I-DNAMutation
marking	O
the	O
difference	O
between	O
neonatal	O
encephalopathy	O
and	O
death	O
,	O
on	O
the	O
one	O
hand	O
,	O
and	O
survival	O
with	O
deficits	O
on	O
the	O
other	O
.	O

We	O
therefore	O
generated	O
two	O
mouse	O
models	O
expressing	O
either	O
MeCP2-R270X	B-DNAMutation
or	O
MeCP2-G273X	B-DNAMutation
.	O

The	O
mice	O
developed	O
phenotypes	O
at	O
strikingly	O
different	O
rates	O
and	O
showed	O
differential	O
ATRX	O
nuclear	O
localization	O
within	O
the	O
nervous	O
system	O
,	O
over	O
time	O
,	O
coinciding	O
with	O
phenotypic	O
progression	O
.	O

We	O
discovered	O
that	O
MeCP2	B-DNAMutation
contains	O
three	O
AT-hook-like	O
domains	O
over	O
a	O
stretch	O
of	O
250	O
amino	O
acids	O
,	O
like	O
HMGA	O
DNA-bending	O
proteins	O
;	O
one	B-DNAMutation
conserved	I-DNAMutation
AT-hook	I-DNAMutation
is	I-DNAMutation
disrupted	I-DNAMutation
in	O
MeCP2-R270X	B-DNAMutation
,	O
lending	O
further	O
support	O
to	O
the	O
notion	O
that	O
one	O
of	O
MeCP2's	B-DNAMutation
key	O
functions	O
is	O
to	O
alter	O
chromatin	O
structure	O
.	O

Molecular	O
basis	O
of	O
tubulin	B-DANMutation
transport	O
within	O
the	O
cilium	O
by	O
IFT74	B-DANMutation
and	O
IFT81	B-DANMutation
.	O

Intraflagellar	O
transport	O
(IFT)	O
of	O
ciliary	O
precursors	O
such	O
as	O
tubulin	B-DNAMutation
from	O
the	O
cytoplasm	O
to	O
the	O
ciliary	O
tip	O
is	O
involved	O
in	O
the	O
construction	O
of	O
the	O
cilium	O
,	O
a	O
hairlike	O
organelle	O
found	O
on	O
most	O
eukaryotic	O
cells	O
.	O

However	O
,	O
the	O
molecular	O
mechanisms	O
of	O
IFT	O
are	O
poorly	O
understood	O
.	O

Here	O
,	O
we	O
found	O
that	O
the	O
two	O
core	O
IFT	O
proteins	O
IFT74	B-DNAMutation
and	O
IFT81	B-DNAMutation
form	O
a	O
tubulin-binding	B-DNAMutation
module	O
and	O
mapped	O
the	O
interaction	O
to	O
a	O
calponin	O
homology	O
domain	O
of	O
IFT81	B-DNAMutation
and	O
a	O
highly	O
basic	O
domain	O
in	O
IFT74	B-DNAMutation
.	O

Knockdown	B-DNAMutation
of	I-DNAMutation
IFT81	I-DNAMutation
and	O
rescue	O
experiments	O
with	O
point	O
mutants	O
showed	O
that	O
tubulin	B-DNAMutation
binding	O
by	O
IFT81	B-DNAMutation
was	O
required	O
for	O
ciliogenesis	O
in	O
human	O
cells	O
.	O

Imbalanced	O
OPA1	B-DANMutation
processing	O
and	O
mitochondrial	O
fragmentation	O
cause	O
heart	O
failure	O
in	O
mice	O
.	O

Mitochondrial	O
morphology	O
is	O
shaped	O
by	O
fusion	O
and	O
division	O
of	O
their	O
membranes	O
.	O

Here	O
,	O
we	O
found	O
that	O
adult	O
myocardial	O
function	O
depends	O
on	O
balanced	O
mitochondrial	O
fusion	O
and	O
fission	O
,	O
maintained	O
by	O
processing	O
of	O
the	O
dynamin-like	O
guanosine	O
triphosphatase	O
OPA1	B-DNAMutation
by	O
the	O
mitochondrial	O
peptidases	O
YME1L	O
and	O
OMA1	B-DNAMutation
.	O

Cardiac-specific	O
ablation	O
of	O
Yme1l	O
in	O
mice	O
activated	O
OMA1	B-DNAMutation
and	O
accelerated	O
OPA1	B-DNAMutation
proteolysis	O
,	O
which	O
triggered	O
mitochondrial	O
fragmentation	O
and	O
altered	O
cardiac	O
metabolism	O
.	O

This	O
caused	O
dilated	O
cardiomyopathy	O
and	O
heart	O
failure	O
.	O

Cardiac	O
function	O
and	O
mitochondrial	O
morphology	O
were	O
rescued	O
by	O
Oma1	B-DNAMutation
deletion	I-DNAMutation
,	O
which	O
prevented	O
OPA1	B-DNAMutation
cleavage	O
.	O

Feeding	O
mice	O
a	O
high-fat	O
diet	O
or	O
ablating	O
Yme1l	O
in	O
skeletal	O
muscle	O
restored	O
cardiac	O
metabolism	O
and	O
preserved	O
heart	O
function	O
without	O
suppressing	O
mitochondrial	O
fragmentation	O
.	O

Thus	O
,	O
unprocessed	O
OPA1	B-DNAMutation
is	O
sufficient	O
to	O
maintain	O
heart	O
function	O
,	O
OMA1	B-DNAMutation
is	O
a	O
critical	O
regulator	O
of	O
cardiomyocyte	O
survival	O
,	O
and	O
mitochondrial	O
morphology	O
and	O
cardiac	O
metabolism	O
are	O
intimately	O
linked	O
.	O

Mammalian	I-DANMutation
polymerase	I-DANMutation
θ	O
promotes	O
alternative	O
NHEJ	O
and	O
suppresses	O
recombination	O
.	O

The	O
alternative	O
non-homologous	O
end-joining	O
(NHEJ)	O
machinery	O
facilitates	O
several	O
genomic	O
rearrangements	O
,	O
some	O
of	O
which	O
can	O
lead	O
to	O
cellular	O
transformation	O
.	O

This	O
error-prone	O
repair	O
pathway	O
is	O
triggered	O
upon	O
telomere	O
de-protection	O
to	O
promote	O
the	O
formation	O
of	O
deleterious	O
chromosome	O
end-to-end	O
fusions	O
.	O

Using	O
next-generation	O
sequencing	O
technology	O
,	O
here	O
we	O
show	O
that	O
repair	O
by	O
alternative	O
NHEJ	O
yields	O
non-TTAGGG	O
nucleotide	O
insertions	O
at	O
fusion	O
breakpoints	O
of	O
dysfunctional	O
telomeres	O
.	O

Investigating	O
the	O
enzymatic	O
activity	O
responsible	O
for	O
the	O
random	O
insertions	O
enabled	O
us	O
to	O
identify	O
polymerase	O
theta	O
(	I-DNAMutation
Polθ	I-DNAMutation
;	O
encoded	O
by	B-DNAMutation
Polq	I-DNAMutation
in	O
mice	O
)	O
as	O
a	O
crucial	O
alternative	O
NHEJ	O
factor	O
in	O
mammalian	O
cells	B-DNAMutation
.	I-DNAMutation
Polq	I-DNAMutation
inhibition	O
suppresses	O
alternative	O
NHEJ	O
at	O
dysfunctional	O
telomeres	O
,	O
and	O
hinders	O
chromosomal	O
translocations	O
at	O
non-telomeric	O
loci	O
.	O

In	O
addition	O
,	O
we	O
found	O
that	B-DNAMutation
loss	I-DNAMutation
of	I-DNAMutation
Polq	I-DNAMutation
in	O
mice	O
results	O
in	O
increased	O
rates	O
of	O
homology-directed	O
repair	O
,	O
evident	O
by	O
recombination	O
of	O
dysfunctional	O
telomeres	O
and	O
accumulation	O
of	O
RAD51	O
at	O
double-stranded	O
breaks	O
.	O

Lastly	O
,	O
we	O
show	O
that	O
depletion	O
of	B-DNAMutation
Polθ	I-DNAMutation
has	O
a	O
synergistic	O
effect	O
on	O
cell	O
survival	O
in	O
the	O
absence	O
of	O
BRCA	O
genes	O
,	O
suggesting	O
that	O
the	O
inhibition	O
of	O
this	O
mutagenic	O
polymerase	O
represents	O
a	O
valid	O
therapeutic	O
avenue	O
for	O
tumours	O
carrying	O
mutations	O
in	O
homology-directed	O
repair	O
genes	O
.	O

Specific	O
disruption	O
of	O
thalamic	O
inputs	O
to	O
the	O
auditory	O
cortex	O
in	O
schizophrenia	O
models	O
.	O

Auditory	O
hallucinations	O
in	O
schizophrenia	O
are	O
alleviated	O
by	O
antipsychotic	O
agents	O
that	O
inhibit	O
D2	B-DNAMutation
dopamine	I-DNAMutation
receptors	I-DNAMutation
Drd2s	B-DNAMutation
.	O

The	O
defective	O
neural	O
circuits	O
and	O
mechanisms	O
of	O
their	O
sensitivity	O
to	O
antipsychotics	O
are	O
unknown	O
.	O

We	O
identified	O
a	O
specific	O
disruption	O
of	O
synaptic	O
transmission	O
at	O
thalamocortical	O
glutamatergic	O
projections	O
in	O
the	O
auditory	O
cortex	O
in	O
murine	O
models	O
of	O
schizophrenia-associated	O
22q11	B-DNAMutation
deletion	I-DNAMutation
syndrome	I-DNAMutation
22q11DS	B-DNAMutation
.	O

This	O
deficit	O
is	O
caused	O
by	O
an	O
aberrant	O
elevation	O
of	O
Drd2	B-DNAMutation
in	O
the	O
thalamus	O
,	O
which	O
renders	O
22q11DS	B-DNAMutation
thalamocortical	O
projections	O
sensitive	O
to	O
antipsychotics	O
and	O
causes	O
a	O
deficient	O
acoustic	O
startle	O
response	O
similar	O
to	O
that	O
observed	O
in	O
schizophrenic	O
patients	O
.	O

Haploinsufficiency	O
of	O
the	O
microRNA-processing	O
gene	O
Dgcr8	B-DNAMutation
is	O
responsible	O
for	O
the	O
Drd2	B-DNAMutation
elevation	O
and	O
hypersensitivity	O
of	O
auditory	O
thalamocortical	O
projections	O
to	O
antipsychotics	O
.	O

This	O
suggests	O
that	O
Dgcr8-microRNA-Drd2-dependent	B-DNAMutation
thalamocortical	O
disruption	O
is	O
a	O
pathogenic	O
event	O
underlying	O
schizophrenia-associated	O
psychosis	O
.	O

Mitochondrial	O
dynamics	O
controlled	O
by	O
mitofusins	O
regulate	O
Agrp	B-DANMutation
neuronal	O
activity	O
and	O
diet-induced	O
obesity	O
.	O

Mitochondria	O
are	O
key	O
organelles	O
in	O
the	O
maintenance	O
of	O
cellular	O
energy	O
metabolism	O
and	O
integrity	O
.	O

Here	O
,	O
we	O
show	O
that	O
mitochondria	O
number	O
decrease	O
but	O
their	O
size	O
increase	O
in	O
orexigenic	O
agouti-related	O
protein	O
Agrp	B-DNAMutation
neurons	O
during	O
the	O
transition	O
from	O
fasted	O
to	O
fed	O
to	O
overfed	O
state	O
.	O

These	O
fusion-like	O
dynamic	O
changes	O
were	O
cell-type	O
specific	O
,	O
as	O
they	O
occurred	O
in	O
the	O
opposite	O
direction	O
in	O
anorexigenic	B-DNAMutation
pro-opiomelanocortin	I-DNAMutation
POMC	B-DNAMutation
neurons	O
.	O

Interfering	O
with	O
mitochondrial	O
fusion	O
mechanisms	O
in	O
Agrp	B-DNAMutation
neurons	O
by	O
cell-selectively	O
knocking	B-DNAMutation
down	I-DNAMutation
mitofusin	I-DNAMutation
1	I-DNAMutation
(Mfn1)	I-DNAMutation
or	I-DNAMutation
mitofusin	I-DNAMutation
2	I-DNAMutation
(Mfn2)	I-DNAMutation
resulted	O
in	O
altered	O
mitochondria	O
size	O
and	O
density	O
in	O
these	O
cells	O
.	O

Deficiency	O
in	O
mitofusins	O
impaired	O
the	O
electric	O
activity	O
of	O
Agrp	B-DNAMutation
neurons	O
during	O
high-fat	O
diet	O
(HFD)	O
,	O
an	O
event	O
reversed	O
by	O
cell-selective	O
administration	O
of	O
ATP	O
.	O

Agrp-specific	B-DNAMutation
Mfn1	B-DNAMutation
or	I-DNAMutation
Mfn2	I-DNAMutation
knockout	I-DNAMutation
mice	O
gained	O
less	O
weight	O
when	O
fed	O
a	O
HFD	O
due	O
to	O
decreased	O
fat	O
mass	O
.	O

Overall	O
,	O
our	O
data	O
unmask	O
an	O
important	O
role	O
for	O
mitochondrial	O
dynamics	O
governed	O
by	O
Mfn1	B-DNAMutation
and	O
Mfn2	B-DNAMutation
in	O
Agrp	B-DNAMutation
neurons	O
in	O
central	O
regulation	O
of	O
whole-body	O
energy	O
metabolism	O
.	O

miR-34a	B-DANMutation
blocks	O
osteoporosis	O
and	O
bone	O
metastasis	O
by	O
inhibiting	O
osteoclastogenesis	O
and	O
Tgif2	O
.	O

Bone-resorbing	O
osteoclasts	O
significantly	O
contribute	O
to	O
osteoporosis	O
and	O
bone	O
metastases	O
of	O
cancer	O
.	O

MicroRNAs	O
play	O
important	O
roles	O
in	O
physiology	O
and	O
disease	O
,	O
and	O
present	O
tremendous	O
therapeutic	O
potential	O
.	O

Nonetheless	O
,	O
how	O
microRNAs	O
regulate	O
skeletal	O
biology	O
is	O
underexplored	O
.	O

Here	O
we	O
identify	O
miR-34a	B-DNAMutation
as	O
a	O
novel	O
and	O
critical	O
suppressor	O
of	O
osteoclastogenesis	O
,	O
bone	O
resorption	O
and	O
the	O
bone	O
metastatic	O
niche	O
.	O

miR-34a	B-DNAMutation
is	O
downregulated	O
during	O
osteoclast	O
differentiation	O
.	O

Osteoclastic	O
miR-34a-overexpressing	B-DNAMutation
transgenic	O
mice	O
exhibit	O
lower	O
bone	O
resorption	O
and	O
higher	O
bone	O
mass	O
.	O

Conversely	O
,	O
miR-34a	B-DNAMutation
knockout	I-DNAMutation
and	I-DNAMutation
heterozygous	I-DNAMutation
mice	O
exhibit	O
elevated	O
bone	O
resorption	O
and	O
reduced	O
bone	O
mass	O
.	O

Consequently	O
,	O
ovariectomy-induced	O
osteoporosis	O
,	O
as	O
well	O
as	O
bone	O
metastasis	O
of	O
breast	O
and	O
skin	O
cancers	O
,	O
are	O
diminished	O
in	O
osteoclastic	O
miR-34a	B-DNAMutation
transgenic	O
mice	O
,	O
and	O
can	O
be	O
effectively	O
attenuated	O
by	O
miR-34a	B-DNAMutation
nanoparticle	O
treatment	O
.	O

Mechanistically	O
,	O
we	O
identify	O
transforming	O
growth	O
factor-β-induced	O
factor	O
2	O
(Tgif2)	O
as	O
an	O
essential	O
direct	B-DNAMutation
miR-34a	I-DNAMutation
target	O
that	O
is	O
pro-osteoclastogenic	O
.	I-DNAMutation
Tgif2	I-DNAMutation
deletion	I-DNAMutation
reduces	O
bone	O
resorption	O
and	O
abolishes	B-DNAMutation
miR-34a	I-DNAMutation
regulation	O
.	O

Together	O
,	O
using	O
mouse	O
genetic	O
,	O
pharmacological	O
and	O
disease	O
models	O
,	O
we	O
reveal	B-DNAMutation
miR-34a	I-DNAMutation
as	O
a	O
key	O
osteoclast	O
suppressor	O
and	O
a	O
potential	O
therapeutic	O
strategy	O
to	O
confer	O
skeletal	O
protection	O
and	O
ameliorate	O
bone	O
metastasis	O
of	O
cancers	O
.	O

Histone	O
H3	O
lysine-to-methionine	O
mutants	O
as	O
a	O
paradigm	O
to	O
study	O
chromatin	O
signaling	O
.	O

Histone	O
H3	O
lysine(27)-to-methionine	B-DNAMutation
H3K27M	B-DNAMutation
gain-of-function	O
mutations	O
occur	O
in	O
highly	O
aggressive	O
pediatric	O
gliomas	O
.	O

We	O
established	O
a	O
Drosophila	O
animal	O
model	O
for	O
the	O
pathogenic	O
histone	O
H3K27M	B-DNAMutation
mutation	O
and	O
show	O
that	O
its	O
overexpression	O
resembles	O
polycomb	O
repressive	O
complex	O
2	O
(PRC2)	O
loss-of-function	O
phenotypes	O
,	O
causing	O
derepression	O
of	O
PRC2	O
target	O
genes	O
and	O
developmental	O
perturbations	O
.	O

Similarly	O
,	O
an	O
H3K9M	B-DNAMutation
mutant	O
depletes	O
H3K9	O
methylation	O
levels	O
and	O
suppresses	O
position-effect	O
variegation	O
in	O
various	O
Drosophila	O
tissues	O
.	O

The	O
histone	O
H3K9	O
demethylase	O
KDM3B/JHDM2	O
associates	O
with	O
H3K9M-containing	B-DNAMutation
nucleosomes	O
,	O
and	O
its	O
misregulation	O
in	O
Drosophila	O
results	O
in	O
changes	O
of	O
H3K9	O
methylation	O
levels	O
and	O
heterochromatic	O
silencing	O
defects	O
.	O

We	O
have	O
established	O
histone	O
lysine-to-methionine	O
mutants	O
as	O
robust	O
in	O
vivo	O
tools	O
for	O
inhibiting	O
methylation	O
pathways	O
that	O
also	O
function	O
as	O
biochemical	O
reagents	O
for	O
capturing	O
site-specific	O
histone-modifying	O
enzymes	O
,	O
thus	O
providing	O
molecular	O
insight	O
into	O
chromatin	O
signaling	O
pathways	O
.	O